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Cysteine proteases are important drug targets due to their involvement in many 
biological processes such as protein turnover, digestion, blood coagulation, apoptosis, 
cell differentiation, cell signaling, and the immune response.  In this thesis, we have 
reported the design, synthesis and evaluation of clan CA and clan CD cysteine protease 
inhibitors. 
In the first project, we focused on the design, synthesis and evaluation of aza-
peptidyl Michael acceptor and epoxide inhibitors for asparaginyl endopeptidases 
(legumains) from the bloodfluke, Schistosoma mansoni (SmAE) and the hard tick, Ixodes 
ricinus (IrAE).  Structure activity relationships (SARs) were determined for a set of forty 
one aza-peptide Michael acceptors and eight aza-peptide epoxides.  For both enzymes, 
SARs were similar, but with some notable exceptions.  Both enzymes prefer disubstituted 
amides to monosubstituted amides in the P1' position and potency increased as we 
increased the hydrophobicity of the inhibitor in this position.  Extending the inhibitor to 
P5 resulted in increased inhibitory potency, especially against IrAE, and both enzymes 
prefer small over large hydrophobic residues in the P2 position.  Aza-peptide Michael 
acceptor inhibitors are more potent than aza-peptide epoxide inhibitors and, for some of 
these compounds, second order inhibition rate constants are the fastest yet discovered. 
For the second project, we synthesized seventeen aza-peptidyl Michael acceptor 
and epoxide inhibitors for the parasitic cysteine proteases; cruzain, rhodesain and 
TbCatB.  We have found that monosubstituted amides were favored over disubstituted 
amides indicating the involvement of the amide hydrogen in a H-bond network.  We have 
 xviii 
shown that aza-peptide epoxides were as potent as Michael acceptors and we have 
obtained compounds with IC50 values as low as 20 nM. 
In the third project, we worked on the synthesis of heterocyclic peptidyl !-
ketoamides, peptidyl ketones and aza-peptidyl ketones as calpain inhibitors.  We have 
synthesized peptidyl !-ketoamides with nucleotide bases in the primed region to create 
compounds that can cross the blood-brain barrier.  Based on the crystal structure obtained 
with previous heterocyclic peptidyl !-ketoamides synthesized by our group, we have 
improved the potency by introducing a hydrophobic group on the adenine ring.  We have 
obtained compounds with Ki values in the nanomolar range.  We have also designed two 
new classes of inhibitors for calpain; peptidyl aminoketones and aza-peptidyl ketones.  
Peptidyl aminoketones were less potent than peptidyl !-ketoamides but still reasonable 
inhibitors of calpain that have the potential to cross the BBB.  Aza-peptidyl ketones, on 










 Proteases or proteolytic enzymes catalyze the breakdown of proteins by 
hydrolysis of peptide bonds.  Proteases were first organized as clans and families by 
Rawlings and Barrett in 1993.
1
  Proteases use different catalytic mechanisms for substrate 
hydrolysis.  In the MEROPS database, proteases are divided into eight groups: serine, 
cysteine, threonine, aspartic, metallo, glutamic, mixed and unknown. Each group is 
further divided into families and clans according to their similarities in structure and 
evolutionary origin.   
 Proteases specifically cleave protein substrates either in the middle of the 
molecule (endopeptidases) and/or from the N or C termini (aminopeptidases and 
carboxypeptidases, respectively).  
 
 




 Proteases are found in all organisms in the animal kingdom and involved in 
important physiological processes including cell differentiation and proliferation, cell 
death, DNA replication, tissue remodelling, wound healing, the immune response, protein 
turnover, digestion and signal transduction.  Dysregulation of protease activities have 
been associated with many diseases including cardiovascular and inflammatory diseases, 
cancer, osteoporosis and neurological.  Proteases are ideal targets for the development of 








 The nomenclature of protease subsites are first described by Berger and 
Schechter.
3
  The surface of the protease that accommodates a single side chain of a 
substrate residue is called the subsite.  Subsites are numbered S1, S2, etc. upwards 
towards the N terminus of the substrate (non-primed sites), and S1", S2", etc. towards the 
C terminus (primed sites), beginning from the sites on each side of the scissile bond. The 
substrate residues they accommodate are numbered P1, P2, etc, and P1", P2", etc.; 
 3 
respectively.  Substrate specificity of a protease, which is determined by the structure of 
the active site of the protease, determines which substrate residues can bind to specific 




 Cysteine proteases have a cysteine residue in their active side and therefore 
employ the sulfhydryl group of the side chain of a cysteine residue as the catalytic 
nucleophile.  The first step of the peptide hydrolysis mechanism involves the 
deprotonation of the sulfhydryl group in the enzyme's active site by the histidine residue.  
A catalytic dyad is formed with the imidazole side chain of histidine residue and the 
sulfhydryl group of the active site cysteine.  Some of the cysteine proteases use an extra 
amino acid to provide additional stabilization via hydrogen bonds, thus forming a 
catalytic triad.  The next step is the nucleophilic attack of the thiolate anion to the 
carbonyl carbon of the peptide bond to be cleaved and a tetrahedral intermediate is 
formed.  The tetrahedral intermediate is stabilized by the oxyanion hole via hydrogen 
bonds to the backbone amides.  Collapse of the tetrahedral intermediate releases the 
amino terminus of the substrate and results in the formation of an acyl intermediate.  
Abstraction of a proton from a water molecule by the catalytic histidine forms an 
activated water molecule.  The thioester bond of the acyl intermediate is then hydrolyzed 




Figure 1.3.  Substrate Hydrolysis Mechanism of Cysteine Proteases  
 
Cysteine proteases currently consist of 10 clans.  We will focus on clan CA and 
clan CD cysteine proteases since the inhibitors reported in this thesis are designed for the 
enzymes belong to these two clans.  Clan CA and clan CD cysteine proteases differ 
slightly in their substrate hydrolysis mechanism.  A catalytic dyad of Cys and His is 
employed by clan CD whereas a catalytic triad of Cys, His, and Asn is used by clan CA 
cysteine proteases.  Stabilization of the tetrahedral intermediate occurs by H bonding to 
the backbone NH of active site Cys and to the NH2 group of the Gln side chain in clan 
CA.
4
  The oxyanion hole consists of only backbone NH groups in clan CD cysteine 
proteases.   
 5 
Clan CA Cysteine Proteases 
The majority of cysteine proteases belong to clan CA and these cysteine proteases 
have been found in viruses, bacteria, protozoa, plants and mammals.
5
  Clan CA contains 
all the families of peptidases that have similar structures to papain.   
Papain is a cysteine protease extracted from the tropical papaya fruit.  It is the first 
cysteine protease to be discovered and has been the subject of mechanism and structural 
studies for many years and it is also the first enzyme to have its crystal structure 
determined.
6
  The substrate specificity of clan CA enzymes is primarily controlled by the 
S2 subsite.  Papain has a very broad specificity compared to other clan CA proteases.  It 
prefers bulky hydrophobic residues in the P2 position, while the S1 subsite is not as 




Cathepsin B is a lysosomal cysteine protease with both endopeptidase and 
dipeptidyl carboxypeptidase activities.  The substrate specificity of cathepsin B is similar 
to papain family and the primary determinant of specificity is the S2 subsite.  Cathepsin 
B can accommodate hydrophobic residues together with arginine in the P2 position due 
to the location of Glu245 in the S2 subsite.
8
  Cathepsin B is implicated in diseases such as 
arthritis, muscular dystrophy, gingivitis and cancer.
9
   
Calpains are a unique family of cysteine proteases since they require calcium to 
become activated.  The major isoforms of calpain (calpain I and calpain II) are nearly 
identical and differ mostly in the amount calcium they require for activation.
10
  Calpain 
activation is utilized in many cellular processes such as apoptosis, cell differentiation and 
protein turnover.
11
  Calpains prefer hydrophobic residues like Val or Leu in the P2 
 6 
position but are less selective in the P1 position.
12
  Overactivation of calpain has been 
observed in a variety of disorders, including cataracts, muscular dystrophy, cancer and 
neurodegenerative diseases.
13
   
 Cruzain is the only parasitic cysteine protease with a crystal structure.
14-16
  
Cruzain is expressed in all life cycles of Trypanasoma cruzi,
5
 which is the causative 
agent of Chagas’ disease in Central America.  Cruzain can accommodate hydrophobic 
residues like phenylalanine together with basic residues such as arginine in the S2 pocket.  
Cruzain is an excellent target for the development of irreversible inhibitors due to the 
presence of the enzyme in all stages in the life cycle of the parasite. 
 Rhodesain is the major cysteine protease of T. brucei rhodesiense, the causative 
agent of African sleeping sickness.
17
  Rhodesain is an important target for the 
development of antiparasitic chemotherapy due to the involvement of the enzyme in 
regulating the replication of the parasite.  Therefore, inhibition of the enzyme will block 
the life cycle of the parasite in infected mammalian cells. 
 TbCatB has recently been identified in T. brucei as a key enzyme in host protein 
turnover and iron acquisition.
18
  TbcatB, a cathepsin B-like enzyme, is an ideal target for 
the development of new anti-trypanosomal chemotheraphy.      
 
Clan CD Cysteine Proteases 
 Clan CD is a smaller class of cysteine proteases compared to clan CA cysteine 
proteases.  Clostripain (C11), legumains (C13), caspases (C14), gingipain (C25), separase 
(C50) and self-cleaving toxin A (C80) belong to clan CD cysteine proteases.  The 
substrate specificity of the members of this class is determined by the residue in the P1 
 7 
position, such as Asp for caspases, Arg for clostripain, Asn for legumain family, Arg or 
Lys for gingipain family, Arg for separase family and Leu for self-cleaving toxin A 
family.  Unlike clan CA cysteine proteases, clan CD enzymes employ a catalytic dyad 
(His-Cys) for substrate hydrolysis.  
 Asparagine endopeptidases (legumains) cleave their peptide substrates 
specifically after an asparagine residue.  Asparagine endopeptidases (AEs) have been 
linked to osteoclast formation and bone resorption,
19
 processing of bacterial antigens
20
 
and elevated levels of human AE was found in many tumors, including carcinomas of the 
breast, colon, and prostate.
21
   AE of the bloodfluke Schistosoma mansoni and AE of the 
hard tick Ixodes ricinus have an indirect role in host hemoglobin digestion
22, 23
 and 




An inhibitor is a compound that decreases the rate of an enzyme catalyzed 
reaction and this inhibition can be either irreversible or reversible depending on the 
nature of binding of inhibitor to the enzyme. 
 
Reversible enzyme kinetics 
 Reversible inhibition can be competitive, uncompetitive or linear mixed type.  
The inhibitors studied in this thesis are competitive inhibitors of cysteine proteases since 
they are competing with the substrate for binding to the active site cysteine residue.  The 
equations for the competitive inhibition are derived by using the following model.  In this 
 8 
model, E is the enzyme, S is the substrate, I is the inhibitor, P is the product of the 
hydrolysis reaction, ES is the enzyme-substrate complex and EI is the enzyme-inhibitor 
complex.   
 
 
Ks is the enzyme-substrate dissociation constant, kcat is the rate of formation of product 
from ES complex and Ki is the inhibition constant or enzyme-inhibitor dissociation 
constant. 
Ks = ([E][S])/[ES] 
Ki = ([E][I])/[EI] 
v = kcat [ES] 
Ki can be determined from the Michaelis-Menten equation and equal to 
Ki = (Vmax [S])/(Km (1 + [I]/Ki) + [S])  
This equation can be rearranged as   
1/v = [(1/Vmax) (1 + Km/[S])] + [([I] Km)/(Vmax Ki [S])] 
The plot of 1/v against [I] at constant [S], which is called Dixon plot,
24
 will be a straight 
line.  Ki can be easily calculated based on this equation; when rates are measured at many 
different inhibitor concentrations but only a limited number of substrate concentrations.  
Low Ki values indicate the higher potency of the inhibitor.  
 9 
Irreversible enzyme kinetics 
Irreversible inhibition of an enzyme proceeds through the formation of an 
intermediate non-covalent enzyme-inhibitor complex (E•I) and which is then followed by 
the formation of a covalent enzyme-inhibitor complex (E-I) in a time-dependent manner.  
 
E is the enzyme, I is the inhibitor, Ki is the dissociation constant of the non-covalent 
enzyme-inhibitor complex and k2 is the first order rate constant for the formation of 
covalent enzyme-inhibitor complex. 
One of the methods used for the determination of irreversible enzyme kinetics, 
developed by Kitz and Wilson, is called the incubation assay method.
25
  In this method, 
enzyme and a large excess of inhibitor are incubated together in buffer, and then an 
aliquot of this solution is diluted into a buffer solution containing the substrate and the 
rate of substrate hydrolysis is measured.  When [I] > [E], pseudo-first order kinetics can 
be assumed and the rate can be calculated from the equation, 
ln (vt/v0) = -kobst 
where v0 is the initial rate of hydrolysis without the presence of the inhibitor and vt is the 
rate of hydrolysis at time t, kobs is the pseudo-first-order rate constant for inactivation. 
Pseudo-first-order kinetics are also described by the equation, 
kobs = k2/(1 + Ki/[I]) 
This equation can be rearranged as  
1/kobs = Ki/k2[I] + 1/k2 
 10 
where Ki (Ki = [E][I]/[E#I]) is the dissociation constant of the enzyme-inhibitor complex.  
The rate constant k2 is a first-order rate constant, and k2/Ki is a second order rate constant 
and the most commonly used parameter to report inhibition data. 
For very potent inhibitors where rates are too fast to measure using the pseudo-
first order kinetics, the inhibitor concentration is decreased until [I] $ [E], then second-
order rate constant can be calculated from the equation, 
k2ndt = [1/(i – e)]ln[e(i – x)/i(e – x)] 
where e – x is the residual enzyme concentration and i is the initial inhibitor 
concentration.  Since inhibitor concentration is included in the calculation, the second- 
order rate constant k2nd can be determined from the equation.   
Another method, developed by Tian and Tsou,
26
 is used for the measurement of 
irreversible inhibition rates of very fast inhibitors.  In this method, substrate hydrolysis is 
measured continuously upon addition of enzyme to a mixture of substrate and inhibitor.  
This method is referred to as the progress curve method and the reaction in the progress 
curve method is initiated by the addition of the enzyme.  The observed inhibition rate 
constant kobs can be calculated from the equation where [P] and [P%] are the product 
concentrations at t and t = %; respectively. 
ln ([P%] – [P]) = ln [P%] – kobs[I]t 
The observed inhibition rate constant kobs can be easily calculated from the slope of the 
plot ln ([P%] – [P]) versus t at a particular substrate concentration.  The progress curve 
method has the advantage of consuming less enzyme and substrate since relatively few 
separate kinetic measurements are needed.  
 
 11 
The inhibitor concentration required to decrease the activity of the enzyme by 
50% is called the IC50 value of the inhibitor.  The incubation time is an important factor 
for IC50 assays of irreversible inhibitors since a longer incubation time resulted in a lower 
IC50 value.  It is possible to establish a mathematical relationship between the pseudofirst 
order inactivation rate kobs and IC50 values.  If it is assumed that IC50 is the inhibitor 
concentration necessary to reduce the enzyme activity by 50% during the time of the 
incubation, then the assay time (tassay) should be equal to the half-life t1/2 for the first order 
inactivation rate.   
kobs = ln 2/t1/2 = 0.693/tassay 
kobs/[I] = 0.693/(tassay x IC50) 
 12 
CHAPTER 2 
AZA-PEPTIDYL MICHAEL ACCEPTORS AND EPOXIDES AS 
INHIBITORS OF SCHISTOSOMA MANSONI AND IXODES RICINUS 




The helmintic disease, schistosomiasis is the second most important parasitic 
disease after malaria in tropical areas.  It infects over 200 million people in 









 Immature and adult bloodflukes live in the cardiovascular system, ingest red 
blood cells and utilize hemoglobin as a source of amino acids for growth, development 
and reproduction.  In the parasite gut, cysteine and aspartic proteases contribute to the 
proteolytic degradation of hemoglobin.
29
  Among these are a legumain (SmAE) that, in 
vitro, degrades hemoglobin
30
 and trans-activates the major gut cathepsin B protease.
31
  
As a central digestive enzyme, therefore, SmAE may represent a useful target for 
selective inhibitors that impair the parasite’s ability to feed.   
Hard ticks of the genus Ixodes are vectors of Lyme disease caused by the 
spirochetes Borrelia burgdorferi sensu lato.  The multiplication of spirochetes in the tick 
gut and subsequent infection of the host requires unimpaired bloodmeal uptake and 
digestion.
32
  As for SmAE, a gut-associated AE in Ixodes ricinus (IrAE) is thought to 
contribute to hemoglobin degradation either directly or indirectly by the trans-activation 
of other digestive cysteine and aspartic proteases.
33, 34
  Accordingly, IrAE may represent 
a drug or vaccine target to prevent or retard transmission of disease. 
Asparaginyl endopeptidases (AEs) or legumains (EC.3.4.22.34) belong to the C13 
family of clan CD cysteine proteases which also includes caspases, gingipains, 
clostripain, and separase.
35
  AEs are acidic lysosomal enzymes that cleave substrates 
specifically after an asparagine residue in the P1 position.
36
  Legumains were first 
discovered in the human blood fluke, Schistosoma mansoni,
37





 and most recently in the ticks, Ixodes ricinus
33
 and Haemaphysalis 
longicornis.
42
  Plant legumain functions as a processing enzyme of storage proteins 
during seed germination.
43
  Mammalian legumain is involved in the inhibition of 
osteoclast formation and bone resorption.
44
  It has also been shown that human legumain 
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is highly expressed in many tumors, including carcinomas of the breast, colon, and 
prostate.
21




Synthetic AE inhibitors that have been tested against mammalian  
AEs
46, 47





), Michael acceptors derived from Asn (Cbz-Ala-Ala-









).  It has also been shown 
that the aspartyl peptidyl fluoromethyl ketones designed for caspase inhibition also 
moderately inhibit mammalian AE.
48
  It has been recently reported that aza-asparaginyl 
Michael acceptor inhibitors are potent and selective inhibitors of S. mansoni, I. ricinus 
and Trichomonas vaginalis (a parasitic protozoan) AEs.
49
  In this study, the inhibitor 
sequence Cbz-Ala-Ala-AAsn was maintained while substituents on the reactive warhead 
were changed in order to measure the effects of modifying the P1' position.  SAR studies 
revealed that the most potent inhibitors have esters or disubstituted amides with aromatic 




Aza-peptide Michael acceptors and epoxide inhibitors are selective and potent 
inhibitors of SmAE and IrAE.
49, 50
  Previously synthesized inhibitors have the peptide 
sequence of Cbz-Ala-Ala-AAsn as a template since Cbz-Ala-Ala-Asn-NHMec (NHMec 
= 7-(4-methyl)coumarylamide) is an optimal substrate sequence for legumain.
51




Figure 2.2.  Design of Aza-peptide Epoxide and Michael Acceptors. 
 
In this study, we used Boc-NHNHCH2CONH2, YCO-Ala-NHNHCH2CONH2 and 
YCO-Ala-Ala-NHNHCH2CONH2 peptide sequences where the Y groups are piperidine, 
morpholine, piperazine, tert-butoxypiperazine and benzyloxycarbonyl piperazine.  These 
groups were chosen to increase the bioavailability of the inhibitors and to study the 
interactions of the P4 (YCO-Ala-AAsn-CH=CH-COR) and P5 (YCO-Ala-Ala-AAsn-
CH=CH-COR, YCO-Ala-Ala-AAsn-EP-COR) positions of the inhibitor with SmAE and 
IrAE.  Work by other investigators with the vinyl sulfone inhibitors of cysteine proteases 




  Accordingly, we expanded upon our previous design 
of aza-peptide Michael acceptors and epoxides by introducing groups at the N-terminus 
in order to both extend the compounds to P4 and P5 and potentially increase 
bioavailability.   
For the inhibitor design, the !-carbon of the asparagine (Asn) residue is replaced 
by a nitrogen atom.  This replacement results in an aza-peptide containing the aza-
asparagine (AAsn) residue.  Presence of an aza-asparagine residue at P1 makes the 
synthesis of aza-peptide Michael acceptor and epoxide inhibitors easier compared to 
peptide Michael acceptor and epoxide inhibitors as the synthesis involves coupling of an 
acid and an aza-peptide precursor.  Aza-peptides are ideal inhibitors because they are 
resistant to cleavage by proteases in vivo
53, 54
 and can incorporate a reactive warhead.  We 
chose the epoxide and Michael acceptor double bonds as these warheads can be easily 
modified in the P' position to study interactions with the S' subsites of the enzymes.  
We have designed aza-peptide epoxides and Michael acceptor inhibitors that 




  Placement of the carbonyl 
group of the epoxide moiety or fumarate derivative in the inhibitor places it in a location 
identical to that of the carbonyl of the scissile peptide bond in a legumain substrate. This 
design allows the peptide chain of the inhibitor to exactly match that of a good substrate 
from the N-terminus across to the scissile peptide carbonyl group.  Aza-peptide epoxides 
and Michael acceptors have the advantage of being easily extended in the P' direction, 
allowing interactions with the S' subsites of AE. 
We have also synthesized inhibitors with the Cbz-Ala-AA-AAsn peptide 
sequence where AA is valine, isoleucine or phenylalanine to study the effect of 
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modification in the P2 position.  Aza-peptide substrate analogs were also synthesized 





The synthesis of the aza-peptide fumarate and epoxide analogs are based on the 
previous syntheses of aza-peptide Michael acceptor
55
 and epoxide inhibitors.
56
  The 
inhibitors are obtained by coupling a peptidyl hydrazide to a monoester or amide of 
fumaric acidor to a monoester or amide of epoxysuccinic acid. 
 
Reagents: (i) NMM, iBCF, CH2Cl2, HNR1R2; (ii) 1. NaOH, 2. HCl, EtOH. 
Figure 2.3.  Synthesis of Fumarate Precursors. 
 
Monoethyl fumarate (2a) was commercially available and all the Michael 
acceptor warheads were synthesized using this compound as a precursor.  The 
monobenzyl fumarate (2b) was formed from monoethyl fumarate and benzyl alcohol 
using NMM and DCC as the coupling reagent and followed by deprotection of the ethyl 
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ester in ethanol using aqueous NaOH.  The fumarate precursors (2c - p) were prepared 
from monoethyl fumarate and the corresponding primary or secondary amines by 
standard mixed anhydride coupling using NMM and iBCF; and followed by hydrolysis of 





Reagents: (i) NMM, iBCF, CH2Cl2, HNR1R2; (ii) 1. KOH, 2. HCl, EtOH. 
Figure 2.4.  Synthesis of Epoxysuccinate Derivatives. 
 
A previously described procedure
56
 was used for the synthesis of (2S,3S)-oxirane-
2,3-dicarboxylic acid monoethyl ester (3).  The epoxide warheads (4r, 4s) were 
synthesized from monoethyl epoxysuccinate and the corresponding primary or secondary 
amines using the standard mixed anhydride coupling procedure with NMM and iBCF, 
followed by deprotection of the ethyl ester in ethanol using aqueous KOH (Figure 2.4).  
The monoethyl ester of cis-oxirane-2,3-dicarboxylic acid monoethyl ester (5) was 
synthesized following a previously described procedure.
57
  Coupling of the 
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dibenzylamine to the monoethyl ester epoxysuccinate to form compound 6t was 
performed using the standard mixed anhydride coupling procedure and followed by 
deprotection as decribed above.  The disubstituted aromatic amines were synthesized by 
reductive amination starting with an aromatic aldehyde precursor and an aromatic 
primary amine. 
The hydrazide Boc-NHNHCH2CONH2 was synthesized by the monoalkylation of 
tert-butyl carbazate (7) with ethyl bromoacetate and the conversion of the ethyl ester to 
the amide by ammonolysis was done with catalytic amounts of NaCN according to the 




Reagents: (i) BrCH2COOEt, NMM, DMF; (ii) NH3, cat. NaCN, MeOH, DMF. 
Figure 2.5.  Synthesis of the Aza-asparagine Precursor.
 
 
For the synthesis of acyl dipeptide aza-asparagine precursors (12 - 14), we first 
prepared the alanine methyl ester isocyanate (10) by reacting the hydrochloride salt of 
alanine (9) with phosgene according to the procedure by Nowick et al.
59
  Alanine methyl 
ester isocyanate (10) was then reacted with piperidine, morpholine, tert-
butoxycarbonylpiperazine, benzyloxycarbonylpiperazine to form Y-CO-Ala-OCH3 (11u - 
x) respectively.
60





 were synthesized 
according to the literature.  The ester Y-CO-Ala-OCH3 (11u - x) was then reacted with 
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excess hydrazine (NH2NH2) in methanol to form Y-CO-Ala-NH-NH2.  To introduce the 
aza-asparagine side chain, Y-CO-Ala-NH-NH2 was reacted with ethyl bromoacetate and 
NMM.  The ethyl ester group was then reacted with 7N NH3 in methanol in the presence 
of catalytic NaCN to form the acyl dipeptide aza-asparagine precursor (Y-CO-Ala-




Reagents: (i) H2NNH2, MeOH; (ii) BrCH2COOEt, NMM, DMF; (iii) NH3, cat. NaCN, 
MeOH, DMF. 
Figure 2.6.  Synthesis of the Acyl Dipeptide Aza-asparagine Precursors. 
 
For the synthesis of the acyl tripeptide aza-asparagine precursors (15 - 18), we 
first hydrolyzed the esters 11u – x (Y-CO-Ala-OCH3) with 1M NaOH in methanol to 
form acyl alanine derivatives (Y-CO-Ala-OH).  The acyl alanine then was coupled to 
alanine methyl ester using HOBt and DCC to form the dipeptides Y-CO-Ala-Ala-OCH3.  
The dipeptide esters Y-CO-Ala-Ala-OCH3 were then reacted with excess hydrazine and 
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the asparagine side chain was introduced as mentioned previously to form the acyl 
tripeptide aza-asparagine precursors (Y-CO-Ala-Ala-NHNHCH2CONH2) (Figure 2.7).   
 
Reagents: (i) 1. NaOH, 2. HCl; (ii) HCl#H2N-Ala-OCH3, HOBt, DCC, DMF; (iii) 
H2NNH2, MeOH; (iv) BrCH2COOEt, NMM, DMF; (v) NH3, cat. NaCN, MeOH, DMF. 
Figure 2.7.  Synthesis of the Acyl Tripeptide Aza-asparagine Precursors. 
 
For the synthesis of Cbz-Ala-Val(Ile, Phe)-NHNHCH2CONH2, we reacted Cbz-
Ala-OH with valine methyl ester, isoleucine methyl ester, or phenylalanine methyl ester.  
The peptidyl methyl ester was then reacted with hydrazine and finally the asparagine side 
chain was attached by alkylation with ethyl bromoacetate followed by ammonolysis 
(Figure 2.8).  
 
Reagents: (i) HCl#H-Val-OCH3, HCl#H-Ile-OCH3 or HCl#H-Phe-OCH3, HOBt, DCC, 
DMF (ii) H2NNH2, MeOH, (iii) BrCH2COOEt, NMM, DMF; (iv) NH3, cat. NaCN, 
MeOH, DMF. 
Figure 2.8.  Synthesis of Cbz-Ala-AA-NHNHCH2CONH2. 
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  The aza-asparagine precursors (8, 12 – 14, 15 – 18, 20 - 22) were then coupled 
to a variety of substituted fumarate analogs (2a - p), epoxide moieties (4q – s and 6t) 




Figure 2.9.  Coupling of Fumarate Precursors and Epoxide Moieties to Aza-asparagine 
Precursors. 
 
Aza-peptide Michael acceptors and epoxides with Boc-Piz-Ala-Ala-AAsn peptide 
sequence (29, 36 a - r) were treated with TFA in dichloromethane to form the simple 
piperazine derivatives Piz-Ala-Ala-AAsn (37, 38 a - r). 
Aza-peptidyl substrate analogs were synthesized in three different ways (Figure 
2.10).  Aza-peptide precursor (13) was reacted with hydrocinnamic acid using HOBt and 
EDC coupling procedure to form compound 39.  Different isocyanates were added to a 
solution of aza-peptide precursors in dichloromethane to form compounds (40-42).  Aza-
 23 
peptide precursor (16) was reacted with benzylchloroformate in the presence of pyridine 
to form compound (43).   
 
Figure 2.10.  Synthesis of Aza-peptidyl Substrate Analogs. 
 
RESULTS AND DISCUSSION 
 
Inhibition of SmAE and IrAE with Aza-peptidyl Michael Acceptors.  We 
synthesized four simple Boc-protected aza-asparagine inhibitors (23a, d, f, h) with 
different Michael acceptor warheads.  Only the monoethyl ester derivative (SmAE IC50 > 
2,000 nM, IrAE IC50 = 750 nM) inhibited the enzymes, whereas no inhibition was 
detected with the other three compounds (Table 2.1).  Clearly, inhibitors with a single 




Table 2.1.  Inhibition of SmAE and IrAE by Michael Acceptors with the Boc-AAsn 







23a Boc-AAsn-CH=CH-COOEt >2,000 750 
23d Boc-AAsn-CH=CH-NHCH2-cyclohexyl N.I. N.I. 
23f Boc-AAsn-CH=CH-CONHBzl N.I. N.I. 
23h Boc-AAsn-CH=CH-CONHCH2CH2CH2Ph N.I. N.I. 
 
 Due to this result, we next synthesized acyl dipeptide aza-asparagine Michael 
acceptor inhibitors.  The results are shown in Table 2.2.  Monosubstituted amides (24k, 
25c, e, i, h, k, 26j, k) were either poor or non-inhibitory.  Replacement of the 
monosubstituted amides with the disubstitued amides (24k, 25k, 26j - k) yielded 
increased potency.  Inhibitors 24k, 25k, and 26k have the same isoquinoline moiety in 
their P1' position, however, they have different acyl groups.  Both enzymes seem to favor 
the presence of a piperidine residue in the P3 position rather than morpholine or 
benzyloxypiperazine.  Probably, the oxygen of the morpholine is disturbing the H-bond 
network around the active site of the AEs, whereas the benzyloxypiperazine is not 
accommodated in the P3 position due to the bulkiness of the group.  Although the 













24k Pip-Ala-AAsn-CH=CH-CO-tetrahydroisoquinoline 600 150 
25c Mu-Ala-AAsn-CH=CH-CONH-cyclopropyl N.I. N.I. 
25e Mu-Ala-AAsn-CH=CH-CONHCH2-2-furyl N.I. N.I. 
25i Mu-Ala-AAsn-CH=CH-CONHCH2Ph-3,4-OCH3 >2,000 >2,000 
25h Mu-Ala-AAsn-CH=CH-CONHCH2CH2CH2Ph >2,000 N.I. 
25k Mu-Ala-AAsn-CH=CH-CO-tetrahydroisoquinoline 750 600 
26j Cbz-Piz-Ala-AAsn-CH=CH-CO-tetrahydroquinoline 750 850 
26k Cbz-Piz-Ala-AAsn-CH=CH-CO-tetrahydroisoquinoline 750 800 
 
 
In view of these results, acyl tripeptide aza-asparagine Michael acceptors were 
synthesized.  The results are shown in Table 2.3.  Among the inhibitors with Pip-Ala-
Ala-AAsn sequence, the ethyl ester derivative (27a) was as effective (SmAE IC50 = 80 
nM, IrAE IC50 = 15 nM) as the dibenzyl amide analog (27l) (SmAE IC50 = 80 nM, IrAE 
IC50 = 17 nM).  Again, the disubstituted amides (27l, o, p) were more potent than the 
monosubstituted amide analog (27g).  The dinaphthylmethylene derivative (27p) was the 
most potent of the acyl tripeptide inhibitors against SmAE (IC50 = 57 nM), whereas the 






Table 2.3.  Inhibition of SmAE and IrAE by Acyl Tripeptide Michael Acceptors.  







27a Pip-Ala-Ala-AAsn-CH=CH-COOEt 80 15 
27g Pip-Ala-Ala-AAsn-CH=CH-CONHCH2CH2Ph 750 400 
27l Pip-Ala-Ala-AAsn-CH=CH-CON(Bzl)2 80 17 
27o Pip-Ala-Ala-AAsn-CH=CH-CON(Bzl)-CH2-1-naphthyl 100 2.4 
27p Pip-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naphthyl)2 57 8 
28a Mu-Ala-Ala-AAsn-CH=CH-COOEt 101 0.23 
28h Mu-Ala-Ala-AAsn-CH=CH-CONHCH2CH2CH2Ph 1450 >2,000 
28k Mu-Ala-Ala-AAsn-CH=CH-CO-tetrahydroisoquinoline 103 65 
28p Mu-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naphthyl)2 45 3.3 
37a Piz-Ala-Ala-AAsn-CH=CH-COOEt 300 8.5 
37b Piz-Ala-Ala-AAsn-CH=CH-COOBzl 250 13 
37l Piz-Ala-Ala-AAsn-CH=CH-CON(Bzl)2 90 31 
37n Piz-Ala-Ala-AAsn-CH=CH-CON(CH3)CH2-1-naphthyl 40 3.8 
37p Piz-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naphthyl)2 70 2.6 
29a Boc-Piz-Ala-Ala-AAsn-CH=CH-COOEt 80 8.5 
29b Boc-Piz-Ala-Ala-AAsn-CH=CH-COOBzl 45 7.5 
29l Boc-Piz-Ala-Ala-AAsn-CH=CH-CON(Bzl)2 45 30 
29n Boc-Piz-Ala-Ala-AAsn-CH=CH-CON(CH3)CH2-1-naphthyl 58 20 
29p Boc-Piz-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naphthyl)2 68 5 
30a Cbz-Piz-Ala-Ala-AAsn-CH=CH-COOEt 70 0.14 
30n Cbz-Piz-Ala-Ala-AAsn-CH=CH-CON(CH3)CH2-1-naphthyl 70 0.35 




Among the inhibitors with the Mu-Ala-Ala-AAsn peptide sequence, the ethyl 
ester analog (28a) was as effective (IC50 = 101 nM) as the disubstituted amide analog 
(28k) (IC50 = 103 nM) against SmAE.  However, in the case of IrAE, replacement of the 
ethyl ester (IC50 = 0.23 nM) with the disubstituted amide analog, tetrahydroisoquinoline 
(IC50 = 65 nM), result in 300-fold decrease in potency.  This is one of very few examples 
where the parasite AEs diverged markedly in their SAR.  We conclude that even though 
IrAE does prefer disubstituted amides, for example, the dinaphthylmethylene analog 
(28p) (IC50 = 3.3 nM), it does not favor constrained amides in the P1'.  The monoamide 
analog (28h) (SmAE, IC50 = 1450 nM; IrAE, IC50 >2,000 nM) was a poor inhibitor of 
both enzymes. There can be two reasons for this; either the alkyl spacer puts the phenyl 
group in an unfavorable position or the presence of a hydrogen bond donor group is not 
favored in the S1' position.   
Next, we synthesized five inhibitors with Piz-Ala-Ala-AAsn peptide sequence.    
The two ester derivatives (ethyl ester, 37a and benzyl ester, 37b) were moderate 
inhibitors of both SmAE (IC50 = 300 nM and IC50 = 250 nM, respectively) and IrAE (IC50 
= 8.5 nM and IC50 = 13 nM, respectively).  However, the disubstituted amide derivatives 
(37l, n, p) were better against SmAE (IC50 = 90 nM, IC50 = 40 nM and IC50 = 70 nM).  
Because these compounds contain aromatic groups in their warheads, we conclude that 
the presence of such groups at P1' improves binding of the inhibitors due to !-stacking in 
either S1' or S2' of SmAE.  Piz-Ala-Ala-AAsn-CH=CH-CON(CH3)CH2-1-naphthyl (37n) 
was the most potent inhibitor against SmAE (IC50 = 40 nM) among all the compounds 
synthesized.  Probably, the methyl group interacts with a small hydrophobic pocket in the 
S1', whereas the naphthyl group reaches to a larger hydrophobic pocket in the S2'.   
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Then, we synthesized eight compounds with protecting groups on the piperazine; 
five of these (29a-b, l, n, p) contain the tert-butoxycarbonyl (Boc) group whereas the 
other three (30a, n, p) contain the benzyloxycarbonyl (Cbz) group.  Interestingly, all the 
compounds with Boc-Piz-Ala-Ala-AAsn and Cbz-Piz-Ala-Ala-AAsn peptide sequences 
were potent inhibitors of both SmAE and IrAE.  We speculate that there is a hydrophobic 
pocket that is interacting with hydrophobic groups (Boc and Cbz) in the P5 position.  In 
particular, the Cbz-Piz-Ala-Ala-AAsn peptide sequence (30a, n, p) produced the best 
inhibitors of IrAE (IC50 = 0.14, 0.35 and 0.37 nM, respectively) herein reported.  As the 
Boc-Piz-Ala-Ala-AAsn compounds were not as potent as those containing Cbz-Piz-Ala-
Ala-AAsn, we conclude that the increased !-stacking of the aromatic residues in the S5 
pocket improves inhibitor binding. 
   
 
Figure 2.11.  Proposed Mode of Binding of Aza-peptide Michael Acceptor to the Active 
Site of Asparagine Endopeptidases. 
 
Asparagine endopeptidases belong to clan CD cysteine proteases.  Clan CD 
cysteine proteases contains families with a protein fold or sequence motifs similar to 
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those found in the caspase family.  Since there is no crystal structure determined for 
asparagine endopeptidases, we studied the crystal structures of caspases to predict the 
interaction sites of inhibitors with the enzyme (Figure 2.11).  The crystal structures of 
caspase-3 in complex with aza-peptide Michael acceptors demonstrated that there are two 
hydrophobic pockets in the primed site.  One of the hydrophobic pockets formed by Tyr 
204, Thr166, and Glu123 while the other one formed by Met61 and Phe128.  The P1 
carbonyl group is stabilized by hydrogen bonds to the backbone amide nitrogens of 
Gly122 and Cys163.  The most interesting discovery was the hydrophobic pocket in the 
S5 site of caspases.  The inhibitors with Boc-Piz-Ala-Ala-AAsn and Cbz-Piz-Ala-Ala-
AAsn peptide sequence were the most potent inhibitors presented here and we proposed 
that the protecting groups (Boc and Cbz) are interactiong with the hydrophobic pocket 
formed by Phe252 and Val178.  Especially, the inhibitors with Cbz-Piz-Ala-Ala-AAsn 
peptide sequence have the lowest IC50 values and we proposed that the phenyl ring of the 
Cbz group stacks against the phenylalanine residue in the hydrophobic pocket.         
To study the effect of P2 residue on inhibitor potency, we synthesized seven 
compounds with Cbz-Ala-AA-AAsn (AA= Val, Ile, and Phe) peptide sequence.  The 
results are shown in Table 2.4.  Compounds with valine (31a, m, j) or isoleucine (32a) 
residue at P2 were good to poor inhibitors whereas, those containing phenylalanine at P2 
(33e, j, k) were extremely poor against SmAE and IrAE, confirming that both enzymes 
do not prefer large hydrophobic groups in the S2 position.  With respect to the ethyl ester 
compounds 31a and 32a that differ only at P2, SmAE reacted with both equally, whereas 
inhibition of IrAE was 100-fold better with 32a.  This is a second example of divergent 
SAR between these enzymes and suggests that IrAE can accept larger aliphatic 
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hydrophobic residues at S2.  Previous studies with positional scanning substrate 




 demonstrated that the preferred 
amino acids at P2 are Ala>Val>Ile>Phe and Ile>Ala>Val>Phe, respectively.  Thus, our 
results are in good agreement with these data. 
                
Table 2.4.  Inhibition of SmAE and IrAE by Cbz Protected Tripeptide Michael 







31a Cbz-Ala-Val-AAsn-CH=CH-COOEt 100 65 
31m Cbz-Ala-Val-AAsn-CH=CH-CONHCH2-1-naphthyl 1050 350 
31j Cbz-Ala-Val-AAsn-CH=CH-CO-tetrahydroquinoline 138 13 
32a Cbz-Ala-Ile-AAsn-CH=CH-COOEt 280 0.52 
33e Cbz-Ala-Phe-AAsn-CH=CH-CONHCH2-2-furyl >2,000 1,800 
33j Cbz-Ala-Phe-AAsn-CH=CH-CO-tetrahydroquinoline >2,000 500 
33k Cbz-Ala-Phe-AAsn-CH=CH-CO-tetrahydroisoquinoline >2,000 500 
 
 
Inhibition of SmAE and IrAE with Aza-peptidyl Epoxides.  The IC50 values of 
eight aza-peptide epoxide inhibitors are listed in Table 2.5.  Comparison of the three aza-
peptidyl epoxide inhibitors with Pip-Ala-Ala-AAsn sequence showed that the ester 
analog (34q) and the monosubstituted amide analog (34s) were moderate inhibitors 
against SmAE with the IC50 values of 220 and 160 nM, respectively; however, the 
disubstituted amide derivative (34r) was best with an IC50 value of 72 nM.  For IrAE, all 
compounds were moderate inhibitors but unlike SmAE, IrAE favored the 
 31 
monosubstituted amide analog (IC50 = 8.5 nM) to the ethyl ester analog (IC50 = 30 nM) 
and the disubstituted amide analog (IC50 = 12 nM).  These results showed that the two 
enzyme differs in their S1' or S2' positions slightly.  Replacement of the piperidine 
residue in the P4 position of compound 34s (SmAE, IC50 = 160 nM, IrAE, IC50 = 8.5 nM) 
with a morpholine residue in compound 35s (IC50 = 60 nM) resulted in an almost three-
fold increase in potency against SmAE, whereas it had almost no effect against IrAE 
(IC50 = 6 nM).   
 







34q Pip-Ala-Ala-AAsn-EP(S,S)-COOEt 220 30 
34r Pip-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 72 12 
34s Pip-Ala-Ala-AAsn-EP(S,S)-CONHCH2-1-naphthyl 160 8.5 
35s Mu-Ala-Ala-AAsn-EP(S,S)-CONHCH2-1-naphthyl 60 6 
35r Mu-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 90 1.7 
35t Mu-Ala-Ala-AAsn-EP(cis)-CON(Bzl)2 N.I. N.I. 
38r Piz-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 150 11 
36r Boc-Piz-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 80 270 
 
To study the effect of stereochemistry on inhibitor potency, we synthesized two 
dibenzyl amide epoxide warheads with (S,S) and cis configurations, and coupled them to  
the Mu-Ala-Ala-AAsn peptidyl precursor to form compounds 35r and 35t, respectively.  
Compound 35t (cis) was inactive against both enzymes, whereas the (S,S) compound 
retained potency.  Accordingly, we suggest that the (cis) stereochemistry of the epoxide 
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unfavorably changes the orientation of the prime side substituents to cause a loss of 
inhibition.  Piz-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 (38r) was a moderate inhibitor against 
both SmAE and IrAE with IC50 values of 150 and 11 nM, respectively.  Replacement of 
the piperazine with tert-butoxycarbonyl piperazine (36r) increased the potency 2-fold 
against SmAE.  On the other hand, the same replacement resulted in 24-fold decrease in 
potency against IrAE.  Extension of the aza-peptides to the P5 position by introduction of 
Boc group resulted in increased potency in all compounds except this one example. 
 
Inhibition of SmAE and IrAE with Aza-peptidyl substrate analog inhibitors. 
Finally, we synthesized five aza-peptidyl substrate analog inhibitors, however, none of 
these compounds inhibited SmAE or IrAE (Table 2.6).   
 







39 Mu-Ala-AAsn-COCH2CH2Ph N.I. N.I. 
40 Pip-Ala-AAsn-CONHPh-2-OPh N.I. N.I. 
41 Mu-Ala-AAsn-CONH-1-naphthyl N.I. N.I. 
42 Cbz-Piz-Ala-AAsn-CONHCH2Ph N.I. N.I. 
43 Mu-Ala-Ala-AAsn-COOCH2Ph N.I. N.I. 
 
Second order inhibition rate constants for a selection of the aza-peptide Michael 
acceptors and epoxides are presented in Table 2.7.  We compared the rates of our 











 for IrAE).  In the case of 
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 0.16 0.64 
Piz-Ala-Ala-AAsn-CH=CH-COOBzl 0.046 0.17 
Boc-Piz-Ala-Ala-AAsn-CH=CH-COOBzl 0.023 0.67 
Piz-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 0.03 0.10 
Pip-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 0.037 0.45 
Boc-Piz-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 0.01 0.39 
Boc-Piz-Ala-Ala-AAsn-CH=CH-CON(Bzl)2 0.04 0.35 
Mu-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naph)2 0.4 1.98 
Pip-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naph)2 0.27 0.77 
Cbz-Piz-Ala-Ala-AAsn-CH=CH-CON(CH3)CH2-1-naph 0.084 1.79 
Piz-Ala-Ala-AAsn-CH=CH-CON(CH3)CH2-1-naph 0.16 0.22 
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) have higher rates 





the same rate.  All three compounds have Michael acceptors as a warhead and 
disubstituted amides with aromatic residues. In general, aza-peptide Michael acceptors 













 have higher rates 
than Cbz-Ala-Ala-AAsn-CH=CH-COOEt.  Again, all compounds were aza-peptide 
Michael acceptors with aromatic residues in the P1' position.      
  
Mechanism of Inhibition.  Aza-peptide Michael acceptors and epoxides are 
irreversible inhibitors of Clan CD cysteine proteases.
55
   
 
 
Figure 2.12.  Mechanism of Inhibition of Cysteine Proteases by Michael Acceptor and 
Epoxide Inhibitors. 
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The mechanism of inhibition involves nucleophilic attack by the catalytic cysteine 
residue on the Michael acceptor double bond or epoxide forming a covalent bond and 
irreversibly inhibiting the enzyme.
63
  Theoretically, either C2 or C3 carbon of the 
Michael acceptor and epoxide moiety could be attacked by the active site cysteine 
residue.  X-ray crystal structures of aza-peptide Michael acceptor inhibitors bound to 
caspase-3 and caspase-8 have shown that the nucleophilic attack of the active site 
cysteine residue occurs at the C2 carbon of the double bond.
64
  On the other hand, crystal 
structures of aza-peptide epoxide inhibitors bound to caspase-3 have shown that the site 
of attack is at the C3 carbon of the epoxide moiety.
65
  These structures demonstrate that 
the site of attack is the same in both warheads, i.e., the carbon closest to the aza-peptide 
nitrogen atom (see Figure 2.12 for different numbering of Michael acceptor and epoxide 
moieties).  In view of these data, we suggest that, for AEs, the covalent bond forms at the 
C2 carbon of the Michael acceptors and at the C3 carbon of the epoxides.  
   
CONCLUSION 
 
We have demonstrated that aza-peptide Michael acceptors and epoxides with the 
general structure Boc-AAsn-trans-CH=CHCOR, YCO-Ala-AAsn-trans-CH=CHCOR, 
YCO-Ala-Ala-AAsn-trans-CH=CHCOR and YCO-Ala-Ala-AAsn-EP-COR are 
inhibitors of SmAE and IrAE.  We have shown that tripeptides (YCO-Ala-Ala-AAsn-
trans-CH=CHCOR) are favored over dipeptides (YCO-Ala-AAsn-trans-CH=CHCOR) 
that, in turn, are favored over monopeptides (Boc-AAsn-trans-CH=CHCOR).   
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This research discovered the importance of the S5 subsite in the active sites of 
both SmAE and IrAE.  Extension of the inhibitor structure to P5 with the introduction of 
Cbz and Boc groups resulted in increased potenty.  For some of these compounds, we 
obtained IC50 values as low as 0.14 nM and second order inhibiton rate constants are the 
fastest yet discovered.  We have shown the possible interactions of the aza-peptide 
Michael acceptor inhibitor with the enzyme by studing the crystal structures of caspase-3.  
We proposed for the first time that the inhibitors which are extended to the P5 position 
are interacting with a hydrophobic pocket in the S5 site of SmAE and IrAE.  Both 
enzymes prefer disubstituted amides to monosubstituted amides in the P1' position and 
we found that potency of the inhibitors increased as we increased the hydrophobicity in 
the P1'.   
Aza-peptide Michael acceptor inhibitors were more potent than aza-peptide 
epoxide inhibitors.  We have also determined that the stereochemistry of the epoxide 
warhead is important; (S,S) is favored over (cis).  In addition, both enzymes prefer small 
hydrophobic amino acids like valine and isoleucine in the P2 position, whereas large 
hydrophobic amino acids such as phenylalanine are not tolerated.   
There has been no success in the determination of a crystal structure of the 
asparaginyl endopeptidases. Therefore potent and selective irreversible inhibitors would 
help to determine the structural and enzymatic specificities of the active site of 
asparagine endopeptidases.  There is also an urgent need for the development of new 
inhibitors of SmAE and IrAE due to increasing resistance of the parasites to the current 
drugs.  We have synthesized the most potent inhibitors against same and IrAE reported in 
the literature.  Given the central functions of these enzymes in nutrient acquisition by 
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both parasites, the data and SAR presented here may facilitate the design of selective 
anti-parasitic drugs.   
Significance 
This research increased our understanding of the active sites of both enzymes and 
the interactions of the inhibitors with these enzymes.  The data from this research will 
facilitate the development of therapeutically useful compounds which will be beneficial 




Material and Methods.  Materials were obtained from Acros, Bachem 
Bioscience Inc., or Sigma Aldrich and used without further purification.  The purity of 
each compound was confirmed by TLC, 
1
H NMR, MS, and elemental analysis.  
Chemical shifts are reported in ppm relative to an internal standard (trimethylsilane).  
TLC was performed on Sorbent Technologies (250 µm) silica gel plates.  The 
1
H NMR 
spectra were obtained on a Varian Mercury 400 MHz spectrometer.  Electrospray 
ionization (ESI), fast-atom-bombardment (FAB) and high-resolution mass spectrometry 
were obtained using Micromass Quattro LC and VG Analytical 70-SE instruments.  
Elemental analysis was carried out by Atlantic Microlab Inc., Norcross, GA.  The 
synthetic aza-peptide inhibitors were tested against S. mansoni and I. ricinus AEs by Dr. 




Determination of IC50 values and second-order inhibition rates for 
Asparagine Endopeptidases.  IC50 values were determined exactly as previously 
described.
49
  For second-order rate inhibitions, the substrate Cbz-Ala-Ala-Asn-AMC and 
inhibitors were prepared as 10 and 20 mM stock solutions, respectively, in DMSO.  
Assays were performed at 25
o
C and incorporated either activated recombinant, I. ricinus 
asparaginyl endopeptidase
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or activated recombinant S. mansoni asparaginyl 
endopeptidase.
66
  An aliquot of (100 &l) S. mansoni AE in assay buffer (0.1M citrate-
phosphate buffer at pH 6.8 containing 4 mM DTT) was added to 100 &l inhibitor in assay 
buffer with 20 &M substrate and inhibitor present at 2, 1, 0.8, 0.6, 0.4, 0.2 and 0.1 &M (or 
DMSO alone) added as a 1 &l aliquot.  The progress of inhibition was followed for 2 to 5 
minutes, while the uninhibited activity was linear.  An aliquot of (100 &l) I. ricinus AE in 
assay buffer (0.1M citrate-phosphate buffer at pH 6.8 containing 4 mM DTT with 0.1 M 
NaCl) was added to inhibitor, in 100&l assay buffer with inhibitor present at 1, 0.8, 0.5, 
0.25, 0.125, 0.0625, 0.03125 &M and DMSO alone, as above.  Release of free AMC was 
measured at emission and excitation wavelengths of 355 and 460 nm, respectively, in a 
Molecular Devices Flex-Station fluorometer.  Measurements were taken every 1.52 s.  
The rate of inhibition (kobs) was determined at each inhibitor concentration according to 
[P] =/vo / kobs x/[1-/exp(-/kobs x/t )], where [P] is the concentration of product formed over 
time t and vo the initial rate, using non-linear regression analysis (GRAPHPAD PRISM 
3.0a).  If the kobs versus inhibitor concentration could reliably fit a two-step irreversible 
mechanism (r
2
 >/0.9), the inhibition constant Ki and the inactivation constant kinact were 
determined by nonlinear regression analysis according to kobs =/kinact x /[I]o / ([I]o +/K*I x 
/(1+/[S]o / Km)) where [I]o and [S]o are the concentrations of inhibitor and substrate, 
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respectively, and K*I =/Ki x/ (1=/[S]o  /Km).  For those inhibitors with which kobs was 
linear with increasing concentrations of inhibitor, linear regression analysis was used to 
obtain the association constant kass using kobs =/kass x [I]o / (1+/[S]o/Km).  Multiple 
determinations at each inhibitor concentration were performed. 
 General Procedure for the Synthesis of Acyl Alanine Methyl Ester (YCO-
Ala-OCH3).  Alanine methyl ester isocyanate, which is synthesized from alanine 
hydrochloride salt according to the procedure by Nowick et al.,
60
 is dissolved in CH2Cl2 
and cooled down to 0 °C.  Y-H groups, which are commercially available except the 
benzyloxycarbonyl piperazine and tert-butoxycarbonyl piperazine are added to the stirred 
solution of alanine methyl ester isocyanate.  Reaction mixture was stirred vigorously for 
16 h at room temperature.  Solvent was removed under vacuum Purification on a silica 
gel column with the proper eluent gave the product with yields of 72-93%.   
 tert-Butoxycarbonyl piperazine (Boc-Piz).  A solution of di-tert-butyl dicarbonate 
(1 eq) in dichloromethane was added slowly to a solution of piperazine (2 eq) in 
dichloromethane at 0 °C. The reaction mixture was stirred at room temperature overnight. 
The dichloromethane solution was washed with saturated NaHCO3 and water. Diethyl 
ether was added, and the organic phase was washed with water. The organic phase was 
dried with anhydrous Na2SO4 and evaporated. Purification was by column 
chromatography gave the product with 57% yield.  
1
H NMR (CDCl3): 1.42 (s, 9H, Boc), 
2.00 (br s, 1H), 2.78 (m, 4H, piperazine), 3.36 (m, 4H, piperazine).  MS (ESI) m/z 187.1 
[(M + 1)
+
].    
 Benzyloxycarbonyl piperazine (Cbz-Piz).  Monoprotection of piperazine was 
done with benzyl chloroformate (1 eq) and Et3N (1 eq) in dichloromethane.  The solvent 
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was evaporated and the crude product was purified by column chromatography to obtain 
the product with 55% yield.  
1
H NMR (DMSO-d6): 2.33 (s, 1H, NH), 2.62 (m, 4H, 
piperazine), 3.30-3.36 (m, 4H, piperazine), 5.00 (s, 2H, Cbz), 7.15-7.22 (m, 5H, Ph).  MS 
(ESI) m/z 221.0 [(M + 1)
+
].    
The piperidine derivative Pip-Ala-OCH3 was prepared by adding piperidine to 
alanine isocyanate and purified by column chromatography on silica gel using 2:18:5 
MeOH:CH2Cl2:EtOAc as the eluent; white solid, yield 83%.  1H NMR (CDCl3-d): 1.32 
(d, 3H, Ala-CH3), 1.48 (m, 6H, piperidine), 3.27 (m, 4H, piperidine), 3.67 (s, 3H, OCH3), 
4.41 (m, 1H, !-H), 5.05 (d, 1H, NH).  MS (ESI) m/z 215.0 [(M + 1)
+
].   
The morpholine derivative Mu-Ala-OCH3 was prepared by adding morpholine to 
alanine isocyanate and purified by column chromatography on silica gel using 10% 
MeOH/CH2Cl2 as the eluent; yellowish solid, yield 93%.  1H NMR (CDCl3-d): 1.29 (d, 
3H, Ala-CH3), 3.28 (m, 4H, morpholine), 3.58 (m, 4H, morpholine), 3.64 (s, 3H, OCH3), 
4.38 (m, 1H, !-H), 5.25 (s, 1H, NH).  MS (ESI) m/z 217.0 [(M + 1)
+
].   
The tert-butoxycarbonyl piperazine derivative Boc-Piz-Ala-OCH3 was prepared 
by adding tert-butoxycarbonyl piperazine to alanine isocyanate and purified by column 
chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent; white solid, yield 
80%. 
1
H NMR (CDCl3-d): 1.37 (d, 3H, Ala-CH3), 1.44 (s, 9H, Boc), 3.34-3.44 (m, 8H, 
piperazine), 3.72 (s, 3H, OCH3), 4.47 (m, 1H, !-H), 5.08 (s, 1H, NH).  MS (ESI) m/z 
316.2 [(M + 1)
+
].   
The benzyloxycarbonyl piperazine derivative Cbz-Piz-Ala-OCH3 was prepared by 
adding benzyloxycarbonyl piperazine to alanine isocyanate and was purified by column 
chromatography on silica gel using 2:18:5 MeOH:CH2Cl2:EtOAc as the eluent; white 
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solid, yield 72%.  1H NMR (CDCl3-d): 1.31 (d, 3H, Ala-CH3), 3.34-3.36 (m, 4H, 
piperazine), 3.44-3.47 (m, 4H, piperazine), 3.65 (s, 3H, OCH3), 4.39 (m, 1H, !-H), 5.07 
(s, 2H, Cbz), 5.41 (d, 1H, NH), 7.23-7.29 (m, 5H, Ph).  MS (ESI) m/z 350.2 [(M + 1)
+
].   
General Procedure for the Synthesis of Acyl Dipeptide Methyl Ester (YCO-
Ala-Ala-OCH3).  The methyl ester group of Y-Ala-OCH3 was hydrolyzed in MeOH 
using 1 M aqueous NaOH (1.1 eq) under standard deblocking conditions. Y-Ala-OH is 
then coupled to alanine methyl ester hydrochloride (HCl#NH2-Ala-OCH3) using 
DCC/HOBt coupling.  To a stirred solution of the Y-Ala-OH (1 eq) in DMF at -15 °C, 
HOBt (1.5 eq) was added.  Hydrochloride salt of the alanine methyl ester was pretreated 
with NMM (1.5 eq) at -15 °C DMF prior to addition.  DCC (1.5 eq) was added to the 
solution and reaction mixture was allowed to react for 16 h at room temperature.  The 
DMF was evaporated, and the residue was redissolved in EtOAc.  The organic layer was 
washed with 2% citric acid, saturated NaHCO3, saturated NaCl, dried over MgSO4, and 
concentrated.  Purification on a silica gel column with the proper eluent gave the product 
with yields of 60-89%.  
Pip-Ala-OH was obtained by hydrolysis of Pip-Ala-OCH3 in MeOH using 1 M 
aqueous NaOH (1.1 eq); white solid, yield 85%.  
1
H NMR (DMSO-d6): 1.23 (d, 3H, Ala-
CH3), 1.39 (m, 4H, piperidine), 1.49, (d, 2H, piperidine), 3.24 (s, 4H, piperidine), 4.03 
(m, 1H, !-H), 6.50 (d, 1H, NH). 
After coupling Pip-Ala-OH with HCl#NH2-Ala-OCH3, Pip-Ala-Ala-OCH3 was 
purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent; 
white solid, yield 78%.  
1
H NMR (CDCl3-d): 1.37-1.40 (m, 6H, 2 x Ala-CH3), 1.54-1.59 
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(m, 6H, piperidine), 3.31-3.34 (m, 4H, piperidine) 3.73 (s, 3H, OCH3), 4.45-4.53 (m, 2H, 
2 x !-H), 5.21 (s, 1H, NH), 7.12 (s, 1H, NH).  MS (FAB) m/z 286.0 [(M + 1)
+
].   
Mu-Ala-OH was obtained by hydrolysis of Pip-Ala-OCH3 in MeOH using 1 M 
aqueous NaOH (1.1 eq); white solid, yield 89%.  
1
H NMR (DMSO-d6): 1.24 (d, 3H, Ala-
CH3), 3.26 (t, 4H, morpholine) 3.51 (t, 4H, morpholine), 4.05 (m, 1H, !-H), 6.65 (d, 1H, 
NH), 12.21 (br s, 1H, COOH).  MS (FAB) m/z 202.9 [(M + 1)
+
].   
After coupling Mu-Ala-OH with HCl#NH2-Ala-OCH3, Mu-Ala-Ala-OCH3 was 
purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent; 
white solid, yield 60%.  
1
H NMR (CDCl3-d): 1.37 (d, 3H, Ala-CH3), 1.39 (d, 3H, Ala-
CH3), 3.34-3.36 (m, 4H, morpholine), 3.65-3.67 (m, 4H, morpholine) 3.73 (s, 3H, OCH3), 
4.45-4.53 (m, 2H, 2 x !-H), 5.32 (s, 1H, NH), 7.02 (d, 1H, NH).  MS (FAB) m/z 288.2 
[(M + 1)
+
].   
Boc-Piz-Ala-OH was obtained by hydrolysis of Boc-Piz-Ala-OCH3 in MeOH 
using 1 M aqueous NaOH (1.1 eq); white solid, yield 94%.  
1
H NMR (DMSO-d6): 1.24 
(d, 3H, Ala-CH3), 1.38 (s, 9H, Boc), 3.26 (s, 8H, piperazine), 4.04 (m, 1H, !-H), 6.69 (d, 
1H, NH).  
After coupling Boc-Piz-Ala-OH with HCl#NH2-Ala-OCH3, Boc-Piz-Ala-Ala-
OCH3 was purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as 
the eluent; white solid, yield 85%.  
1
H NMR (CDCl3-d): 1.36-1.39 (m, 6H, 2 x Ala-CH3), 
1.44 (s, 9H, Boc), 3.34-3.39 (m, 8H, piperazine), 3.72 (s, 3H, OCH3), 4.44-4.54 (m, 2H, 2 
x !-H), 5.38 (d, 1H, NH), 7.09 (d, 1H, NH). 
Cbz-Piz-Ala-OH was obtained by hydrolysis of Cbz-Piz-Ala-OCH3 in MeOH 
using 1 M aqueous NaOH (1.1 eq); white solid, yield 87%.  
1
H NMR (DMSO-d6): 1.25 
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(d, 3H, Ala-CH3), 3.32-3.34 (m, 8H, piperazine), 4.06 (m, 1H, !-H), 5.07 (s, 2H, Cbz), 
6.72 (d, 1H, NH), 7.28-7.37 (m, 5H, Ph).  
After coupling Cbz-Piz-Ala-OH with HCl#NH2-Ala-OCH3, Cbz-Piz-Ala-Ala-
OCH3 was purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as 
the eluent; white solid, yield 89%.  
1
H NMR (CDCl3-d): 1.38 (m, 6H, Ala-CH3), 3.38 (m, 
4H, piperazine), 3.50 (m, 4H, piperazine), 3.72 (s, 3H, OCH3), 4.46 (m, 1H, !-H), 5.12 (s, 
2H, Cbz), 7.34 (m, 5H, Ph). 
General Procedure for the Synthesis of Cbz Protected Dipeptide Methyl 
Esters (Cbz-Ala-Val(Ile, Phe)-OCH3).  Cbz-Ala-OH is coupled to valine methyl ester 
(isoleucine methyl ester, or phenylalanine methyl ester) using DCC and HOBt coupling.  
To a stirred solution of the Cbz-Ala-OH (1 eq) in DMF at -15 °C, HOBt (1.5 eq) was 
added.  Hydrochloride salt of the valine methyl ester was pretreated with NMM (1.5 eq) 
at -15 °C DMF prior to addition.  DCC (1.5 eq) was added to the solution and reaction 
mixture was allowed to react for 16 h at room temperature.  The DMF was evaporated, 
and the residue was redissolved in EtOAc.  The organic layer was washed with 2% citric 
acid, saturated NaHCO3, saturated NaCl, dried over MgSO4, and concentrated.   
After coupling Cbz-Ala-OH with HCl#NH2-Val-OCH3, Cbz-Ala-Val-OCH3 was 
purified by column chromatography on silica gel using 10% MeOH/CH2Cl2 as the eluent; 
white solid, yield 85%.  
1
H NMR (CDCl3-d): 0.88 (m, 6H, 2 x Val-CH3), 1.39 (d, 3H, 
Ala-CH3), 2.16 (m, 1H, CH), 3.74 (s, 3H, OCH3), 4,27 (m, 1H, !-H), 4.52 (m, 1H, !-H), 
5.12 (s, 2H, Cbz), 5.36 (d, 1H, NH), 6.54 (d, 1H, NH), 7.36–7.32 (m, 5H, Ph).  MS (ESI) 
m/z 337.1 [(M + 1)
+
].   
 44 
After coupling Cbz-Ala-OH with HCl#NH2-Ile-OCH3, Cbz-Ala-Ile-OCH3 was 
purified by column chromatography on silica gel using 1:1 EtOAc:Hexanes as the eluent; 
white solid, yield 89%.  
1
H NMR (CDCl3-d): 0.85-0.89 (m, 6H, 2 x Ile-CH3), 1.08-1.19 
(m, 2H, CH2), 1.29-1.43 (m, 3H, Ala-CH3), 1.86 (m, 1H, CH), 3.70 (s, 3H, OCH3), 4.34 
(q, 1H, !-H), 4.55 (q, 1H, !-H), 5.09 (m, 2H, Cbz), 5.63 (d, 1H, NH), 6.82 (d, 1H, NH), 
7.26-7.36 (m, 5H, Ph).   
After coupling Cbz-Ala-OH with HCl#NH2-Phe-OCH3, Cbz-Ala-Phe-OCH3 was 
purified by column chromatography on silica gel using 2:1 EtOAc:hexane as the eluent; 
white solid, yield 86%.  
1
H NMR (CDCl3-d): 1.32 (d, 3H, Ala-CH3), 3.03-3.16 (m, 2H, 
CH2Ph), 3.70 (s, 3H, OCH3), 4.25 (q, 1H, !-H), 4.85 (q, 1H, !-H), 5.08 (m, 2H, Cbz), 
5.38 (d, 1H, NH), 7.08 (d, 1H, NH), 7.21-7.34 (m, 10 H, 2 x Ph).  MS (ESI) m/z 385.0 
[(M + 1)
+
].   
Peptidyl Hydrazides. Anhydrous hydrazine (10 equiv) was added to a stirred 
solution of a peptidyl methyl ester (1 equiv) in MeOH and the reaction mixture was 
stirred vigorously for 16 h at room temperature. Excess hydrazine and solvent were 
removed under vacuum and the residue was washed with ether several times to give the 
peptidyl hydrazide as a white solid. Compounds were purified further on silica gel 
column using the eluent 10% MeOH/CH2Cl2 when needed.  
Pip-Ala-NH-NH2, white solid, yield 97%.  
1
H NMR (DMSO-d6): 1.15 (d, 3H, 
Ala-CH3), 1.36-1.41 (m, 4H, piperidine), 1.46-1.49 (m, 2H, piperidine), 3.22-3.25 (m, 
4H, piperidine), 4.06-4.12 (m, 3H, "-H and NH2), 6.28 (d, 1H, NH), 8.96 (s, 1H, NH). 
MS (ESI) m/z 215.0 [(M + 1)
+
].   
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Mu-Ala-NH-NH2, white solid, yield 97%.  
1
H NMR (DMSO-d6): 1.16 (d, 3H, 
Ala-CH3), 3.23-3.26 (m, 4H, morpholine), 3.49-3.52 (m, 4H, morpholine), 4.07-4.14 (m, 
3H, "-H and NH2), 6.45 (d, 1H, NH), 8.97 (s, 1H, NH). MS (ESI) m/z 217.0 [(M + 1)
+
].   
Cbz-Piz-Ala-NH-NH2, white solid, yield 98%.  
1
H NMR (DMSO-d6): 1.16 (d, 
3H, AlaCH3), 3.30-3.34 (m, 8H, piperazine), 4.11 (m, 3H, "-H and NH2), 5.07 (s, 2H, 
Cbz), 6.51 (d, 1H, NH), 7.34 (m, 5H, Ph), 8.95 (s, 1H, NH). 
Pip-Ala-Ala-NH-NH2, white solid, yield 91%.  
1
H NMR (DMSO-d6): 1.15-1.18 
(m, 6H, 2 x Ala-CH3), 1.38-1.40 (m, 4H, piperidine), 1.48-1.52 (m, 2H, piperidine), 3.25-
3.27 (m, 4H, piperidine), 4.06 (m, 1H, "-H), 4.17-4.21 (m, 3H, "-H and NH2), 6.40 (d, 
1H, NH), 7.71 (d, 1H, NH), 9.01 (s, 1H, NH).  MS (ESI) m/z 286.0 [(M + 1)
+
].   
Mu-Ala-Ala-NH-NH2, white solid, yield 92%.  
1
H NMR (DMSO-d6): 1.15-1.18 
(m, 6H, 2 x Ala-CH3), 3.25-3.28 (m, 4H, morpholine), 3.51-3.53 (m, 4H, morpholine), 
4.09 (q, 1H, "-H), 4.16-4.23 (m, 3H, "-H and NH2), 6.53 (d, 1H, NH), 7.77 (d, 1H, NH), 
8.99 (s, 1H, NH). 
Boc-Piz-Ala-Ala-NH-NH2, white solid, yield 66%.  
1
H NMR (DMSO-d6): 1.15-
1.19 (m, 6H, 2 x Ala-CH3), 1.38 (s, 9H, boc), 3.27 (s, 8H, piperazine), 4.08 (q, 1H, !-H), 
4.18-4.19 (m, 3H, !-H and NH2), 6.56 (d, 1H, NH), 7.76 (d, 1H, NH), 8.99 (s, 1H, NH). 
Cbz-Piz-Ala-Ala-NH-NH2, white solid, yield 98%.  
1
H NMR (DMSO-d6): 1.15-
1.18 (m, 6H, 2 x Ala-CH3), 3.45 (s, 8H, piperazine), 4.03-4.08 (m, 1H, !-H), 4.15-4.19 
(m, 3H, !-H and NH2), 5.06 (s, 2H, Cbz), 6.58 (d, 1H, NH), 7.29-7.35 (m, 5H, Ph), 7.78 
(d, 1H, NH), 9.00 (s, 1H, NH). 
Cbz-Ala-Val-NH-NH2, white solid, yield 98%.  
1
H NMR (DMSO-d6): 0.78-0.81 
(m, 6H, 2 x Val-CH3), 1.15 (d, 3H, Ala-CH3), 1.82 (m, 1H, Val-CH), 4.02-4.11 (m, 2H, 2 
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x !-H), 4.23 (s, 2H, NH2), 4.99 (s, 2H, Cbz), 7.29-7.34 (m, 5H, Ph),7.46 (d, 1H, NH), 
7.68 (d, 1H, NH), 9.15 (s, 1H, NH). 
 Cbz-Ala-Ile-NH-NH2, white solid, yield 98%.  
1
H NMR (DMSO-d6): 0.71-0.84 
(m, 6H, 2 x Ala-CH3), 0.97-1.05 (m, 1H, CH), 1.15 (d, 3H, CH3), 1.38-1.44 (m, 1H, CH), 
1.61-1.63 (m, 1H, CH), 4.05-4.13 (m, 2H, 2 x !-H), 4.23 (s, 2H, NH2), 4.99 (m, 2H, 
Cbz), 7.29-7.36 (m, 5H, Ph),7.45 (d, 1H, NH), 7.70 (d, 1H, NH), 9.16 (s, 1H, NH). 
Cbz-Ala-Phe-NH-NH2, white solid, yield 97%.  
1
H NMR (DMSO-d6): 1.08 (d, 
3H, Ala-CH3), 2.78-2.97 (m, 2H, CH2Ph), 3.99 (q, 1H, !-H), 4.20 (br s, 2H, NH2), 4.42 
(q, 1H, !-H), 4.99 (m, 2H, Cbz), 7.14-7.39 (m, 11 H, 2 x Ph and NH), 7.92 (d, 1H, NH), 
9.14 (s, 1H, NH).  MS (ESI) m/z 385.2 [(M + 1)
+
].   
General Procedure for the Amidation of Peptidyl-NH-NH-CH2COOEt.  To a 
stirred solution of a peptidyl hydrazide (1 equiv) in DMF, NMM (1.1 equiv) and  tert-
butyl bromoacetate (1.1 equiv) were added dropwise at -15 °C and the mixture was 
allowed to react for 36 h at room temperature. The solvent was removed under vacuum.  
Purification on a silica gel column with the proper eluent gave the products with yields of 
20-90%.  
Boc-NH-NH-CH2COOEt was purified by column chromatography on silica gel 
using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 90%.  
1
H NMR (DMSO-d6): 
1.26 (t, 3H, NHCH2COCH2CH3), 1.45 (m, 9H, Boc), 4.11 (s, 2H, NCH2CO), 4.19 (q, 2H, 
NHCH2COCH2CH3).  MS (ESI) m/z 219.2 [(M + 1)
+
].  
Pip-Ala-NH-NH-CH2COOEt was purified by column chromatography on silica 
gel using 15% MeOH/CH2Cl2 as the eluent; yellow oil, yield 26%.  
1
H NMR (DMSO-d6): 
0.78-0.84 (m, 3H, NHCH2COCH2CH3), 1.13-1.19 (m, 3H, Ala-CH3), 1.38-1.41 (m, 4H, 
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piperidine), 1.47-1.50 (m, 2H, piperidine), 3.23-3.25 (m, 4H, piperidine), 3.45 (d, 2H, 
NHCH2COCH2CH3), 4.03-4.09 (m, 3H, !-H and NHCH2COCH2CH3), 5.09 (q, 1H, NH), 
6.32 (d, 1H, NH), 9.16 (d, 1H, NH).  MS (ESI) m/z 301.0 [(M + 1)
+
].   
Mu-Ala-NH-NH-CH2COOEt was purified by column chromatography on silica 





H NMR (DMSO-d6): 0.78-0.84 (m, 3H, NHCH2COCH2CH3), 1.14-1.18 (m, 
3H, Ala-CH3), 3.20-3.29 (m, 4H, morpholine), 3.45 (d, 2H, NHCH2COCH2CH3), 3.49-
3.55 (m, 4H, CH2OCH2 morpholine), 4.03-4.10 (m, 3H, !-H and NHCH2COCH2CH3), 
5.10 (d, 1H, NH), 6.48 (d, 1H, NH), 9.23 (d, 1H, NH).  
Cbz-Piz-Ala-NH-NH-CH2COOEt was purified by column chromatography on 
silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 44%.  
1
H NMR 
(DMSO-d6): 1.14-1.18 (m, 6H, Ala-CH3 and NHCH2COCH2CH3), 3.30-3.33 (m, 8H, 
piperazine) 3.45 (d, 2H, NHCH2COCH2CH3), 4.03-4.10 (m, 3H, !-H and 
NHCH2COCH2CH3), 5.07 (s, 2H, Cbz), 6.55 (d, 1H, NH), 7.29-7.36 (m, 5H, Ph), 9.23 (d, 
1H, NH).  MS (ESI) m/z 436.3 [(M + 1)
+
].   
Pip-Ala-Ala-NH-NH-CH2COOEt was purified by column chromatography on 
silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 20%.  
1
H NMR 
(DMSO-d6): 1.13-1.18 (m, 9H, 2 x Ala-CH3 and NHCH2COCH2CH3), 1.37-1.40 (m, 4H, 
piperidine), 1.48-1.52 (m, 2H, piperidine), 3.25 (t, 4H, piperidine), 3.44 (d, 2H, 
NHCH2COCH2CH3), 4.04-4.09 (m, 3H, !-H and NHCH2COCH2CH3), 4.15 (m, 1H, !-
H), 5.15 (m, 1H, NH), 6.40 (d, 1H, NH), 7.74 (d, 1H, NH), 9.32 (d, 1H, NH).  
Mu-Ala-Ala-NH-NH-CH2COOEt was purified by column chromatography on 




(DMSO-d6): 0.78-0.84 (m, 6H, 2 x CH3), 1.14-1.18 (m, 6H, 2 x CH3), 3.25-3.32 (m, 4H, 
morpholine), 3.44 (d, 2H, NHCH2COCH2CH3), 3.50-3.53 (m, 4H, morpholine), 4.04-
4.09 (m, 3H, !-H and NHCH2COCH2CH3), 4.18 (q, 1H, !-H), 5.15 (m, 1H, NH), 6.52 (d, 
1H, NH), 7.81 (d, 1H, NH), 9.29 (d, 1H, NH).  
Boc-Piz-Ala-Ala-NH-NH-CH2COOEt was purified by column chromatography 
on silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 50%.  
1
H NMR 
(DMSO-d6): 1.26 (t, 3H, NHCH2COCH2CH3), 1.34-1.37 (m, 6H, 2 x Ala-CH3), 1.45 (s, 
9H, Boc), 3.37-3.42 (m, 10H, piperazine and NHCH2COCH2CH3), 4.15-4.22 (m, 2H, 
NHCH2COCH2CH3), 4.39 (m, 1H, !-H), 4.46 (m, 1H, !-H) and NHCH2COCH2CH3), 
5.54 (d, 1H, NH), 7.35 (d, 1H, NH), 8.89 (s, 1H, NH). 
Cbz-Piz-Ala-Ala-NH-NH-CH2COOEt was purified by column chromatography 
on silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 57%.  
1
H NMR 
(DMSO-d6): 1.12-1.18 (m, 9H, 2 x Ala-CH3 and NHCH2COCH2CH3), 3.32-3.34 (m, 8H, 
piperazine) 3.44 (d, 2H, NHCH2COCH2CH3), 4.03-4.10 (m, 4H, 2 x !-H and 
NHCH2COCH2CH3), 5.04 (s, 2H, Cbz), 6.59 (d, 1H, NH), 7.29-7.35 (m, 5H, Ph), 7.81 (d, 
1H, NH), 9.29 (d, 1H, NH). 
Cbz-Ala-Val-NH-NH-CH2COOEt was purified by column chromatography on 
silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 64%.  
1
H NMR 
(DMSO-d6): 0.78-0.84 (m, 6H, 2 x CH3), 1.14-1.18 (m, 6H, 2 x CH3), 1.84 (m, 1H, CH) 
3.48 (d, 2H, NHCH2COCH2CH3), 4.02-4.08 (m, 4H, 2 x !-H and NHCH2COCH2CH3), 
4.99 (m, 2H, Cbz), 7.28-7.34 (m, 5H, Ph), 7.46 (d, 1H, NH), 7.70 (d, 1H, NH).  
Cbz-Ala-Ile-NH-NH-CH2COOEt was purified by column chromatography on 




(DMSO-d6): 0.72-0.82 (m, 6H, 2 x CH3), 0.97 (m, 1H, CH), 1.14 (m, 6H, 2 x CH3), 1.35 
(m, 1H, CH), 1.60 (m, 1H, CH), 3.38 (s, 2H, NHCH2CO), 4.03-4.19 (m, 4H, COCH2CH3 
and 2 x !-H), 4.99 (m, 2H, Cbz), 7.29-7.34 (m, 5H, Ph), 7.46 (d, 1H, NH), 7.66 (d, 1H, 
NH), 9.44 (s, 1H, NH). 
Cbz-Ala-Phe-NH-NH-CH2COOEt was purified by column chromatography on 
silica gel using 10% MeOH/CH2Cl2 as the eluent; white solid, yield 53%.  
1
H NMR 
(DMSO-d6): 1.09 (d, 3H, Ala-CH3), 1.15-1.19 (t, 3H, NHCH2COCH2CH3), 2.71 (s, 1H, 
NH) 2.76-2.92 (m, 2H, CH2Ph), 3.33-3.39 (m, 2H, NHCH2COCH2CH3) 3.98-4.08 (m, 
3H, !-H and NHCH2COCH2CH3), 4.21 (s, 1H, NH), 4.43 (q, 1H, !-H), 4.99 (m, 2H, 
Cbz), 7.15-7.41 (m, 10H, 2 x Ph), 7.93 (d, 1H, NH), 9.13 (s, 1H, NH).  
General Procedure for the Synthesis of Peptidyl-NH-NH-CH2CONH2.  The 
peptidyl-NH-NHCH2COOEt (1 eq) was dissolved in a 7 N solution (100 eq) of NH3 in 
methanol and a small amount of DMF, and allowed to stir on an ice bath.  To this 
solution was added catalytic NaCN (0.1 eq).  The flask was closed with a rubber septum 
and allowed to stir at 4 °C for five days.  The solvent was evaporated and the product was 
purified by column chromatography on a silica gel using the proper eluent gave the 
products with yields of 34-86%.  
Boc-NH-NH-CH2CONH2 was purified by column chromatography on silica gel 
using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 80%.  
1
H NMR (DMSO-d6): 
1.36 (s, 9H, Boc), 3.16 (s, 2H, NCH2CO), 4.96 (d, 1H, NH), 7.16 (s, 1H, NH), 7.38 (s, 
1H, NH), 8.24 (s, 1H, NH).  MS (ESI) m/z 189.9 [(M + 1)
+
].   
Pip-Ala-NH-NH-CH2CONH2 was purified by column chromatography on silica 




d6): 1.15 (d, 3H, Ala-CH3), 1.38-1.41 (m, 4H, piperidine), 1.47-1.50 (m, 2H, piperidine), 
3.17 (d, 2H, NCH2CO), 3.23-3.26 (m, 4H, piperidine), 4.04 (q, 1H, !-H), 5.13 (d, 1H, 
NH), 5.36 (d, 1H, NH), 7.10 (s, 1H, NH), 7.46 (s, 1H, NH), 9.18 (d, 1H, NH).  MS (ESI) 
m/z 272.0 [(M + 1)
+
].   
Mu-Ala-NH-NH-CH2CONH2 was purified by column chromatography on silica 
gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 53%.  
1
H NMR (DMSO-
d6): 1.16 (d, 3H, Ala-CH3), 3.18 (d, 2H, NCH2CO), 3.25-3.26 (m, 4H, morpholine), 3.50-
3.52 (m, 4H, morpholine), 4.02-4.09 (m, 1H, !-H), 5.14 (d, 1H, NH), 6.52 (d, 1H, NH), 
7.12 (s, 1H, NH), 7.46 (s, 1H, NH), 9.23 (d, 1H, NH).  MS (ESI) m/z 274.0 [(M + 1)
+
].  
Cbz-Piz-Ala-NH-NH-CH2CONH2 was purified by column chromatography on 
silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 62%.  
1
H NMR 
(DMSO-d6): 1.16 (d, 3H, Ala-CH3) 3.18 (d, 2H, NCH2CO), 3.31-3.33 (m, 8H, 
piperazine), 4.05 (m, 1H, !-H), 5.07 (s, 2H, Cbz), 5.15 (d, 1H, NH), 6.58 (d, 1H, NH), 
7.11 (s, 1H, NH), 7.30-7.38 (m, 5H, Ph), 7.45 (s, 1H, NH), 7.85 (d, 1H, NH), 9.23 (d, 1H, 
NH). 
Pip-Ala-Ala-NH-NH-CH2CONH2 was purified by column chromatography on 
silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 58%.  
1
H NMR 
(DMSO-d6): 1.15-1.18 (m, 6H, 2 x Ala-CH3), 1.40 (s, 4H, piperidine), 1.48-1.51 (m, 2H, 
piperidine), 3.17 (d, 2H, NCH2CO), 3.21-3.27 (m, 4H, piperidine), 4.06 (q, 1H, !-H), 
4.13 (q, 1H, !-H), 5.19 (d, 1H, NH), 6.40 (d, 1H, NH), 7.11 (s, 1H, NH), 7.42 (s, 1H, 
NH), 7.79 (d, 1H, NH), 9.29 (d, 1H, NH).  MS (ESI) m/z 343.1 [(M + 1)
+
].   
Mu-Ala-Ala-NH-NH-CH2CONH2 was purified by column chromatography on 




(DMSO-d6): 1.16-1.19 (m, 6H, 2 x Ala-CH3), 3.17 (d, 2H, NCH2CO), 3.26-3.27 (m, 4H, 
morpholine), 3.50-3.53 (m, 4H, morpholine), 4.07 (q, 1H, !-H), 4.14 (q, 1H, !-H), 5.19 
(d, 1H, NH), 6.54 (d, 1H, NH), 7.12 (s, 1H, NH), 7.42 (s, 1H, NH), 7.86 (d, 1H, NH), 
9.27 (d, 1H, NH). 
Boc-Piz-Ala-Ala-NH-NH-CH2CONH2 was purified by column chromatography 
on silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 67%.  
1
H NMR 
(DMSO-d6): 1.16-1.19 (m, 6H, 2 x Ala-CH3), 1.39 (s, 9H, Boc), 3.17 (d, 2H, NCH2CO), 
3.27-3.33 (m, 8H, piperazine), 4.07 (q, 1H, !-H), 4.14 (q, 1H, !-H), 5.19 (d, 1H, NH), 
6.57 (d, 1H, NH), 7.11 (s, 1H, NH), 7.41 (s, 1H, NH), 7.85 (d, 1H, NH), 9.26 (d, 1H, 
NH). 
Cbz-Piz-Ala-Ala-NH-NH-CH2CONH2 was purified by column chromatography 
on silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 34%.  
1
H NMR 
(DMSO-d6): 1.15-1.19 (m, 6H, 2 x Ala-CH3), 3.17 (d, 2H, NCH2CO), 3.27-3.32-3.35 (m, 
8H, piperazine), 4.07 (q, 1H, !-H), 4.14 (q, 1H, !-H), 5.07 (s, 2H, Cbz), 5.20 (d, 1H, 
NH), 6.60 (d, 1H, NH), 7.12 (s, 1H, NH), 7.23-7.35 (m, 5H, Ph), 7.41 (s, 1H, NH), 7.87 
(d, 1H, NH), 9.27 (d, 1H, NH). 
Cbz-Ala-Val-NH-NH-CH2CONH2 was purified by column chromatography on 
silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 41%.  
1
H NMR 
(DMSO-d6): 0.78-0.81 (m, 6H, 2 x Val-CH3), 1.16 (d, 3H, Ala-CH3), 1.85 (m, 1H, CH) 
3.40 (d, 2H, NHCH2CO), 4.09-4.13 (m, 2H, 2 x !-H), 4.99 (m, 2H, Cbz), 5.27 (d, 1H, 
NH) 7.13 (s, 1H, NH) 7.28-7.32 (m, 5H, Ph), 7.45 (s, 1H, NH), 7.73 (d, 1H, NH), 9.46 (d, 
1H, NH).  
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Cbz-Ala-Ile-NH-NH-CH2CONH2 was purified by column chromatography on 
silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 25%.  
1
H NMR 
(DMSO-d6): 0.76-0.79 (m, 6H, 2 x Ile-CH3), 1.02 (m, 1H, CH), 1.14 (d, 3H, Ala-CH3), 
1.40 (m, 1H, CH), 1.63 (m, 1H, CH),  3.18 (d, 2H, NHCH2CO), 4.00-4.10 (m, 2H, 2 x !-
H), 4.99 (m, 2H, Cbz), 5.29 (d, 1H, NH), 7.15-7.46 (m, 7H, Ph and 2 x NH), 7.77 (d, 1H, 
NH), 9.47 (d, 1H, NH). 
Cbz-Ala-Phe-NH-NH-CH2CONH2 was purified by column chromatography on 
silica gel using 15% MeOH/CH2Cl2 as the eluent; white solid, yield 64%.  
1
H NMR 
(DMSO-d6): 1.10 (d, 3H, Ala-CH3), 2.80-2.89 (m, 2H, CH2Ph), 3.13 (d, 2H, NHCH2CO) 
4.00 (q, 1H, !-H), 4.38 (q, 1H, !-H), 4.99 (m, 2H, Cbz), 5.21 (d, 1H, NH), 7.12-7.40 (m, 
12H, 2 x Ph and 2 x NH), 7.93 (s, 1H, NH), 7.97 (s, 1H, NH).  
General Procedure for the Synthesis of Fumaric Acid Monoamides by the 
Mixed Anhydride Coupling Method.  Coupling of the amine precursors to monoethyl 
fumarate was accomplished using the mixed anhydride coupling method.  To a solution 
of the monoethyl fumarate (1 eq) in CH2Cl2 at -20 °C was added N-methylmorpholine 
(NMM, 1 eq) followed by isobutyl chloroformate (iBCF, 1 eq).  After the reaction 
mixture was allowed to stir for 30 min, the amine (1 eq) was added to the mixture.  
Hydrochloride salts of the amine were pretreated with NMM (1 eq) at -20 °C in CH2Cl2 
prior to addition.  After 30 min the reaction was continued to stir overnight at room 
temperature.  The methylene chloride was evaporated and the residue was redissolved in 
ethyl acetate and washed with 2% citric acid, saturated NaHCO3, saturated NaCl, dried 
over MgSO4, and concentrated. The product was purified by column chromatography as 
needed.   
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trans-3-Benzyloxycarbonylpropenoic Acid or Monobenzyl Fumarate (2b, 
HOOCCH=CHCOOBzl).  Equimolar amounts of fumaric acid and benzyl alcohol were 
dissolved in anhydrous DMF.  NMM (1 eq) was added at 0 ºC followed by EDC after 15 
minutes.  The reaction was stirred over night at room temperature.  DMF was evaporated 
and the crude residue was redissolved in EtOAc.  The product was extracted with 
saturated aqueous NaHCO3.  The aqueous layer was then acidified with 1 N HCl to pH 2.  
The product was extracted with EtOAc, and the organic layer was washed with water and 
dried with MgSO4.  The solvent was evaporated and the crude residue was subjected to 
column chromatography to give a white powder (51% yield).  
1
H-NMR (DMSO-d6): 5.21 
(s, 2H, CH=CH-COOCH2Ph), 6.73 (s, 2H, CH=CH-COOCH2Ph), 7.29-7.43 (m, 5H, Ph).  
MS (ESI) m/z 207 [(M + 1)
+
]. 
trans-3-Cyclopropylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONH-cyclopropyl) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and cyclopropylamine.  Purification by 
column chromatography using 2:1 Hexanes:EtOAc as the eluent gave a white powder 
(84% yield).  
1
H-NMR (CDCl3): 0.56-0.59 (m, 2H, CH2), 0.80-0.82 (m, 2H, CH2), 1.28 
(t, 3H, CH3), 2.81-2.84 (m, 1H, CH), 4.20 (q, 2H, CH2CH3) 6.77-6.81 (d, 2H, 
CH=CHCON and NH), 6.90-6.94 (d, 1H, CH=CHCON). 
 trans-3-Cyclopropylcarbamoylpropenoic Acid (2c, HOOCCH=CHCONH-
cyclopropyl).  EtOOCCH=CHCONH-cyclopropyl was hydrolyzed in EtOH using NaOH 
(1 M aqueous, 1.1 eq) under standard deblocking conditions to give a white solid (91% 
yield).  
1
H-NMR (DMSO, d6): 0.41-0.45 (m, 2H, CH2), 0.64-0.69 (m, 2H, CH2), 2.69-
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2.76 (m, 1H, CH), 6.45-6.49 (d, 1H, CH=CHCON), 6.78-6.62 (d, 1H, CH=CHCON), 
8.53 (d, 1H, NH). 
trans-3-Cyclohexylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONH-cyclohexyl) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and cyclohexylamine.  Purification by column 
chromatography using 2:1 EtOAc:hexane as the eluent gave a white powder (63% yield). 
 
trans-3-Cyclohexylcarbamoylpropenoic Acid (2d, HOOCCH=CHCONH-
cyclohexyl).  EtOOCCH=CHCONH-cyclohexyl was hydrolyzed in EtOH using NaOH (1 
M aqueous, 1.1 eq) under standard deblocking conditions to give a white solid (81% 
yield).  
1
H-NMR (DMSO-d6): 0.82-0.90 (m, 2H, CH2), 1.07-1.39 (m, 4H, 2 x CH2), 1.59-
1.65 (m, 5H, 2 x CH2 and CH), 2.98 (t, 2H, NHCH2), 6.45-6.49 (d, 1H, J = 15.6, 
CH=CHCON), 6.91-6.95 (d, 1H, J = 15.6, CH=CHCON), 8.43 (t, 1H, NH).
 
trans-3-(2-Furyl)carbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONHCH2-2-furyl) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and furylamine.  Purification by column 
chromatography using 5% MeOH/CH2Cl2 as the eluent gave yellow oil. (84% yield). 
1
H-
NMR (CDCl3): 1.26 (t, 3H, CH3CH2), 4.14-4.19 (q, 2H, CH3CH2), 4.50 (d, 2H, NHCH2), 
6.22-6.23 (d, 1H, furyl), 6.28-6.29 (d, 1H, furyl), 6.79-6.83 (d, 1H, CH=CHCON) 6.92 (t, 
1H, NH) 6.98-7.02 (d, 1H, CH=CHCON), 7.32 (s, 1H, furyl).
 
trans-3-(2-Furyl)carbamoylpropenoic Acid (2e, HOOCCH=CHCONHCH2-2-
furyl).  EtOOCCH=CHCONHCH2-2-furyl was hydrolyzed in EtOH using NaOH (1 M 
aqueous, 1.1 eq) under standard deblocking conditions to give a white solid (79% yield).  
1
H-NMR (DMSO-d6): 4.38 (d, 2H, NHCH2), 6.29-6.30 (d, 1H, furyl), 6.40-6.41 (d, 1H, 
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furyl), 6.53-6.57 (d, 1H, CH=CHCON), 6.93-6.97 (d, 1H, CH=CHCON), 7.60 (s, 1H, 
furyl), 8.96 (t, 1H, NH).
 
trans-3-Benzylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONHBzl) was obtained by mixed anhydride coupling of equimolar 
amounts of monoethyl fumarate and benzylamine.  Purification by column 
chromatography using 5% MeOH/CH2Cl2 gave a white powder (81% yield).  
1
H-NMR 
(DMSO-d6): 1.20-1.24 (t, 3H, CH2CH3), 4.14-4.19 (q, 2H, CH2CH3), 4.37 (d, 2H, 
NCH2Ph), 6.57-6.61 (d, 1H, CH=CHCON), 7.03-7.07 (d, 1H, CH=CHCON), 7.22-7.34 
(m, 5H, Ph), 9.04 (t, 1H, NH).
 
trans-3-Benzylcarbamoylpropenoic Acid (2f, HOOCCH=CHCONHBzl).  
EtOOCCH=CHCONHBzl was hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) 
under standard deblocking conditions to give a white solid (73% yield).  
1
H-NMR 
(DMSO-d6): 4.36 (d, 2H, NCH2Ph), 6.52-6.56 (d, 1H, CH=CHCON), 6.95-6.99 (d, 1H, 
CH=CHCON), 7.23-7.33 (m, 5H, Ph), 8.98 (t, 1H, NH).  MS (ESI) m/z 206 [(M + 1)
+
]. 
trans-3-Phenylethylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONHCH2CH2Ph) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and phenylethylamine to give a clear colorless 
syrup (78% yield).   
trans-3-Phenylethylcarbamoylpropenoic Acid (2g, 
HOOCCH=CHCONHCH2CH2Ph).  EtOOCCH=CHCONHCH2CH2Ph was hydrolyzed 
in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking conditions to give 
a clear, colorless syrup (81% yield).  
1
H-NMR (DMSO-d6): 3.54 (t, 2H, N-CH2-CH2-Ph), 
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3.61 (t, 2H, N-CH2-CH2-Ph) 6.43-6.47 (d, 1H, J = 15.2 Hz, CH=CHCON), 6.98-7.02 (d, 
1H, J = 15.6 Hz, CH=CHCON), 7.14-7.31 (m, 5H, Ph). 
 trans-3-Phenylpropylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONHCH2CH2CH2Ph) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and 3-phenyl-1-propylamine.  Purification by 
column chromatography using 1:1 EtOAc:hexane gave a white powder (80% yield).   
trans-3-Phenylpropylcarbamoylpropenoic Acid (2h, 
HOOCCH=CHCONHCH2CH2CH2Ph).  EtOOCCH=CHCONHCH2CH2CH2Ph was 
hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white powder (81% yield).  
1
H-NMR (DMSO-d6): 1.68-1.76 (m, 2H, 
NH-CH2-CH2-CH2-Ph), 2.49-2.59 (t, 2H, NH-CH2-CH2-CH2-Ph), 3.12-3.17 (q, 2H, NH-
CH2-CH2-CH2-Ph) 6.47-6.51 (d, 1H, J = 15.6 Hz, CH=CHCON), 6.90-6.94 (d, 1H, J = 
15.6 Hz, CH=CHCON), 7.15-7.28 (m, 5H, Ph), 8.51 (t, 1H, NH). 
trans-3-(3,4-Dimethoxybenzylcarbamoyl)propenoic Acid Ethyl Ester 
(EtOOCCH =CH-CONHCH2Ph-3,4-OCH3) was obtained by mixed anhydride 
coupling of equimolar amounts of monoethyl fumarate and 3,4-
dimethoxyphenylmethanamine.  Purification by column chromatography using 5% 
MeOH/CH2Cl2 gave a white powder (69% yield).  
1
H-NMR (DMSO-d6): 1.22 (t, 3H, 
CH3), 3.70-3.72 (d, 6H, 2 x OCH3), 4.16 (q, 2H, CH2CH3), 4.29 (d, 2H, NHCH2), 6.57-
6.61 (d, 1H, CH=CHCON), 6.76-6.79 (d, 1H, Ph), 6.87-6.89 (d, 2H, Ph), 7.02-7.06 (d, 
1H, CH=CHCON), 8.92 (t, 1H, NH). 
trans-3-(3,4-Dimethoxybenzylcarbamoyl)propenoic Acid (2i, HOOCCH 
=CH-CONHCH2Ph-3,4-OCH3).  EtOOCCH =CH-CONHCH2Ph-3,4-OCH3 was 
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hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white powder (72% yield).   
trans-3-(3,4-Dihydro-2H-quinolin-1-ylcarbonyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CHCO-tetrahydroquinoline) was obtained by mixed anhydride coupling 
of equimolar amounts of monoethyl fumarate and 1,2,3,4-tetrahydroquinoline to give a 
brown syrup (83% yield).  
1
H-NMR (CDCl3): 1.29 (t, 3H, CH3CH2OC), 1.99-2.02 (m, 
2H, N-CH2-CH2-CH2), 2.73-2.76 (t, 1H, N-CH2-CH2-CH2), 3.86-3.98 (t, 1H, N-CH2-
CH2-CH2), 4.24-4.30 (q, 2H, CH3CH2OOC), 6.78-6.82 (dd, 1H, J = 14.8 Hz, 
CH=CHCON), 7.18-7.22 (m, 4H, quinoline), 7.44-7.48 (d, 1H, J = 14.8 Hz, 
CH=CHCON). 
trans-3-(3,4-Dihydro-2H-quinolin-1-ylcarbonyl)propenoic Acid (2j, 
HOOCCH=CHCO-tetrahydroquinoline).  EtOOCCH=CHCO-tetrahydroquinoline was 
hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a clear syrup, which was recrystallized using cold EtOAc to give a 
yellow powder. (78% yield).  
1
H-NMR (DMSO-d6): 1.84-1.91 (m, 2H, N-CH2-CH2-
CH2), 2.68-2.71 (t, 1H, N-CH2-CH2-CH2), 3.71-3.75 (t, 1H, N-CH2-CH2-CH2), 6.56-6.60 
(d, 1H, J = 15.6 Hz, CH=CHCON), 7.06-7.24 (m, 5H, quinoline and CH=CHCON). 
trans-3-(3,4-Dihydro-2H-quinolin-1-ylcarbonyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CHCO-tetrahydroisoquinoline) was obtained by mixed anhydride 
coupling of equimolar amounts of monoethyl fumarate and 1,2,3,4-
tetrahydroisoquinoline to give a brown syrup (83% yield).  
1
H-NMR (CDCl3): 1.29 (t, 
3H, CH3CH2OC), 1.99-2.02 (m, 2H, N-CH2-CH2-CH2), 2.73-2.76 (t, 1H, N-CH2-CH2-
CH2), 3.86-3.98 (t, 1H, N-CH2-CH2-CH2), 4.24-4.30 (q, 2H, CH3CH2OOC), 6.78-6.82 
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(dd, 1H, J = 14.8 Hz, CH=CHCON), 7.18-7.22 (m, 4H, quinoline), 7.44-7.48 (d, 1H, J = 
14.8 Hz, CH=CHCON). 
trans-3-(3,4-Dihydro-2H-quinolin-1-ylcarbonyl)propenoic Acid (2k, 
HOOCCH=CHCO-tetrahydroisoquinoline).  EtOOCCH=CHCO-tetrahydroquinoline 
was hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a clear syrup, which was recrystallized using cold EtOAc to give a 
yellow powder (68% yield).  
1
H-NMR (DMSO-d6): 1.2.78-2.87 (m, 2H, CH2NCH2CH2), 
3.71-3.78 (m, 2H, CH2NCH2CH2), 4.66-4.76 (d, 2H, CH2NCH2CH2CH2), 6.50-6.54 (d, 
1H, CH=CHCON), 7.16-7.21 (m, 4H, quinoline), 7.43-7.49 (d, 1H, CH=CHCON). 
trans-3-Dibenzylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCON(Bzl)2) was obtained by mixed anhydride coupling of equimolar 
amounts of monoethyl fumarate and dibenzylamine to give a clear, pink syrup (87% 
yield). 
 
trans-3-Dibenzylcarbamoylpropenoic Acid (2l, HOOCCH=CHCON(Bzl)2). 
EtOOCCH=CHCON(Bzl)2 was hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) 
under standard deblocking conditions to give a white powder (91% yield).  
1
H-NMR 
(DMSO-d6): 4.57 (s, 2H, NCH2Ph), 4.65 (s, 2H, NCH2Ph), 6.61-6.65 (d, 1H, 
CH=CHCON), 7.15-7.17 (d, 1H, CH=CHCON), 7.25-7.50 (m, 10H, 2 x Ph). 
trans-3-(1-Naphthylmethylcarbamoyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CH-CONHCH2-1-Naphth) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and 1-naphthylmethylamine.  Purification by 
column chromatography using 2:1 Hexanes:EtOAc to give white powder (86% yield).  
1
H-NMR (CDCl3): 1.20 (t, 3H, CH3), 3.99 (q, 2H, CH2), 4.93 (d, 2H, CH2-naphth), 6.84 
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(d, 1H, CH=CHCON), 6.90 (d. 1H, CH=CHCON), 7.38-7.44 (m, 2H, naphthyl), 7.47-
7.54 (m, 2H, naphthyl), 7.79 (d, 1H, naphthyl), 7.84 (d, 1H, naphthyl), 7.95 (d, 1H, 
naphthyl).  
trans-3-(1-Naphthylmethylcarbamoyl)propenoic Acid (2m, HOOCCH=CH-
CONHCH2-1-Naphth).  EtOOCCH=CHCONHCH2-1-naphth  was hydrolyzed in EtOH 
using NaOH (1 M aqueous, 1.1 eq) under standard deblocking conditions to give a white 
solid (76% yield).  
1
H-NMR (DMSO-d6): 4.82 (d, 2H, CH2-naphth), 6.56-6.60 (d, 1H, J 
= 15.6 Hz, CH=CHCON), 6.91-6.95 (d. 1H, , J = 15.6 Hz, CH=CHCON), 7.40-7.57 (m, 
4H, naphthyl), 7.84-7.86 (m, 1H, naphthyl), 7.94 (d, 1H, naphthyl), 8.03 (d, 1H, 
naphthyl), 9.00 (t, 1H, NH).  
trans-3-(Methyl-1-naphthylmethylcarbamoyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH3)CH2-1-Naphth) was obtained by mixed anhydride coupling 
of equimolar amounts of monoethyl fumarate and N-methyl-1-naphthylmethylamine 
hydrochloride.  Purification by column chromatography using 1:1 EtOAc:hexane gave a 
white powder (62% yield).  
1
H-NMR (CDCl3): 1.29 (t, 3H, CH3), 3.01 (s, 3H, CH3), 5.11 
(s, 2H, CH2), 6.87-6.92 (d, 1H, CH=CHCON), 7.40-7.52 (m, 5H, CH=CHCON and 
naphthyl), 7.78-7.89 (m, 3H, naphthyl). 
trans-3-(Methyl-1-naphthylmethylcarbamoyl)propenoic Acid (2n, 
HOOCCH=CHCON(CH3)CH2-1-Naphth).  EtOOCCH=CHCON(CH3)CH2-1-Napth  
was hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white solid (13% yield).  
1
H-NMR (DMSO-d6): 3.01 (s, 3H, CH3), 
5.01 (s, 2H, CH2), 6.61-6.65 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.17-7.21 (d, 1H, 
CH=CHCON), 7.37-7.60 (m, 4H, naphthyl), 7.85-8.01 (m, 3H, naphthyl). 
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trans-3-(Benzyl-1-naphthylmethylcarbamoyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CHCON(Bzl)-CH2-1-Naphth) was obtained by mixed anhydride coupling 
of equimolar amounts of monoethyl fumarate and benzyl-1 naphthylmethylamine.  
Purification by column chromatography using 1:1 EtOAc:hexane gave a yellow oil (89% 
yield).  
1
H-NMR (CDCl3): 1.31 (t, 3H, CH3CH2), 4.23 (q, 2H, CH3CH2), 4.55-4.69 (d, 
2H, N-CH2), 4.71-4.81 (d, 2H, N-CH2), 6.91-6.95 (d, 1H, J = 14.4 Hz, CH=CHCON), 
7.16-7.18 (d, 1H, CH=CHCON), 7.23-7.57 (m, 10H, naphthyl and Ph), 7.85 (m, 2H, 
naphthyl).
 
trans-3-(Benzyl-1-naphthylmethylcarbamoyl)propenoic Acid (2o, 
HOOCCH=CHCON(Bzl)-CH2-1-Naphth).  EtOOCCH=CHCON(Bzl)-1-CH2-Napth  
was hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white solid after recrystallization from cold EtOAc (77% yield).  
1
H-
NMR (DMSO-d6): 4.82 (d, 2H, N-CH2), 5.01 (d, 2H, N-CH2), 6.61-6.65 (d, 1H, J = 15.2 
Hz, CH=CHCON), 7.17-7.21 (d, 1H, CH=CHCON), 7.37-7.60 (m, 9H, naphthyl and Ph), 
7.85-8.01 (m, 3H, naphthyl). 
trans-3-(Di-1-naphthylmethylcarbamoyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH2-1-Naphth)2)  was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and N,N-di(1-naphthylmethyl)amine.  
Purification by column chromatography using 2:1 Hexanes:EtOAC gave white solid 
(40% yield).   
1
H-NMR (DMSO-d6): 1.10 (t, 3H, CH3), 4.04 (q, 2H, CH2), 5.22 (s, 4H, N-
1-CH2-Napth), 6.73-6.77 (d, 1H, CH=CHCON), 7.18-7.19 (d, 1H, CH=CHCON), 7.17-
8.11 (m, 14H, N(1-CH2-Napth)2).  
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trans-3-(Di-1-naphthylmethylcarbamoyl)propenoic Acid (2p, 
HOOCCH=CHCON(CH2-1-Naphth)2). EtOOCCH=CHCON(CH2-1-Napth)2)  was 
hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white solid (69% yield).  
1
H-NMR (DMSO-d6): 5.21 (s, 4H, N-1-
CH2-Napth), 6.61-6.62 (d, 1H, CH=CHCON), 6.69-6.72 (d, 1H, CH=CHCON), 7.19-
8.10 (m, 14H, N(1-CH2-Napth)2).  
(2S,3S)-Oxirane-2,3-dicarboxylic Acid Monoethyl Esters (4q, Monoethyl 
Epoxysuccinates, HOOC-EP-COOEt).  The diethyl trans epoxysuccinates were 
synthesized stereoselectively by a procedure adapted from one described previously by 
Mori and Iwasawa.
67
  One ethyl ester was hydrolyzed using 1M KOH (1 eq) in EtOH at     
0 °C.  
1
H NMR (DMSO-d6): 1.19 (t, 3H, OCH2CH3), 3.55 (d, 1H, epoxy CH), 3.64 (d, 
1H, epoxy CH), 4.15 (q, 2H, OCH2CH3). 
cis-Oxirane-2,3-dicarboxylic Acid Monoethyl Ester (Monoethyl 
Epoxysuccinate, HOOC-EP-COOEt).  The diethyl ester cis epoxysuccinate was 
synthesized using the procedure described by Meth-Cohn.
68
  One ethyl ester was 






H NMR (CDCl3): 1.27-
1.36 (m, 3H, OCH2CH3), 3.75-3.81 (dd, 2H, epoxy CH), 4.25-4.37 (m, 2H, OCH2CH3). 
General Procedure for Coupling of the Mono Ethyl Ester Epoxysuccinates to 
Amines.  The method used was the mixed anhydride coupling method.  The mono ethyl 
ester epoxysuccinate (1 eq) was dissolved in CH2Cl2 and cooled to -20 °C. To the 
reaction mixture was added NMM (3 eq) and then iBCF (3 eq).  The reaction mixture 
was stirred at -20 °C for 15-20 minutes and then the amine (3 eq) was added. The 
reaction mixture was then stirred at -20 °C for one hour and then at room temperature 
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overnight. The solvent was removed, and the crude product was dissolved in EtOAc.  The 
organic layer was then washed with of 2% citric acid, saturated NaHCO3 and brine.  The 
product was purified with column chromatography as needed. Hydrolysis of the ethyl 
ester with 1 M NaOH (1.5 eq) in EtOH gave the desired amides. 
(2S,3S)-Oxirane-2,3-dicarboxylic Acid Dibenzyl Amide (4r, HOOC-EP-
CON(Bzl)2) was obtained by mixed anhydride coupling of the mono ethyl ester 
epoxysuccinate and dibenzylamine to give a clear oil and then hydrolyzed in basic 
conditions to the corresponding acid.  
1
 H NMR (DMSO-d6): 3.51 (d, 1H, epoxy CH), 
4.03 (d, 1H, epoxy CH), 4.50 (dd, 2H, NCH2Ph), 4.70 (dd, 2H, NCH2Ph), 7.18-7.36 (m, 
10H, 2 x Ph). 
 (2S,3S)-Oxirane-2,3-dicarboxylic Acid 1-Naphthylmethyl Amide (4s, 
HOOC-EP-CONH-1-CH2-Napth) was obtained by mixed anhydride coupling of the 
mono ethyl ester epoxysuccinate and 1-naphthylmethylamine to give a yellow powder 
and then hydrolyzed in basic conditions to the corresponding acid.  
1
H NMR (Acetone-
d6): 3.59 (d, 1H, epoxy CH), 3.82 (d, 1H, epoxy CH), 5.21-5.36 (m, 4H, N(1-CH2-
Napth)2), 7.37-7.56 (m, 8H, N(1-CH2-Napth)2), 7.84-7.96 (m, 5H, N(1-CH2-Napth)2), 
8.15-8.18 (m, 1H, N(1-CH2-Napth)2).  
(cis)-Oxirane-2,3-dicarboxylic Acid Dibenzyl Amide (6t, HOOC-EP-
CON(Bzl)2) was obtained by mixed anhydride coupling of the mono ethyl ester 
epoxysuccinate and dibenzylamine to give a clear oil and then hydrolyzed in basic 
conditions to the corresponding acid.  
1
H NMR (DMSO-d6): 3.79 (d, 1H, epoxy CH), 
4.13 (d, 1H, epoxy CH), 4.23-4.63 (dd, 4H, NCH2Ph), 7.16 (d, 2H, Ph), 7.24-7.37 (m, 
8H, Ph).  
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General Procedure for the Synthesis of Aza-Peptide Michael Acceptors and 
Aza-Peptide Epoxides by the HOBt and EDC Coupling Method.  To a stirred solution 
of the fumaric acid or epoxide precursor (1.5 eq) in DMF at -10 °C was added HOBt (1.5 
eq), the peptidyl hydrazide precursor (1 eq) and EDC (1.5 eq) was added.  The mixture 
was allowed to react for 16 h at room temperature.  The DMF was evaporated, and the 
residue was redissolved in EtOAc.  The organic layer was washed with 2% citric acid, 
saturated NaHCO3, saturated NaCl, dried over MgSO4, and concentrated.  Column 









ethoxycarbonylpropenoyl)hydrazine (23a, Boc-AAsn-CH=CH-COOEt).  This 
compound was obtained using the HOBt/EDC coupling method and purified by column 
chromatography using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (47% yield).  
1
H-NMR (DMSO-d6):  1.19 (t, 3H, 
CH3), 1.39 (s, 9H, Boc), 3.59 (d, 1H, CH), 4.17 (q, 2H, CH2), 4.43 (d, 1H, CH), 6.59 (d, 
1H, CH=CHCON), 7.19-7.25 (m, 3H, CH=CHCON and NH), 7.43 (s, 1H, NH), 9.93 (s, 
1H, NH).  MS (FAB) m/z 316.1 [(M + 1)
+
].  Anal. Calcd. for 
C13H21N3O6#0.15CH2Cl2#0.2H2O: C, 47.62; H, 6.59; N, 12.67.  Found: C, 47.61; H, 6.32; 









cyclohexyl).  This compound was obtained using the HOBt/EDC coupling method and 
purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
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Recrystallization with EtOAc/hexane gave a white powder (24% yield).  
1
H-NMR 
(DMSO-d6):  0.84-0.89 (m, 2H, cyclohexyl), 1.12-1.19 (m, 4H, cyclohexyl), 1.39 (s, 9H, 
Boc), 1.42-1.64 (m, 5H, cyclohexyl), 2.98 (t, 2H, CH2), 3.57 (d, 1H, CH), 4.38 (d, 1H, 
CH), 6.89 (d, 1H, CH=CHCON), 7.08 (d, 1H, CH=CHCON), 7.17 (s, 1H, NH), 7.41 (s, 
1H, NH), 8.43 (t, 1H, NH), 9.88 (s, 1H, NH).  MS (FAB) m/z 383.2 [(M + 1)
+
].  Anal. 
Calcd. for C18H30N4O5#0.15H2O: C, 56.13; H, 7.93; N, 14.55.  Found: C, 56.14; H, 7.89; 








benzylcarbamoylpropenoyl)hydrazine (23f, Boc-AAsn-CH=CH-CONHBzl).  This 
compound was obtained using the HOBt/EDC coupling method and purified by column 
chromatography using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (44% yield).  
1
H-NMR (DMSO-d6):  0.84-0.89 (m, 
2H, cyclohexyl), 1.12-1.19 (m, 4H, cyclohexyl), 1.39 (s, 9H, Boc), 3.59 (d, 1H, CH), 
4.35-4.41 (m, 3H, CH and CH2), 6.92-6.96 (d, 1H, CH=CHCON), 7.14-7.33 (m, 7H, Ph 
and CH=CHCON and NH), 7.41 (s, 1H, NH), 8.98 (t, 1H, NH), 9.89 (s, 1H, NH).  MS 
(FAB) m/z 377.2 [(M + 1)
+
].  Anal. Calcd. for C18H24N4O5: C, 57.44; H, 6.43; N, 14.88.  









CONHCH2CH2CH2Ph).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (53% yield).  
1
H-NMR 
(DMSO-d6):  1.39 (s, 9H, Boc), 1.67-1.74 (m, 2H, NHCH2CH2CH2Ph), 2.55-2.58 (t, 2H, 
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NHCH2CH2CH2Ph), 3.11-3.16 (m, 2H, NHCH2CH2CH2Ph), 3.59 (d, 1H, CH), 4.41 (d, 
1H, NH), 6.87-6.91 (d, 1H, CH=CHCON), 7.08-7.28 (m, 7H, Ph and CH=CHCON and 
NH), 7.41 (s, 1H, NH), 8.51 (t, 1H, NH), 9.89 (s, 1H, NH).  MS (FAB) m/z 405.3 [(M + 
1)
+
].  Anal. Calcd. for C20H28N4O5#1.2Hexane: C, 60.18; H, 7.29; N, 13.24.  Found: C, 









CH=CHCO-tetrahydroisoquinoline).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(41% yield).  
1
H-NMR (DMSO-d6): 1.23 (d, 3H, CH3), 1.37 (s, 4H, piperidine), 1.48 (2H, 
piperidine), 1.74-1.77 (m, 2H, N-CH2-CH2-CH2), 2.79-2.87 (m, 2H, N-CH2-CH2-CH2), 
3.23 (m, 4H, piperidine), 3.60 (s, 2H, NCH2CO), 3.72-3.75 (m, 2H, N-CH2-CH2), 4.12 
(m, 1H, "-H), 6.55 (d, 1H, NH), 7.06-7.37 (m, 7H, isoquinoline and CH=CHCON and 
NH and CH=CHCON ), 7.57 (s, 1H, NH), 10.53 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C24H33N6O5: 485.2507.  Observed m/z 485.2579.  Anal. Calcd. for C24H32N6O5#1.3H2O: 









cyclopropyl). This compound was obtained using the HOBt/EDC coupling method and 
purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (67% yield).  
1
H-NMR 
(DMSO-d6): 0.40-0.43 (m, 2H, CH2), 0.63-0.68 (m, 2H, CH2), 1.24 (d, 3H, CH3), 2.69-
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2.73 (m, 1H, CH), 3.28-3.29 (m, 4H, morpholine), 3.33 (s, 2H, NCH2CO), 3.51-3.53 (m, 
4H, morpholine), 4.11-4.18 (m, 1H, !-H), 6.71-6.77 (m, 2H, NH and CH=CHCON), 
7.03-7.07 (d, 1H, CH=CHCON), 7.17 (s, 1H, NH), 7.53(s, 1H, NH), 8.47 (d, 1H, NH), 
10.58 (s, 1H, NH).  HRMS (FAB) Calcd. for C17H27N6O6: 411.1987.  Observed m/z 
411.1981.  Anal. Calcd. for C17H26N6O6#1H2O: C, 47.66; H, 6.59; N, 19.62.  Found: C, 









furyl).  This compound was obtained using the HOBt/EDC coupling method and purified 
by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization 
with EtOAc/hexane gave a yellow powder (48% yield).  
1
H-NMR (DMSO-d6): 1.24 (d, 
3H, CH3), 3.27-3.28 (m, 4H, morpholine), 3.34 (s, 2H, NCH2CO), 3.50-3.52 (m, 4H, 
morpholine), 4.11-4.18 (m, 1H, !-H), 4.34 (d, 2H, NHCH2), 6.24-6.25 (d, 1H, furyl), 
6.37-6.38 (d, 1H, furyl), 6.71 (d, 1H, NH), 6.84-6.88 (d, 1H, CH=CHCON), 7.09-7.13 (d, 
1H, CH=CHCON), 7.18 (s, 1H, NH), 7.54-7.56 (d, 2H, NH and furyl), 8.86 (t, 1H, NH), 
10.59 (s, 1H, NH).  HRMS (FAB) Calcd. for C19H27N6O7: 451.1936.  Observed m/z 
451.2037.  Anal. Calcd. for C19H26N6O7#1.3H2O: C, 48.16; H, 6.08; N, 17.74 .  Found: C, 









CONHCH2Ph-3,4-OCH3).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  




(DMSO-d6): 1.24 (d, 3H, CH3), 3.25-3.26 (m, 4H, morpholine), 3.32 (s, 2H, NCH2CO), 
3.49-3.51 (m, 4H, morpholine), 3.70-3.71 (d, 6H, 2 x OCH3), 4.11-4.18 (m, 1H, "-H), 
4.28 (d, 2H, NHCH2), 6.70-6.72 (d, 1H, NH), 6.74-6.76 (d, 1H, CH=CHCON), 6.86-6.91 
(m, 3H, Ph and CH=CHCON), 7.10-7.18 (m, 2H, Ph and NH), 7.53 (s, 1H, NH), 8.82 (t, 
1H, NH), 10.59 (s, 1H, NH).  HRMS (FAB) Calcd. for C23H33N6O8: 521.2354.  Observed 
m/z 521.2431.  Anal. Calcd. for C23H32N6O8#0.1EtOAc#1H2O: C, 51.35; H, 6.41; N, 









CONHCH2CH2CH2Ph).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (41% yield).  
1
H-NMR 
(DMSO-d6): 1.24 (d, 3H, CH3), 1.67-1.75 (m, 2H, NHCH2CH2CH2Ph), 2.55-2.59 (t, 2H, 
NHCH2CH2CH2Ph), 3.09-3.18 (m, 2H, NHCH2CH2CH2Ph), 3.26-3.28 (m, 4H, 
morpholine), 3.33 (s, 2H, NCH2CO), 3.50-3.52 (m, 4H, morpholine), 4.11-4.18 (m, 1H, 
"-H), 6.71 (d, 1H, NH), 6.84-6.88 (d, 1H, CH=CHCON), 7.09-7.14 (d, 1H, 
CH=CHCON), 7.15-7.28 (m, 6H, Ph and NH), 7.53 (s, 1H, NH), 8.45 (t, 1H, NH), 10.58 
(s, 1H, NH).  HRMS (FAB) Calcd. for C23H33N6O6: 489.2462.  Observed m/z 489.2486.  
Anal. Calcd. for C23H32N6O6#0.5H2O: C, 55.52; H, 6.68; N, 16.89.  Found: C, 55.51; H, 









CH=CHCO-tetrahydroisoquinoline).  This compound was obtained using the 
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HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(27% yield).  
1
H-NMR (DMSO-d6): 1.23 (d, 3H, Ala-CH3), 2.78-2.86 (m, 2H, N-CH2-
CH2-CH2), 3.22-3.34 (m, 6H, morpholine and NCH2CO), 3.47-3.58 (m, 6H, N-CH2-CH2-
CH2 and morpholine), 3.71-3.73 (m, 2H, N-CH2-CH2), 4.13 (m, 1H, "-H), 6.69 (d, 1H, 
NH), 7.05-7.39 (m, 7H, CH=CHCON and CH=CHCON and isoquinoline and NH), 7.55 
(s, 1H, NH), 10.58 (s, 1H, NH).  HRMS (FAB) Calcd. for C23H31N6O6: 485.2507.  
Observed m/z 485.2579.  Anal. Calcd. for C23H30N6O6#1.4H2O: C, 53.98; H, 6.46; N, 










tetrahydroquinoline).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a yellow powder (29% yield).  
1
H-NMR 
(DMSO-d6): 1.27 (m, 3H, Ala-CH3), 1.84-1.89 (m, 2H, N-CH2-CH2-CH2), 2.67-2.71 (m, 
2H, N-CH2-CH2-CH2), 3.33 (m, 10H, piperazine and NCH2CO), 3.70-3.76 (m, 2H, N-
CH2-CH2), 4.13-4.20 (m, 1H, "-H), 5.07 (s, 2H, Cbz), 6.79 (d, 1H, NH), 7.05-7.37 (m, 
12H, Ph, quinoline, NH, CH=CHCON and CH=CHCON), 7.53 (s, 1H, NH), 10.60 (s, 
1H, NH).  HRMS (FAB) Calcd. for C31H38N7O7: 620.2827.  Observed m/z 620.2891.  
Anal. Calcd. for C31H37N7O7#0.9H2O: C, 58.55; H, 6.15; N, 15.42.  Found: C, 58.68; H, 











tetrahydroisoquinoline).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (46% yield).  
1
H-NMR 
(DMSO-d6): 1.23 (d, 3H, CH3), 2.75-2.87 (m, 2H, N-CH2-CH2-CH2), 3.30-3.33 (m, 10H, 
piperazine and NCH2CO), 3.69-3.77 (m, 2H, N-CH2-CH2), 4.10-4.15 (m, 1H, "-H), 4.64-
4.74 (m, 2H, NCH2C), 5.07 (s, 2H, Cbz), 6.76 (d, 1H, NH), 7.05-7.39 (m, 12H, Ph, 
isoquinoline, NH,  CH=CHCON and CH=CHCON), 7.55 (s, 1H, NH), 10.57 (s, 1H, 
NH).  HRMS (FAB) Calcd. for C31H38N7O7: 620.2827.  Observed m/z 620.2879.  Anal. 
Calcd. for C31H37N7O7#1H2O#0.5EtOAc: C, 58.14; H, 6.36; N, 14.38.  Found: C, 58.48; 








ethoxycarbonylpropenoyl)hydrazine (27a, Pip-Ala-Ala-AAsn-CH=CH-COOEt).  
This compound was obtained using the HOBt/EDC coupling method and purified by 
column chromatography using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (35% yield).  
1
H-NMR (DMSO-d6): 1.17-1.25 (m, 
9H, 2 x Ala-CH3 and COCH2CH3), 1.39 (s, 4H, piperidine), 1.49 (m, 2H, piperidine), 
3.25 (s, 4H, piperidine), 3.32 (s, 2H, NCH2CO), 4.09-4.19 (m, 3H, !-H and COCH2CH3), 
4.25 (m, 1H, !-H), 6.35 (d, 1H, NH), 6.59 (d, 1H, CH=CHCON), 7.18-7.20 (m, 2H, 
CH=CHCON and NH), 7.51 (s, 1H, NH), 8.04 (br s, 1H, NH), 10.75 (s, 1H, NH).  
HRMS (FAB) Calcd. for C20H33N6O7: 469.2405.  Observed m/z 469.2426.  Anal. Calcd. 
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for C20H32N6O7#0.9H2O: C, 49.56; H, 7.03; N, 17.34.  Found: C, 49.60; H, 7.04; N, 









CONHCH2CH2Ph).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (48% yield).  
1
H-NMR 
(DMSO-d6): 1.19-1.28 (m, 6H, 2 x CH3), 1.39 (s, 4H, piperidine), 1.50 (m, 2H, 
piperidine), 2.75 (t, 2H, CH2), 3.25-3.28 (m, 4H, piperidine), 3.34 (s, 2H, NCH2CO), 
3.35-3.40 (m, 2H, CH2), 4.13 (m, 1H, !-H), 4.27 (m, 1H, !-H), 6.41 (d, 1H, NH), 6.83-
6.87 (d, 1H, CH=CHCON), 7.03-7.07 (d, 1H, CH=CHCON), 7.18-7.31 (m, 6H, Ph and 
NH), 7.52 (s, 1H, NH), 8.07 (s, 1H, NH), 8.56 (t, 1H, NH), 10.69 (br s, 1H, NH).  HRMS 
(FAB) Calcd. for C26H38N7O6: 544.2878.  Observed m/z 544.3001.  Anal. Calcd. for 









CON(Bzl)2).  This compound was obtained using the HOBt/EDC coupling method and 
purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (52% yield).  
1
H-NMR 
(DMSO-d6): 1.18-1.27 (m, 6H, 2 x Ala-CH3), 1.37 (s, 4H, piperidine), 1.46-1.49 (m, 2H, 
piperidine), 3.23-3.25 (m, 4H, piperidine), 3.33 (s, 2H, NCH2CO), 4.11-4.16 (m, 1H, !-
H), 4.24-4.30 (m, 1H, !-H), 4.56-4.63 (d, 4H, 2 x CH2Ph), 6.38 (d,1H, NH), 7.14-7.37 
(m, 13H, 2 x Ph and CH=CHCON and CH=CHCON and NH), 7.49 (s, 1H, NH), 8.05 (s, 
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1H, NH), 10.72 (s, 1H, NH).  HRMS (FAB) Calcd. for C32H42N7O6: 620.3191.  Observed 
m/z 620.3143.  Anal. Calcd. for C32H41N7O6#1.1H2O: C, 60.10; H, 6.81; N, 15.33.  









Ala-AAsn-CH=CH-CON(Bzl)-CH2-1-naphthyl).  This compound was obtained using 
the HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(27% yield).  
1
H-NMR (DMSO-d6): 1.20 (d, 3H, Ala-CH3), 1.27 (d, 3H, Ala-CH3), 1.37 
(s, 4H, piperidine), 1.48 (m, 2H, piperidine), 3.24 (s, 4H, piperidine), 3.33 (s, 2H, 
NCH2CO), 4.13 (m, 1H, !-H), 4.28 (m, 1H, !-H), 4.65-4.67 (m, 2H, CH2Ph), 5.06-5.17 
(m, 2H, CH2Naph) 6.39 (t, 1H, NH), 7.12-7.56 (m, 13H, Ph and Naph and CH=CHCON 
and CH=CHCON and 2 x NH) 7.84-8.05 (m, 4H, Naph and NH), 10.72 (s, 1H, NH).  
HRMS (FAB) Calcd. for C36H44N7O6: 670.3348.  Observed m/z 670.3374.  Anal. Calcd. 
for C36H43N7O6#1.2H2O: C, 62.54; H, 6.62; N, 14.18.  Found: C, 62.55; H, 6.61; N, 









CON(CH2-1-naphthyl)2).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (63% yield).  
1
H NMR 
(DMSO-d6): 1.20 (d, 3H, Ala-CH3), 1.28 (d, 3H, Ala-CH3), 1.35 (s, 4H, piperidine), 1.46 
(m, 2H, piperidine), 3.23 (s, 4H, piperidine), 3.33 (s, 2H, NCH2CO), 4.14 (m, 1H, !-H), 
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4.28 (m, 1H, !-H), 5.21 (s, 4H, 2 x N-CH2-naphthyl), 6.38 (d, 1H, NH), 7.13-7.56 (m, 
12H, naphthyl and CH=CHCON and CH=CHCON and 2 x NH), 7.82-8.10 (m, 7H, 
naphthyl and NH), 10.72 (s, 1H, NH).  HRMS (FAB) Calcd. for C40H46N7O6: 720.3568.  
Observed m/z 720.3504.  Anal. Calcd. for C40H45N7O6#1.3H2O: C, 64.64; H, 6.45; N, 








ethoxycarbonylpropenoyl)hydrazine (28a, Mu-Ala-Ala-AAsn-CH=CH-COOEt).  
This compound was obtained using the HOBt/EDC coupling method and purified by 
column chromatography using 15% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (36% yield).  
1
H-NMR (DMSO-d6): 1.17-1.25 (m, 
9H, 2 x Ala-CH3 and COCH2CH3), 3.24-3.26 (m, 4H, morpholine), 3.32 (s, 2H, 
NCH2CO), 3.50-3.52 (m, 4H, morpholine), 4.09-4.18 (m, 3H, !-H and COCH2CH3), 4.22 
(m, 1H, !-H), 6.50 (d, 1H, NH), 6.57-6.61 (d, 1H, CH=CHCON), 7.17-7.20 (m, 2H, 
CH=CHCON and NH), 7.51 (s, 1H, NH), 8.08 (d, 1H, NH), 10.73 (s, 1H, NH).  HRMS 
(FAB) Calcd. for C19H31N6O8: 471.2227.  Observed m/z 471.2198.  Anal. Calcd. for 









CONHCH2CH2CH2Ph).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (32% yield).  
1
H-NMR 
(DMSO-d6): 1.17-1.26 (d, 6H, 2 x Ala-CH3), 1.68-1.75 (m, 2H, NHCH2CH2CH2Ph), 
2.55-2.59 (t, 2H, NHCH2CH2CH2Ph), 3.11-3.16 (m, 2H, NHCH2CH2CH2Ph), 3.25-3.29 
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(m, 4H, morpholine), 3.35 (s, 2H, NCH2CO), 3.49-3.51 (m, 4H, morpholine), 4.10-4.17 
(m, 1H, "-H), 4.22-4.28 (m, 1H, "-H), 6.53 (d, 1H, NH), 6.85-6.89 (d, 1H, 
CH=CHCON), 7.03-7.07 (d, 1H, CH=CHCON), 7.14-7.28 (m, 6H, Ph and NH), 7.50 (s, 
1H, NH), 8.10 (s, 1H, NH), 8.49 (t, 1H, NH), 10.67 (s, 1H, NH).  HRMS (FAB) Calcd. 
for C26H38N7O7: 560.2834.  Observed m/z 560.2817.  Anal. Calcd. for 









AAsn-CH=CHCO-tetrahydroisoquinoline).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(29% yield).  
1
H-NMR (DMSO-d6): 1.16-1.23 (m, 6H, 2 x Ala-CH3), 2.79-2.85 (m, 2H, 
N-CH2-CH2-CH2), 3.25-3.35 (m, 8H, morpholine and NCH2CO and N-CH2-CH2-CH2), 
3.50 (m, 4H, morpholine), 3.72-3.75 (m, 2H, N-CH2-CH2), 4.12 (m, 1H, "-H), 4.25 (m, 
1H, "-H), 4.65-4.75 (m, 2H, N-CH2-C), 6.50 (d, 1H, NH), 7.04-7.42 (m, 7H, 
isoquinoline, CH=CHCON, CH=CHCON and NH), 7.53 (s, 1H, NH), 8.08 (d, 1H, NH), 
10.68 (s, 1H, NH).  HRMS (FAB) Calcd. for C26H36N7O7: 558.2676.  Observed m/z 
558.2660.  Anal. Calcd. for C26H35N7O7#1.8H2O: C, 52.93; H, 6.59; N, 16.62.  Found: C, 









CON(CH2-1-naphthyl)2).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
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Recrystallization with EtOAc/hexane gave a white solid. (40% yield).  
1
H NMR (DMSO-
d6): 1.21 (d, 3H, Ala-CH3), 1.29 (d, 3H, Ala-CH3), 3.24 (m, 4H, morpholine), 3.29 (s, 2H, 
NCH2CO), 3.48 (m, 4H, morpholine), 4.16 (m, 1H, !-H), 4.28 (m, 1H, !-H), 5.20 (s, 4H, 
2 x N-CH2-naphthyl), 6.52 (d, 1H, NH), 7.12-7.55 (m, 12H, naphthyl and CH=CHCON 
and CH=CHCON and NH2), 7.82-8.10 (m, 7H, naphthyl and NH), 10.71 (s, 1H, NH).  
HRMS (FAB) Calcd. for C39H44N7O7: 722.3340.  Observed m/z 722.3297.  Anal. Calcd. 
for C39H43N7O7#1.6H2O: C, 62.40; H, 6.20; N, 13.06.  Found: C, 62.81; H, 6.23; N, 








ethoxycarbonylpropenoyl)hydrazine (37a, Piz-Ala-Ala-AAsn-CH=CH-COOEt).  
This compound was obtained by the removal of the tert-butyl protecting group of Boc-
Piz-Ala-Ala-AAsn-CH=CH-COOEt with trifluoroacetic acid/methylene chloride (1:1) for 
3 hours at room temperature.  The volatiles were evaporated, and the TFA salt was 
washed several times with to give a white solid. (98% yield).  
1
H-NMR (DMSO-d6): 
1.18-1.25 (m, 9H, 2 x Ala-CH3 and COCH2CH3), 3.04 (s, 4H, piperazine), 3.36-3.50 (m, 
6H, piperazine and NCH2CO), 4.13-4.26 (m, 4H, 2 x !-H and COCH2CH3), 6.57-6.61 (d, 
1H, CH=CHCON), 6.75 (d, 1H, NH), 7.17-7.21 (m, 2H, CH=CHCON and NH), 7.53 (s, 
1H, NH), 8.12 (d, 1H, NH), 8.78 (s, 1H, NH), 10.75 (s, 1H, NH).  HRMS (FAB) Calcd. 
for C19H32N7O7: 470.2358.  Observed m/z 470.2386.  Anal. Calcd. for 











AAsn-CH=CH-COOBzl).  This compound was obtained by the removal of the tert-butyl 
protecting group of Boc-Piz-Ala-Ala-AAsn-CH=CH-COOBzl with trifluoroacetic 
acid/methylene chloride (1:1) for 3 hours at room temperature.  The volatiles were 
evaporated, and the TFA salt was washed several times with to give a white solid. (98% 
yield).  
1
H-NMR (DMSO-d6): 1.18 (s, 6H, 2 x Ala-CH3), 3.03 (s, 4H, piperazine), 3.37-
3.49 (m, 6H, piperazine and NCH2CO), 4.12 (m, 1H, !-H), 4.22 (m, 1H, !-H), 5.19 (s, 
2H, OCH2Ph), 6.64-6.74 (m, 2H, CH=CHCON and NH), 7.20-7.37 (m, 7H, Ph and 
CH=CHCON and NH), 7.52 (s, 1H, NH), 8.11 (s, 1H, NH), 8.85 (s, 1H, NH), 10.76 (s, 
1H, NH).  HRMS (FAB) Calcd. for C24H34N7O7: 532.2520.  Observed m/z 532.2505.  
Anal. Calcd. for C24H33N7O7#1.05TFA#1.5H2O: C, 46.22; H, 5.51; N, 14.45.  Found: C, 









CON(Bzl)2).  This compound was obtained by the removal of the tert-butyl protecting 
group of Boc-Piz-Ala-Ala-AAsn-CH=CH-CON(Bzl)2 with trifluoroacetic acid/methylene 
chloride (1:1) for 3 hours at room temperature.  The volatiles were evaporated, and the 
TFA salt was washed several times with to give a white solid. (99% yield).  
1
H NMR 
(DMSO-d6): 1.19-1.27 (m, 6H, 2 x Ala-CH3), 3.03 (s, 4H, piperazine), 3.49 (m, 6H, 
piperazine and NCH2CO), 4.14 (m, 1H, !-H), 4.26 (m, 1H, !-H), 4.56 (s, 2H, NCH2Ph), 
4.64 (s, 2H, NCH2Ph), 6.76 (d, 1H, NH), 7.14-7.35 (m, 13H, 2 x Ph and CH=CHCON 
and CH=CHCON and NH), 7.50 (s, 1H, NH), 8.13 (s, 1H, NH), 8.81 (s, 1H, NH), 10.71 
(s, 1H, NH).  HRMS (FAB) Calcd. for C31H41N8O6: 621.3179.  Observed m/z 621.3144.  
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Anal. Calcd. for C31H40N8O6#1.7TFA#1.1H2O: C, 49.52; H, 5.30; N, 13.43.  Found: C, 








(methyl-1 naphthylmethylcarbamoyl)propenoyl)hydrazine (37n, Piz-Ala-Ala-AAsn-
CH=CH-CON(CH3)CH2-1-naphthyl).  This compound was obtained by the removal of 
the tert-butyl protecting group of Boc-Piz-Ala-Ala-AAsn-CH=CH-CON(CH3)CH2-1-
naphthyl with trifluoroacetic acid/methylene chloride (1:1) for 3 hours at room 
temperature.  The volatiles were evaporated, and the TFA salt was washed several times 
with to give a white solid. (99% yield).  
1
H-NMR (DMSO-d6): 1.19-1.28 (m, 6H, 2 x Ala-
CH3), 2.98-3.03 (m, 7H, piperazine and N-CH3), 3.50-3.51 (m, 6H, piperazine and 
NCH2CO), 4.13-4.29 (m, 2H, 2 x !-H), 5.04-5.09 (m, 2H, N-CH2-naphthyl), 5.21 (s, 1H, 
NH), 6.76 (d, 1H, NH), 7.07-7.61 (m, 8H, naphthyl and CH=CHCON and CH=CHCON 
and 2 x NH), 7.86-8.13 (m, 3H, naphthyl), 8.83 (s, 1H, NH), 10.71 (s, 1H, NH).  HRMS 
(FAB) Calcd. for C29H39N8O6: 595.2987.  Observed m/z 595.2947.  Anal. Calcd. for 
C29H38N8O6#1.4TFA#2H2O: C, 48.33; H, 5.53; N, 14.18.  Found: C, 48.38; H, 5.64; N, 









CON(CH2-1-naphthyl)2).  This compound was obtained by the removal of the tert-butyl 
protecting group of Boc-Piz-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naphthyl)2 with 
trifluoroacetic acid/methylene chloride (1:1) for 3 hours at room temperature.  The 
volatiles were evaporated, and the TFA salt was washed several times with to give a 
white solid. (93% yield).  
1
H NMR (DMSO-d6): 1.21 (d, 3H, Ala-CH3), 1.29 (d, 3H, Ala-
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CH3), 1.37 (s, 9H, Boc), 3.03 (s, 4H, piperazine), 3.50-3.73 (m, 6H, piperazine and 
NCH2CO), 4.16 (m, 1H, !-H), 4.28 (m, 1H, !-H), 5.21 (s, 4H, 2 x N-CH2-naphthyl), 6.76 
(d, 1H, NH), 7.13-7.56 (m, 12H, naphthyl and CH=CHCON and CH=CHCON and 2 x 
NH), 7.82-8.14 (m, 7H, naphthyl and NH), 8.82 (s, 1H, NH), 10.73 (s, 1H, NH).  HRMS 
(FAB) Calcd. for C39H45N8O6: 721.3384.  Observed m/z 721.3379.  Anal. Calcd. for 
C39H44N8O6#1.6TFA#1H2O: C, 55.02; H, 5.21; N, 12.16.  Found: C, 54.83; H, 5.34; N, 









Ala-Ala-AAsn-CH=CH-COOEt).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography using 10% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with EtOAc/hexane gave a white powder (34% yield).  
1
H-
NMR (DMSO-d6): 1.17-1.25 (m, 9H, 2 x Ala-CH3 and COCH2CH3), 1.38 (s, 9H, Boc), 
3.26 (s, 8H, piperazine), 3.32 (s, 2H, NCH2CO), 4.08-4.26 (m, 4H, 2 x !-H and 
COCH2CH3), 6.53-6.61 (m, 2H, CH=CHCON and NH), 7.17-7.20 (m, 2H, CH=CHCON 
and NH), 7.51 (s, 1H, NH), 8.09 (d, 1H, NH), 10.72 (s, 1H, NH).  HRMS (FAB) Calcd. 
for C24H40N7O9: 570.2882.  Observed m/z 570.2906.  Anal. Calcd. for 









Ala-AAsn-CH=CH-COOBzl).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography using 10% MeOH/CH2Cl2 as 




NMR (DMSO-d6): 1.16-1.21 (m, 6H, 2 x CH3), 1.38 (s, 9H, Boc), 3.25 (s, 8H, 
piperazine), 3.33 (s, 2H, NCH2CO), 4.11 (m, 1H, !-H), 4.21 (m, 1H, !-H), 5.19 (s, 2H, 
O-CH2-Ph), 6.54 (d, 1H, NH), 6.63-6.67 (d, 1H, CH=CHCON), 7.22-7.39 (m, 7H, Ph and 
CH=CHCON and NH), 7.52 (s, 1H, NH), 8.09 (s, 1H, NH), 10.45 (s, 1H, NH).  HRMS 
(FAB) Calcd. for C29H42N7O9: 632.6771.  Observed m/z 632.6753.  Anal. Calcd. for 









Ala-Ala-AAsn-CH=CH-CON(Bzl)2).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(50% yield).  
1
H NMR (DMSO-d6): 1.19 (d, 3H, CH3), 1.26 (d, 3H, CH3), 1.38 (s, 9H, 
Boc), 3.25 (s, 8H, piperazine), 3.32 (s, 2H, NCH2CO), 4.14 (m, 1H, !-H), 4.26 (m, 1H, !-
H), 4.56 (s, 2H, N-CH2-Ph), 4.63 (s, 2H, N-CH2-Ph), 6.55 (d, 1H, NH), 7.14-7.37 (m, 
13H, 2 x Ph and CH=CHCON and CH=CHCON and NH), 7.82-8.10 (m, 7H, naphthyl 
and NH), 7.48 (s, 1H, NH), 8.09 (d, 1H, NH), 10.69 (s, 1H, NH).  HRMS (FAB) Calcd. 
for C36H49N8O8: 721.3668.  Observed m/z 721.3660.  Anal. Calcd. for 










CH=CH-CON(CH3)CH2-1-naphthyl).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
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MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(29% yield).  
1
H-NMR (DMSO-d6): 1.18-1.26 (m, 6H, 2 x CH3), 1.37 (s, 9H, Boc), 2.99 
(d, 3H, N-CH3), 3.26 (s, 8H, piperazine), 3.34 (s, 2H, NCH2CO), 4.14 (m, 1H, !-H), 4.28 
(m, 1H, !-H), 5.04 (m, 2H, N-CH2-naphthyl), 5.21 (s, 1H, NH), 6.58 (d, 1H, NH), 7.07-
7.61 (m, 8H, naphthyl and CH=CHCON and CH=CHCON and NH2), 7.85-8.10 (m, 3H, 
naphthyl), 8.12 (d, 1H, NH), 10.42 (s, 1H, NH), 10.72 (s, 1H, NH).  HRMS (FAB) Calcd. 
for C34H47N8O8: 695.3511.  Observed m/z 695.3559.  Anal. Calcd. for 









(29p, Boc-Piz-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naphthyl)2).  This compound was 
obtained using the HOBt/EDC coupling method and purified by column chromatography 
using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a 
white powder (25% yield).  
1
H NMR (DMSO-d6): 1.20 (d, 3H, CH3), 1.28 (d, 3H, CH3), 
1.37 (s, 9H, Boc), 3.25 (s, 8H, piperazine), 3.33 (s, 2H, NCH2CO), 4.15 (m, 1H, !-H), 
4.25 (m, 1H, !-H), 5.20 (s, 4H, 2 x N-CH2-naphthyl), 6.57 (d, 1H, NH), 7.11-7.56 (m, 
12H, naphthyl and CH=CHCON and CH=CHCON and NH2), 7.82-8.10 (m, 7H, naphthyl 
and NH), 10.43 (s, 1H, NH).  HRMS (FAB) Calcd. for C44H53N8O8: 821.4025.  Observed 
m/z 821.3981.  Anal. Calcd. for C44H52N8O8#1.1H2O: C, 62.86; H, 6.50; N, 13.33.  









Ala-Ala-AAsn-CH=CH-COOEt).  This compound was obtained using the HOBt/EDC 
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coupling method and purified by column chromatography using 15% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with EtOAc/hexane gave a white powder (41% yield).  
1
H 
NMR (DMSO-d6): 1.17-1.25 (m, 9H, 2 x Ala-CH3 and COCH2CH3), 3.31-3.34 (m, 10H, 
piperazine and NCH2CO), 4.09-4.18 (m, 3H, !-H and COCH2CH3), 4.24 (q, 1H, !-H), 
5.07 (s, 2H, Cbz), 6.55-6.61 (m, 2H, NH and CH=CHCON), 7.18-7.38 (m, 7H, Ph and 
NH and CH=CHCON), 7.50 (s, 1H, NH), 8.09 (d, 1H, NH), 10.72 (s, 1H, NH).  HRMS 
(FAB) Calcd. for C27H38N7O9: 604.2726.  Observed m/z 604.2777.  Anal. Calcd. for 










CH=CH-CON(CH3)CH2-1-naphthyl).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(38% yield).  1.15-1.28 (m, 6H, 2 x CH3), 2.99 (d, 3H, N-CH3), 3.32 (s, 8H, piperazine), 
3.34 (s, 2H, NCH2CO), 4.14 (m, 1H, !-H), 4.26 (m, 1H, !-H), 5.06 (m, 4H, Cbz and N-
CH2-naphthyl), 5.20 (s, 1H, NH), 6.60 (t, 1H, NH), 7.07-7.61 (m, 12H, naphthyl and 
CH=CHCON and CH=CHCON and NH2), 7.85-8.10 (m, 4H, naphthyl), 10.43 (s, 1H, 
NH).  HRMS (FAB) Calcd. for C37H45N8O8: 729.3355.  Observed m/z 729.3376.  Anal. 
Calcd. for C37H44N8O8#1.3H2O: C, 59.08; H, 6.24; N, 14.90.  Found: C, 59.17; H, 6.27; 










(30p, Cbz-Piz-Ala-Ala-AAsn-CH=CH-CON(CH2-1-naphthyl)2).  This compound was 
obtained using the HOBt/EDC coupling method and purified by column chromatography 
using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a 
white powder (39% yield).  1.20 (d, 3H, Ala-CH3), 1.28 (d, 3H, Ala-CH3), 3.31 (m, 8H, 
piperazine), 3.34 (s, 2H, NCH2CO), 4.16 (m, 1H, !-H), 4.27 (m, 1H, !-H), 5.06 (s, 2H, 
Cbz), 5.20 (s, 4H, N-CH2-Ph and N-CH2-naphthyl), 6.59 (d, 1H, NH), 7.12-7.54 (m, 17H, 
naphthyl and Ph and CH=CHCON and CH=CHCON and NH2), 7.82-8.13 (m, 5H, 
naphthyl and NH), 10.44 (s, 1H, NH).  HRMS (FAB) Calcd. for C47H51N8O8: 855.3838.  
Observed m/z 855.3824.  Anal. Calcd. for C47H50N8O8#1.2H2O: C, 64.40; H, 6.03; N, 








ethoxycarbonylpropenoyl)hydrazine (31a, Cbz-Ala-Val-AAsn-CH=CH-COOEt).  
This compound was obtained using the HOBt/EDC coupling method and purified by 
column chromatography using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (25% yield).  
1
H NMR (DMSO-d6): 0.84-0.85 (d, 
6H, 2 x Val-CH3), 1.15-1.21 (m, 6H, Ala-CH3 and COCH2CH3), 1.97 (s, 1H, CH), 3.32 
(s, 2H, NHCH2CO), 4.08-4.17 (m, 4H, 2 x !-H and COCH2CH3), 4.95-5.02 (m, 2H, 
Cbz),  6.57-6.61 (d, 1H, CH=CHCON), 7.18-7.44 (m, 7H, Ph and CH=CHCON and NH), 
7.50 (s, 1H, NH), 7.92 (s, 1H, NH), 10.90 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C24H34N5O8: 520.2456.  Observed m/z 520.2402.  Anal. Calcd. for 










CONHCH2-1-naphthyl).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (11% yield).  
1
H NMR 
(DMSO-d6): 0.85 (s, 6H, 2 x Val-CH3), 1.17 (d, 3H, Ala-CH3), 2.00 (s, 1H, CH), 3.32 (s, 
2H, NHCH2CO), 4.11-4.22 (m, 2H, 2 x !-H), 4.81 (d, 2H, NHCH2-Naph), 4.99 (s, 2H, 
Cbz),   6.91-6.95 (d, 1H, CH=CHCON), 7.13-7.54 (m, 12H, Ph and Naph and 
CH=CHCON and NH), 7.73-8.02 (m, 3H, Naph and NH), 8.96 (s, 1H, NH), 10.85 (s, 1H, 
NH).  HRMS (FAB) Calcd. for C33H39N6O7: 631.2875.  Observed m/z 631.2885.  Anal. 
Calcd. for C33H38N6O7#1.4H2O: C, 60.43; H, 6.27; N, 12.81.  Found: C, 60.46; H, 5.96; 









CH=CH-CO-tetrahydroquinoline).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography using 10% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with EtOAc/hexane gave a yellowish solid (36% yield).  
1
H 
NMR (DMSO-d6): 0.86-0.88 (d, 6H, 2 x CH3), 1.79 (d, 3H, Ala-CH3), 1.83-1.89 (m, 2H, 
N-CH2-CH2-CH2), 2.00 (s, 1H, CH), 2.67-2.70 (t, 2H, N-CH2-CH2-CH2), 3.32 (s, 2H, 
NHCH2CO), 3.70-3.73 (m, 2H, N-CH2-CH2-CH2), 4.12 (m, 1H, !-H), 4.23 (m, 1H, !-H), 
4.96-5.03 (m, 2H, Cbz),  7.07-7.44 (m, 13H, Ph, quinoline, CH=CHCON, CH=CHCON 
and NH), 7.49 (s, 1H, NH), 7.93 (s, 1H, NH), 10.88 (s, 1H, NH).  HRMS (FAB) Calcd. 
for C31H39N6O7: 607.2875.  Observed m/z 607.2910.  Anal. Calcd. for 









ethoxycarbonylpropenoyl)hydrazine (32a, Cbz-Ala-Ile-AAsn-CH=CH-COOEt).  
This compound was obtained using the HOBt/EDC coupling method and purified by 
column chromatography using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white solid (23% yield).  
1
H NMR (DMSO-d6): 0.79-0.82 (m, 6H, 
2 x Ile-CH3), 1.15-1.24 (m, 7H, CH and Ala-CH3 and COCH2CH3), 1.43 (m, 1H, CH), 
1.73 (m, 1H, CH), 3.32 (s, 2H, NHCH2CO), 4.06-4.24 (m, 4H, 2 x !-H and COCH2CH3), 
4.99 (s, 2H, Cbz),  6.58-6.62 (d, 1H, CH=CHCON), 7.19-7.36 (m, 7H, Ph and 
CH=CHCON and NH), 7.49 (s, 1H, NH), 7.94 (s, 1H, NH), 10.90 (s, 1H, NH).  HRMS 









CONHCH2-2-furyl).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a yellowish solid (7% yield).  
1
H NMR 
(DMSO-d6): 1.11 (d, 3H, Ala-CH3), 2.81-2.98 (m, 2H, CH2Ph), 3.32 (d, 2H, NHCH2CO) 
4.01 (m, 1H, !-H), 4.34 (d, 2H, CH2-furyl), 4.53 (m, 1H, !-H), 4.96-4.99 (m, 2H, Cbz), 
6.24 (d, 1H, furyl CH), 6.36 (t, 1H, furyl CH), 6.87-6.91 (d, 1H, CH=CHCON), 7.09-7.13 
(d, 1H, CH=CHCON),  7.18-7.34 (m, 11H, 2 x Ph and NH), 7.43 (s, 1H, NH), 7.55 (d, 
1H, furyl CH), 8.19 (s, 1H, NH), 8.91 (t, 1H, NH), 10.89 (s, 1H, NH).  HRMS (FAB) 
Calcd. for C31H35N6O8: 619.2511.  Observed m/z 619.2575.  Anal. Calcd. for 










AAsn-CH=CH-CO-tetrahydroquinoline).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a yellowish 
solid (27% yield).  
1
H NMR (DMSO-d6): 1.12 (d, 3H, Ala-CH3), 1.84-1.89 (m, 2H, N-
CH2-CH2-CH2), 2.67-2.70 (t, 2H, NCH2CH2CH2), 2.87-3.01 (m, 2H, CH2Ph), 3.32 (s, 
2H, NHCH2CO), 3.70-3.71 (m, 2H, NCH2CH2CH2), 4.03 (m, 1H, !-H), 4.58 (m, 1H, !-
H), 4.94-5.02 (m, 2H, Cbz),  7.05-7.34 (m, 17H, 2 x Ph, quinoline, CH=CHCON, 
CH=CHCON and NH), 7.48 (s, 1H, NH), 8.18 (s, 1H, NH), 10.92 (s, 1H, NH).  HRMS 
(FAB) Calcd. for C35H39N6O7: 655.2875.  Observed m/z 655.2923.  Anal. Calcd. for 









Phe-AAsn-CH=CH-CO-tetrahydroisoquinoline).  This compound was obtained using 
the HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(11% yield).  
1
H NMR (DMSO-d6): 1.10 (d, 3H, Ala-CH3), 2.76-2.98 (m, 4H, CH2Ph and 
N-CH2-CH2-CH2), 3.35 (s, 2H, NHCH2CO), 3.72 (m, 2H, N-CH2-CH2), 4.02 (m, 1H, !-
H), 4.56 (m, 1H, !-H), 4.65-4.73 (m, 2H, N-CH2-C), 4.94-5.02 (m, 2H, Cbz),  7.00-7.33 
(m, 12H, Ph, isoquinoline, CH=CHCON, CH=CHCON and NH), 7.51 (s, 1H, NH), 8.18 
(s, 1H, NH), 10.89 (s, 1H, NH).  HRMS (FAB) Calcd. for C35H39N6O7: 655.2875.  
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Observed m/z 655.2893.  Anal. Calcd. for C35H38N6O7#0.75EtOAc: C, 63.33; H, 6.15; N, 






carbamoylmethylhydrazinocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester (34q, 
Pip-Ala-Ala-AAsn-EP(S,S)-COOEt).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(3% yield).  
1
H-NMR (DMSO-d6): 1.12-1.20 (m, 9H, 2 x Ala-CH3 and COCH2CH3), 1.39 
(m, 4H, piperidine), 1.49 (m, 2H, piperidine), 3.25 (m, 4H, piperidine), 3.32 (s, 2H, 
NCH2CO), 3.49 (s, 1H, epoxy CH), 3.67 (s, 1H, epoxy CH), 4.05-4.28 (m, 4H, 2 x !-H 
and COCH2CH3), 6.41 (d, 1H, NH), 7.23 (s, 1H, NH) 7.51 (s, 1H, NH) 8.06 (d, 1H, NH), 
10.72 (s, 1H, NH).  HRMS (FAB) Calcd. for C20H33N6O8: 485.2354.  Observed m/z 
485.2363.  Anal. Calcd. for C20H32N6O8#1.2H2O: C, 47.46; H, 6.85; N, 16.61.  Found: C, 







CON(Bzl)2).  This compound was obtained using the HOBt/EDC coupling method and 
purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (29% yield).  
1
H-NMR 
(DMSO-d6): 1.17-1.19 (m, 6H, 2 x Ala-CH3), 1.39 (m, 4H, piperidine), 1.49 (m, 2H, 
piperidine), 3.26 (m, 4H, piperidine), 3.32 (s, 2H, NCH2CO), 3.80 (s, 1H, epoxy CH), 
4.05-4.12 (m, 1H, !-H), 4.23-4.74 (m, 6H, !-H and epoxy CH and 2 x N-CH2-Ph), 6.41 
(d, 1H, NH), 7.21-7.39 (m, 11H, 2 x Ph and NH) 7.47 (s, 1H, NH) 8.09 (s, 1H, NH), 
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10.68 (s, 1H, NH).  HRMS (FAB) Calcd. for C32H42N7O7: 636.3140.  Observed m/z 
636.3129.  Anal. Calcd. for C32H41N7O7#1.1H2O: C, 58.63; H, 6.64; N, 14.96.  Found: C, 







(34s, Pip-Ala-Ala-AAsn-EP(S,S)-CONHCH2-1-naphthyl).  This compound was 
obtained using the HOBt/EDC coupling method and purified by column chromatography 
using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a 
yellowish solid (47% yield).  
1
H NMR (DMSO-d6): 1.14-1.20 (m, 6H, 2 x Ala-CH3), 1.38 
(m, 4H, piperidine), 1.48 (m, 2H, piperidine), 3.25 (m, 4H, piperidine), 3.32 (s, 2H, 
NCH2CO), 3.52 (s, 1H, epoxy CH), 4.10-4.20 (m, 3H, 2 x !-H and epoxy CH), 4.73-4.78 
(m, 2H, N-CH2-naphthyl), 6.36 (d, 1H, NH), 7.21 (s, 1H, NH), 7.43-7.58 (m, 4H, 
naphthyl), 7.45-7.56 (m, 4H, naphthyl), 7.84-8.03 (m, 4H, naphthyl and NH), 9.00 (s, 1H, 
NH), 10.77 (s, 1H, NH).  HRMS (FAB) Calcd. for C29H38N7O7: 596.2827.  Observed m/z 
596.2847.  Anal. Calcd. for C29H37N7O7#1.4H2O: C, 56.10; H, 6.46; N, 15.79.  Found: C, 







(35s, Mu-Ala-Ala-AAsn-EP(S,S)-CONHCH2-1-naphthyl).  This compound was 
obtained using the HOBt/EDC coupling method and purified by column chromatography 
using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a 
white powder (22% yield).  
1
H NMR (DMSO-d6): 1.15-1.21 (m, 6H, 2 x Ala-CH3), 3.26 
(m, 4H, morpholine), 3.34 (s, 2H, NCH2CO), 3.50 (m, 4H, morpholine), 4.12-4.20 (m, 
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4H, 2 x !-H and 2 x epoxy CH), 4.28 (m, 1H, !-H), 4.70-4.82 (m, 2H, N-CH2-naphthyl), 
6.52 (d, 1H, NH), 7.21 (s, 1H, NH), 7.43-7.58 (m, 4H, naphthyl), 7.84-8.10 (m, 4H, 
naphthyl and NH), 9.00 (s, 1H, NH), 10.77 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C28H36N7O8: 598.2620.  Observed m/z 598.2656.  Anal. Calcd. for C28H35N7O8#1.7H2O: 







CON(Bzl)2).  This compound was obtained using the HOBt/EDC coupling method and 
purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (19% yield).  
1
H-NMR 
(DMSO-d6): 1.18 (m, 6H, 2 x Ala-CH3), 3.27 (m, 4H, morpholine), 3.34 (s, 2H, 
NCH2CO), 3.50 (m, 4H, morpholine), 3.80-4.25 (m, 4H, 2 x !-H, 2 x epoxy CH), 4.55-
4.78 (m, 4H, 2 x N-CH2-Ph), 6.55 (d, 1H, NH), 7.22-7.47 (m, 12H, 2 x Ph and 2 x NH), 
8.15 (d, 1H, NH), 10.66 (s, 1H, NH).  HRMS (FAB) Calcd. for C31H40N7O8: 638.2938.  
Observed m/z 638.2937.  Anal. Calcd. for C31H39N7O8#1.4H2O: C, 56.17; H, 6.36; N, 







CON(Bzl)2).  This compound was obtained using the HOBt/EDC coupling method and 
purified by column chromatography using 10% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (13% yield).  
1
H-NMR 
(DMSO-d6): 1.16-1.25 (m, 6H, 2 x Ala-CH3), 3.24 (m, 4H, morpholine), 3.33 (s, 2H, 
NCH2CO), 3.49 (m, 4H, morpholine), 4.04-4.25 (m, 4H, 2 x !-H, 2 x epoxy CH), 4.37-
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4.73 (m, 4H, 2 x N-CH2-Ph), 6.53 (d, 1H, NH), 7.15-7.41 (m, 12H, 2 x Ph and 2 x NH), 
8.16 (d, 1H, NH), 10.87 (s, 1H, NH).  HRMS (FAB) Calcd. for C31H40N7O8: 638.2938.  
Observed m/z 638.2943.  Anal. Calcd. for C31H39N7O8#1.5H2O: C, 56.02; H, 6.37; N, 







CON(Bzl)2).  This compound was obtained by the removal of the tert-butyl  protecting 
group of Boc-Piz-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2 with trifluoroacetic acid/methylene 
chloride (1:1) for 3 hours at room temperature.  The volatiles were evaporated, and the 
TFA salt was washed several times with to give a white solid. (91% yield).  
1
H NMR 
(DMSO-d6): 1.18-1.21 (m, 6H, 2 x Ala-CH3), 3.03 (s, 4H, piperazine), 3.37-3.51 (m, 6H, 
piperazine and NCH2CO), 3.83 (s, 1H, epoxide CH), 4.10-4.33 (m, 3H, 2 x !-H and 
epoxide CH), 4.53-4.57 (d, 4H, 2 x NCH2Ph), 6.76 (d, 1H, NH), 7.21-7.39 (m, 11H, 2 x 
Ph and NH), 7.47 (s, 1H, NH), 8.18 (s, 1H, NH), 8.71 (s, 1H, NH), 10.62 (s, 1H, NH).  
HRMS (FAB) Calcd. for C31H41N8O7: 637.3093.  Observed m/z 637.3032.  Anal. Calcd. 
for C31H40N8O7#1.1TFA#2H2O: C, 49.96; H, 5.70; N, 14.04.  Found: C, 50.36; H, 5.75; 







Piz-Ala-Ala-AAsn-EP(S,S)-CON(Bzl)2).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(22% yield).  
1
H NMR (DMSO-d6): 1.18 (s, 6H, 2 x Ala-CH3), 1.38 (s, 9H, Boc), 3.25-
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3.31 (m, 10H, piperazine and NCH2CO), 3.81 (s, 1H, epoxide CH), 4.08-4.30 (m, 3H, 2 x 
!-H and epoxide CH), 4.57 (s, 2H, NCH2Ph ), 4.70 (s, 2H, NCH2Ph), 6.57 (d, 1H, NH), 
7.17-7.36 (m, 11H, 2 x Ph and NH), 7.46 (s, 1H, NH), 8.14 (s, 1H, NH), 10.67 (s, 1H, 
NH).  HRMS (FAB) Calcd. for C36H49N8O9: 737.3617.  Observed m/z 737.3630.  Anal. 
Calcd. for C36H48N8O9#1.4H2O: C, 56.74; H, 6.72; N, 14.27.  Found: C, 56.66; H, 6.71; 
N, 14.70                
(39, Mu-Ala-AAsn-CO-CH2CH2Ph).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(60% yield).  
1
H NMR (DMSO-d6): 1.20 (d, 3H, Ala-CH3), 2.54-2.58 (m, 2H, 
CH2CH2Ph), 2.73-2.76 (t, 2H, CH2CH2Ph), 3.18-3.26 (m, 4H, morpholine), 3.34 (d, 2H, 
NCH2CO), 3.46-3.48 (m, 4H, morpholine), 4.06-4.13 (m, 1H, !-H), 6.68 (d, 1H, NH), 
7.14-7.25 (m, 6H, Ph and NH), 7.53 (s, 1H, NH), 10.38 (s, 1H, NH).  HRMS (FAB) 
Calcd. for C19H28N5O5: 406.2085.  Observed m/z 406.2093.  Anal. Calcd. for 
C19H27N5O5#0.7H2O: C, 54.59; H, 6.85; N, 16.75.  Found: C, 54.82; H, 6.83; N, 16.82.              
(40, Pip-Ala-AAsn-CONHPh-2-OPh).  2-phenoxybenzeneisocyanate (1 eq) was 
dissolved in CH2Cl2 and cooled down to 0 °C.  Then peptidyl hydrazide (1 eq) was added 
and reaction mixture was stirred at room temperature overnight.  The solvent was 
removed and compound was purified by column chromatography using 15% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(62% yield).  
1
H NMR (DMSO-d6): 1.12 (d, 3H, Ala-CH3), 1.34-1.37 (m, 4H, 
piperidine), 1.45-1.49 (m, 2H, piperidine), 3.15 (d, 2H, NCH2CO), 3.17-3.22 (m, 4H, 
piperidine), 3.95 (m, 1H, !-H), 6.58 (d, 1H, NH), 6.78 (d, 1H, CH), 6.98-7.15 (m, 7H, 2 x 
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Ph and NH), 7.34-7.38 (m, 2H, Ph), 7.56 (s, 1H, NH), 10.23 (s, 1H, NH).  HRMS (FAB) 
Calcd. for C24H31N6O5: 483.2350.  Observed m/z 483.2313.  Anal. Calcd. for 
C24H30N6O5#0.05H2O: C, 59.63; H, 6.28; N, 17.38.  Found: C, 59.65; H, 6.25; N, 17.34.            
(41, Mu-Ala-AAsn-CONH-1-naphthyl).  This compound was obtained from the 
reaction of 1-naphthaleneisocyanate with Mu-Ala-AAsn and purified by column 
chromatography using 15% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (72% yield).  
1
H NMR (DMSO-d6): 1.29 (d, 3H, 
Ala-CH3), 3.15 (d, 2H, NCH2CO), 3.31-3.34 (m, 8H, morpholine), 4.04 (m, 1H, NH), 
4.09 (m, 1H, !-H), 6.99 (d, 1H, NH), 7.21 (s, 1H, NH), 7.38 (d, 1H, CH), 7.43-7.51 (m, 
3H, 3 x CH), 7.72-7.75 (m, 2H, NH and CH), 7.88 (d, 1H, CH), 7.96 (d, 1H, CH), 8.83 (s, 
1H, NH), 10.59 (s, 1H, NH).  HRMS (FAB) Calcd. for C21H27N6O5: 443.2043.  Observed 
m/z 443.2064.  Anal. Calcd. for C21H26N6O5#2.5H2O: C, 51.74; H, 6.14; N, 17.24.  
Found: C, 51.78; H, 6.15; N, 16.92.            
(42, Cbz-Piz-Ala-AAsn-CONHCH2Ph).  This compound was obtained from the 
reaction of benzylisocyanate with Cbz-Piz-Ala-AAsn and purified by column 
chromatography using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (71% yield).  
1
H NMR (DMSO-d6): 1.23 (d, 3H, 
Ala-CH3), 3.17-3.24 (m, 8H, piperazine), 3.36 (s, 2H, NCH2CO), 3.84-3.95 (m, 2H, 
CH2Ph), 4.18-4.26 (m, 1H, !-H), 5.07 (s, 2H, Cbz), 6.98 (d, 1H, NH), 7.14-7.38 (m, 12H, 
2 x Ph and NH2), 7.68 (s, 1H, NH), 10.22 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C26H34N7O6: 540.2571.  Observed m/z 540.2575.  Anal. Calcd. for C26H33N7O6#0.8H2O: 
C, 56.37; H, 6.29; N, 17.70.  Found: C, 56.21; H, 6.29; N, 17.74.          
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(43, Mu-Ala-Ala-AAsn-COOCH2Ph).  Benzylchloroformate (1 eq) was added to 
a stirred solution of peptidyl hydrazide (1 eq) and pyridine (1.2 eq) in CH2Cl2 at -10 °C 
and the reaction mixture was stirred for 16 h at room temperature.  The solvent was 
removed and the compound was purified by column chromatography using 10% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(72% yield).  
1
H NMR (DMSO-d6): 1.10-1.17 (m, 6H, 2 x Ala-CH3), 3.25 (m, 4H, 
morpholine), 3.34 (s, 2H, NCH2CO), 3.50 (m, 4H, morpholine), 3.97 (m, 1H, !-H), 4.14 
(m, 1H, !-H), 5.06 (s, 2H, CH2Ph), 6.52 (d, 1H, NH), 7.19-7.32 (m, 6H, Ph and NH), 
7.58 (s, 1H, NH), 7.95 (d, 1H, NH), 10.31 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C21H31N6O7: 479.2254.  Observed m/z 479.2264.  Anal. Calcd. for C21H30N6O7#0.4H2O: 
C, 51.83; H, 6.40; N, 17.27.  Found: C, 51.69; H, 6.34; N, 17.30. 
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  CHAPTER 3 
AZA-PEPTIDYL MICHAEL ACCEPTORS AND EPOXIDES AS 
INHIBITORS OF PARASITIC CYSTEINE PROTEASES 
INTRODUCTION 
 
Chagas’ disease (American sleeping sickness) is the leading cause of heart disease 
in Latin American countries.  The disease, transmitted by the protozoan parasite 
Trypanosoma cruzi, affects more than 25 million people annually in South America and 
causes more than 45,000 deaths per year.
71
    
 
 




Trypanosoma cruzi is transmitted to humans when an infected insect vector takes 
a bite and releases trypomastigotes in its feces near the site of the bite wound.  
Trypomastigotes enter the host blood-stream through the wound or through intact 
mucosal membranes.  Inside the host, the trypomastigotes invade cells near the site of 
inoculation and differentiate into intracellular amastigotes.  The amastigotes multiply 
within cells, transform back to trypomastigotes, and then are released into the 
bloodstream.  This cycle is repeated in each newly infected cell and clinical 
manifestations result from this infective cycle.  Infection of the cardiac muscle cell leads 
to cardiomyopathy, while infection of the smooth muscle cells in the gut causes the 
destruction leading to enlarged or distended intestines. 
Cruzain (also known as cruzipain) belongs to the family C1 of clan CA cysteine 
proteases.  Cruzain was first purified in 1981
73
 and has been shown to be expressed in the 
three developmental stages of T. cruzi.
74
  Highest level of cruzain expression has been 
observed during the infective stage of the parasite.
75
  Inhibition of cruzain has been 
shown to cure T. cruzi infection in cell culture screens and in mouse models of Chagas 
disease.
76





 inhibitors.  Cruzain is the only parasite cysteine protease 
with a crystal structure.  These crystal structures revealed the presence of the Glu205 
residue located at the bottom of the S2 pocket.  S2 pocket is the major specificity 
determinant for clan CA cysteine proteases and it has been shown that it can 
accommodate both hydrophobic residues like phenylalanine and basic residues like 
arginine.  Presence of cruzain at all important stages of life cycle of the parasite makes it 
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an excellent target for the development of specific, irreversible inhibitors for the 
treatment of the disease. 
African sleeping sickness or human African trypanosomiasis (HAT) is a major 
health problem in Equatorial Africa.  It is estimated that more than 50,000 people are 
infected with the disease and 60 million people in 36 countries are at risk of infection; if 
left untreated, the disease is fatal in human.
77
  Trypanosoma brucei rhodesiense and 
Trypanosoma brucei gambiense are the two organisms responsible for the disease and 




Figure 3.2.  Life Cycle of Trypanosoma brucei rhodesiense
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When an infected tsetse fly takes a bite from the mammalian host, it injects 
metacyclic trypomastigotes into skin tissue.  The parasites enter the lymphatic system and 
pass into the bloodstream.  Once inside the host, they transform into bloodstream 
trypomastigotes and undergo more divisions.  The entire life cycle of this parasite is 
represented by extracellular stages.  The tsetse fly becomes infected by ingesting a blood 
meal from an infected mammalian host.  The parasites transform into procyclic 
trypomastigotes in the fly’s midgut, multiply, leave the midgut, and transform into 
epimastigotes.  The epimastigotes reach the fly’s salivary glands and continue to 
multiply.  The cycle in the fly takes approximately 25-50 days and each fly remains 
infected for life. 
Rhodesain is the major cysteine protease of T. brucei rhodesiense and has been 
identified in all life-cycle stages of the parasite,
79
 it is also belong to clan CA of cysteine 
proteases and involves in regulating the replication of the parasite.  Rhodesain is an 
important target for the development of antiparasitic chemotherapy since the inhibition of 
the enzyme will block the life cycle of the parasite in infected mammalian cells. 
TbCatB is a recently discovered cathepsin B-like clan CA cysteine protease of T. 
brucei.  It has been shown that TbCatB is required for host protein degradation in T. 
brucei
80
 and therefore represents an exploitable target for the development of new 
inhibitors. 
Current drug therapies for these diseases are either ineffective or have serious side 
effects, so there is an urgent need for the development of new medicinal agents.  The 
synthetic inhibitors reported so far for cruzain, rhodesain and TbCatB include 

















 peptidyl allyl sulfones.
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INHIBITOR DESIGN 
Our inhibitors were composed of two parts:  The peptide sequence part that is 
involved in enzyme recognition and the warhead part which reacts with the active site 
cysteine of the cysteine proteases to inhibit the enzyme irreversibly; cruzain and 
rhodesain in this case.  Aza-peptide epoxides
65, 92
 and Michael acceptors
49, 93
 have been 




Figure 3.3.  Design Strategy for Aza-peptide Michael Acceptor and Epoxide Inhibitors.  
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The inhibitors with epoxide and Michael acceptor warhead were designed to 
closely resemble an extended peptide substrate.  Placement of the carbonyl group of the 
epoxide moiety or fumarate derivative in the inhibitor puts it in a location identical to that 
of the carbonyl of the scissile peptide bond in peptide substrate.  This design allowed the 
peptide chain of the inhibitor to exactly match that of a good substrate up to the scissile 
peptide carbonyl group.  Aza-peptide epoxides and Michael acceptors have the advantage 
of being easily extended in the P' direction, thus allowing interactions with the S' subsites 
of the enzyme.   
There is no specific peptide sequence that these parasitic enzymes prefer, however 
they belong to Clan CA cysteine proteases and there are good inhibitors of Clan CA 
cysteine proteases with the peptide sequence Cbz-Leu-Abu.
94, 95
  We decided to 
synthesize inhibitors with Cbz-Leu-AAbu peptide sequence where we change the ! 
carbon of Abu to a nitrogen to form the aza-Abu (AAbu).  Aza-peptides have the 
advantage of being easily extended in the P1' region by the attachment of Michael 
acceptor and epoxide warheads.     
The second peptide sequence we focused on contained more hydrophobic amino 
acids; a phenylalanine (Phe) and an aza-homophenylalanine (AHph) in the P2 and P1 
positions; respectively.  Again we changed the !-carbon of homophenylalanine residue to 
nitrogen to form the aza-peptide.  Aza-peptides are more resistant to enzymatic 
hydrolysis compared to amino acid analogs
81
 and this replacement makes the synthesis of 
final compounds considerably easier since it involves the coupling of an acid and aza-
peptide.  There were inhibitors with Phe-Hph peptide sequence in the literature however 
they were using different warheads, like vinyl sulfones.
96
  Currently, one of these 
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inhibitors, so called K11777 (Me-Piz-Phe-Hph-VS-Phenyl) has completed pre-clinical 
tests for the treatment of Chagas' disease and the inhibitor has been found to be non-toxic 
and non-mutagenic with an acceptable pharmacokinetic profile.
97
  We have decided to 
incorporate N-methyl piperazine and morpholine into our peptide sequences as N-capping 
groups instead of Cbz group to both increase the bioavailability of our compounds and 
study the interactions in the P3 position. 
Aza-peptide precursors (Cbz-Leu-NHNHCH2CH3, Mu-Phe-NHNHCH2CH2Ph 
and Me-Piz-Phe-NHNHCH2CH2Ph) were coupled to epoxides and Michael acceptors 
with a variety of substituents on the prime side such as esters, monosubstituted amides 
and disubstituted amides to study the effect of modification in the P1' position. 
 
CHEMISTRY 
For the synthesis of the aza-peptide precursor Cbz-Leu-NHNHCH2CH3, the 
methyl ester Cbz-Leu-OMe (1) was reacted with excess hydrazine (NH2NH2) in methanol 
to form the hydrazide Cbz-Leu-NH-NH2 (2).  The Abu side chain was introduced  
 
Figure 3.4. Synthesis of Cbz-Leu-NHNHCH2CH3. 
 99 
reacting the hydrazide with acetaldehyde to form the hydrazone Cbz-Leu-NH-N=CH-
CH3 (3) which was reduced with NaBH3CN
98
 to form Cbz-Leu-NHNHCH2CH3 (Figure 
3.4). 
The synthesis of the acyl aza-homophenylalanine precursors (Y-CO-Phe-
NHNHCH2CH2Ph) is shown in Figure 3.5.  The hydrochloride salt of phenylalanine (5) 
was reacted with phosgene to form the phenylalanine ethyl ester isocyanate (6) using the 
procedure of Nowick et al.
99
  The phenylalanine ethyl ester isocyanate (6) was then 
reacted with either morpholine or N-methyl piperazine to form Y-CO-Phe-OEt (7, 8).  
The ethyl ester Y-CO-Phe-OEt (7, 8) was then reacted with excess hydrazine (NH2NH2) 
in methanol to form the hydrazide Y-CO-Phe-NH-NH2 (9, 10).  Introduction of the aza-
homophenylalanine side chain was achieved by first reacting the hydrazide Y-CO-Phe-
NH-NH2 with phenylacetaldehyde in THF to form the hydrazone (11, 12) and then 
reducing the hydrazone in the presence of NaBH3CN to yield the acyl aza-
homophenylalanine precursors (13, 14).   
 
 
Figure 3.5. Synthesis of Acyl Aza-homophenylalanine Precursors. 
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The synthesis of the aza-peptide fumarate and epoxide analogs are based on the 




 inhibitors.  
Monoethyl fumarate (15) was commercially available and all the Michael acceptor 
warheads were synthesized using this compound as a precursor.  The fumarate precursors 
(16 a-k) were prepared from monoethyl fumarate and the corresponding primary or 
secondary amines by standard mixed anhydride coupling procedure using NMM and 
iBCF; and followed by hydrolysis of the ethyl ester with aqueous NaOH (Figure 3.6).   
 
 
Reagents: (i) NMM, iBCF, CH2Cl2, HNR1R2; (ii) 1. NaOH, 2. HCl, EtOH. 




Reagents: (i) NMM, iBCF, CH2Cl2, HNR1R2; (ii) 1. KOH, 2. HCl, EtOH. 
Figure 3.7.  Synthesis of Epoxysuccinate Derivatives. 
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A previously described procedure
92
 was followed for the synthesis of (2S,3S)-
oxirane-2,3-dicarboxylic acid monoethyl ester (17).  The epoxide warheads (18l, m) were 
synthesized from the monoethyl ester epoxysuccinate and the corresponding primary or 
secondary amines by using the standard mixed anhydride coupling procedure using 
NMM and iBCF followed by hydrolysis of the ethyl ester in ethanol using aqueous KOH 
(Figure 3.7.).  
The aza-peptidyl inhibitors were obtained by coupling aza-peptidyl precursor to a 
fumarate acid or an epoxysuccinyl acid derivative using HOBt and EDC (Figure 3.8). 
 
 
Figure 3.8.  Coupling of Fumarate Precursors and Epoxide Moieties to Aza-peptide 
Precursors. 
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RESULTS AND DISCUSSION 
 
Inhibition Studies 
We synthesized two Michael acceptor inhibitors with Cbz-Leu-AAbu peptide 
sequences and the ethyl ester derivative (19a) with an IC50 of 14 µM against cruzain has 
the same potency as the disubstituted amide derivative (19h) with an IC50 of 16 µM.  
Rhodesain favored the ethyl ester derivative with an IC50 of 4 µM to the disubstituted 
amide derivative with an IC50 of 20 µM.  Both compounds were moderate inhibitors of 
cruzain and rhodesain and inactive against TbCatB but displayed some trypanocidal 
activity with an IC50 of 55 µM for compound 19a and 18 µM for compound 19h.      
From the five inhibitors with Mu-Phe-AHph peptide sequence, three of them were 
Michael acceptor inhibitors and two of them were epoxide inhibitors.  Among the three 
Michael acceptor inhibitors, the one with disubstituted amide derivative (20b, IC50 >100 
µM) was a poor inhibitor of both cruzain and rhodesain.  When the methyl group was 
replaced with hydrogen in compound 20c, IC50 value of 0.9 µM against cruzain and IC50 
value of 2 µM against rhodesain was obtained.  This result indicated the importance of 
the amide hydrogen in that position and a possible involvement in hydrogen bonding with 
an amino acid residue of the active site of both enzymes.  Mu-Phe-AHph-CH=CH-
CONH(CH2)2CH(Ph)2 was a poor inhibitor of cruzain and rhodesain (IC50 >100 µM) 
even though it was a monosubstituted amide analog.  We speculated that the alkyl spacer 
and the two phenyl rings may position the inhibitor away from the hydrogen bond 
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Table 3.1.  Inhibition of Cruzain, Rhodesain, TbCatB and T. brucei by Aza-Peptide 










Cbz-Leu-AAbu-CH=CH-COOEt 14 4 55 
Cbz-Leu-AAbu-CH=CH-CON(CH3)CH2-1-naphthyl 16 20 18 
Mu-Phe-AHph-CH=CH-CON(CH3)Ph >100 >100 23 
Mu-Phe-AHph-CH=CH-CONHCH2Ph 0.9 2 18 
Mu-Phe-AHph-CH=CH-CONH(CH2)2CH(Ph)2 >100 >100 11.5 
Mu-Phe-AHph-EP(S,S)-CONHCH2-1-naphthyl 0.09 0.04 7 
Mu-Phe-AHph-EP(S,S)-CON(CH2Ph)2 3 1 6 
Me-Piz-Phe-AHph-CH=CH-CON(CH3)Ph >100 >100 77 
Me-Piz-Phe-AHph-CH=CH-CONHCH2Ph 4 0.8 29 
Me-Piz-Phe-AHph-CH=CH-CONHCH2Ph-4-F 0.2 0.02 26 
Me-Piz-Phe-AHph-CH=CH-CONH(CH2)2Ph 2.8 0.16 17 
Me-Piz-Phe-AHph-CH=CH-CONH(CH2)3Ph 37 0.08 16.2 
Me-Piz-Phe-AHph-CH=CH-CONHCH2-1-naphthyl 3 0.5 5.6 
Me-Piz-Phe-AHph-CH=CH-CON(CH3)CH2-1-naphthyl >100 >100 5.6 
Me-Piz-Phe-AHph-CH=CH-CONH(CH2)2indole 98 1.2 22 
Me-Piz-Phe-AHph-CH=CH-CON(CH2Ph)2 >100 >100 6.6 
Me-Piz-Phe-AHph-CH=CH-CONH(CH2)2CH(Ph)2 52 87 11 
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network and two phenyl rings may not be accommodated in the P1' position due to 
bulkiness of the groups.  Mu-Phe-AHph-EP(S,S)-CONHCH2-1-naphthyl was one of the 
two epoxide inhibitors synthesized and yielded the most potent inhibitor in this series 
with an IC50 of 0.09 µM against cruzain and IC50 of 0.04 µM against rhodesain.  The 
second epoxide inhibitor Mu-Phe-AHph-EP(S,S)-CON(CH2Ph)2, was a disubstituted 
amide derivative and resulted in decrease in potency with an IC50 = 3 µM against cruzain 
and IC50 of 1 µM against rhodesain.  All the compounds with Mu-Phe-AHph peptide 
sequence have IC50 values higher than 100 µM against TbCatB.  In the proliferation 
assay, aza-peptide epoxides, which had large and bulky hydrophobic groups in the P1' 
position, were favored over aza-peptide Michael acceptors. 
   
 
Figure 3.9.  Proposed Mode of Interaction of the Aza-peptide Michael Acceptor Inhibitor 
with the Active Site of Cruzain 
 
We have synthesized 10 Michael acceptor inhibitors with Me-Piz-Phe-AHph 
peptide sequence.  Three compounds (21b, 21, h, 21j) with disubstituted amide analogs 
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were poor inhibitors of both cruzain and rhodesain with IC50 values greater than 100 µM.   
Replacement of the methyl group in compound 21h with hydrogen to obtain compound 
21g (Me-Piz-Phe-AHph-CH=CH-CONHCH2-1-naphthyl, IC50 = 3 µM against cruzain 
and IC50 = 0.5 µM against rhodesain) resulted in increased potency again suggesting the 
importance of amide hydrogen in this position.  Indeed, analysis of the crystal structures 
from the vinyl sulfone inhibitors showed that the side chains of Asp158 and Gln156 were 
positioned toward the amide NH.  Based on the kinetic data and the crystal structures 
available, we proposed that the amide nitrogen is forming hydrogen bonds with Asp158 
and Gln156 side chains (Figure 3.9).  Me-Piz-Phe-AHph-CH=CH-CONH(CH2)2CH(Ph)2 
have IC50 values of 52 and 87 µM against cruzain and rhodesain; respectively.  This 
compound was slightly more potent than the disubstituted amide analogs but still weak 
inhibitor of cruzain and rhodesain due to the presence of bulky hydrophobic groups.  Me-
Piz-Phe-AHph-CH=CH-CONH(CH2)2indole was a weak inhibitor of cruzain with an IC50 
of 98 µM whereas it was a good inhibitor of rhodesain with an IC50 of 1.2 µM.  This is 
one of the two examples where the two parasite enzymes differed markedly in their SAR.  
There is an NH in the indole ring of this compound (21i) and the hydrogen is probably 
involving in a hydrogen bonding network near the active site of rhodesain.  Me-Piz-Phe-
AHph-CH=CH-CONH(CH2)3Ph (21f) was also a weak inhibitor of cruzain with an IC50 
value of 37 µM, probably due to the unfavorable positioning of the phenyl ring by the 
alkyl spacer.  However, in the case of rhodesain, 21f was one of the most potent 
compounds synthesized in this series against this enzyme with an IC50 of 0.08 µM.  As 
the length of the alkyl spacer decreased in compounds 21e (Me-Piz-Phe-AHph-CH=CH-
CONH(CH2)2Ph, IC50 = 2.8 µM and 21c (Me-Piz-Phe-AHph-CH=CH-CONHCH2Ph, 
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IC50 = 4 µM) the inhibition potency of the compounds against cruzain increased.  On the 
other hand, shortening of the alkyl chain by one methylene group resulted in 2-fold 
decrease in potency in compound 21e (IC50 = 0.16 µM) and further shortening of the 
alkyl spacer by removal of another methylene group resulted in 5-fold decrease in 
potency in compound 21c (IC50 = 0.8 µM).  We hypothesized that the length of the alkyl 
spacer was important in positioning the aromatic phenyl group and that phenyl group is 
reaching a hydrophobic pocket in the S2'.  Introduction of an electron withdrawing 
fluorine into the phenyl ring led to the discovery of most potent Michael acceptor 
inhibitor for both cruzain and rhodesain with IC50 values of 0.2 µM and 0.02 µM; 
respectively.  All the compounds with Me-Piz-Phe-AHph peptide sequence have IC50 
values greater than 100 µM against TbCatB.  On the other hand, all the compounds 
inhibited parasite proliferation.  Most potent compounds displayed trypanocidal activity 
in the low micromolar range and it has been observed that as we increased the 
hydrophobicity in the P1' position, the activity against the parasite increased.  In a recent 
study with purine-derived nitrile inhibitors, it has been observed that the trypanocidal 
activity against the parasite increased with increasing the hydrophobicity of the 
compounds.
100
  Two compounds were in particular interest.  Compounds 21h and 21j had 
IC50 values greater than 100 µM against all the enzymes, but inhibited the parasite 
proliferation with IC50 values of 5.6 µM and 6.6 µM; respectively.  
 
Mechanism of Inhibition.  Aza-peptide Michael acceptors and epoxides are 
irreversible inhibitors of clan CD cysteine proteases.  The mechanism of inhibition of 
cysteine proteases by Michael acceptors and epoxides proceeds via a nucleophilic attack 
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of the catalytic cysteine residue on the double bond of the Michael acceptor or the 
epoxide ring, followed by the formation of a covalent bond, and the inhibition of the 
enzyme irreversibly.  With the present inhibitors, nucleophilic attack of the active site 
cysteine thiol could occur at either carbon (C2 or C3) of the Michael acceptor double 
bond (Figure 3.10).  Crystal structures of aza-peptide epoxide inhibitors specifically 
designed to inhibit caspase-3 showed that the cysteine thiol attack occurs at the C3 
carbon of the epoxide.
65
  Crystal structures of several Michael acceptor inhibitors of 
caspase-3 and caspase-8 have been determined.
64
  It has been observed that the cysteine 
thiol attack occurs at the C2 carbon of the Michael acceptor double bond.  As a result, we 
conclude that it is likely that cruzain and rhodesain are also alkylated at the C2 carbon of 
Michael acceptor double bond and C3 carbon of epoxide inhibitors.  Thus, the site of 
alkylation is located at approximately the same distance from the aza-peptide nitrogen 











We have demonstrated the potential of aza-peptidyl Michael acceptors and 
epoxides to inhibit parasitic cysteine proteases; cruzain and rhodesain and also inhibit the 
parasite proliferation.  We have shown that compounds with Mu-Phe-AHph peptide 
sequence are favored over Me-Piz-Phe-AHph and that, in turn, are favored over Cbz-Leu-
AAbu peptide sequence. 
Aza-peptide epoxides were potent inhibitors with IC50 values as low as 90 nM and 
40 nM against cruzain and rhodesain; respectively.  With aza-peptide Michael acceptors, 
we have also obtained IC50 values in the nanomolar range.  We have observed that 
monosubstituted amides were preferred to disubstituted amides indicating the importance 
of hydrogen bonding in that position.  Hence, the study of the available crystal structures 
of cruzain showed two possible hydrogen bonding amino acid residues, Asp158 and 
Gln156, near the active site.  It has been shown before that the phenylalanine residue in 
the P2 position is interacting with the hydrophobic residues Leu67, Ala133, Leu157 and 
Gly160 and hydrogen bonds are formed between the inhibitor’s peptide backbone atoms 
(amide nitrogen and carbonyl oxygen of the P2 residue) and Gly66 in the catalytic cleft.  
Here we report for the first time the involvement of the amide hydrogen in the P1' 
position in a hydrogen network.  We have observed that as we increased the length of the 
alkyl spacer of the hydrophobic groups, the potency decreased in cruzain but it had little 
effect in rhodesain. 
Irreversible cysteine protease inhibitors would have great potential for the short-
term therapeutic administration against parasitic infections.  Recently, a Michael acceptor 
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inhibitor, K11777 (Me-Piz-Phe-Hph-VS-Phenyl) has completed pre-clinical trials for the 
treatment of Chagas' disease.  Here, we have shown that aza-peptide epoxide and Michael 
acceptor inhibitors represent promising drug leads capable of inhibiting the parasitic 
enzymes in the nanomolar range.  Also, there has been no success in determination of a 
crystal structure of rhodesain, and selective irreversible inhibitors reported here may help 
to determine the structural and enzymatic specificities of the rhodesain active site. 
Significance    
African sleeping sickness and Chagas’ disease affect millions of people in South 
America and Africa.  Currently used drugs have serious side effects and the parasite is 
becoming more and more resistant to these drugs, and therefore there is an urgent need 
for the development of new anti-parasitic agents.  This research expanded our knowledge 
about the active sites of the parasitic cysteine proteases, rhodesain and cruzain.  We have 
discovered new sites of interaction of inhibitors with these parasitic cysteine proteases.  
This research will assist in the development of potent inhibitors which in turn will help 




Material and Methods.  Materials were obtained from Acros, Bachem 
Bioscience Inc., or Sigma Aldrich and used without further purification.  The purity of 
each compound was confirmed by TLC, 
1
H NMR, MS, and elemental analysis.  
Chemical shifts are reported in ppm relative to an internal standard (trimethylsilane).  




spectra were obtained on a Varian Mercury 400 MHz spectrometer.  Electrospray 
ionization (ESI), fast-atom-bombardment (FAB) and high-resolution mass spectrometry 
were obtained using Micromass Quattro LC and VG Analytical 70-SE instruments.  
Elemental analysis was carried out by Atlantic Microlab Inc., Norcross, GA.  The 
synthetic aza-peptide inhibitors were tested against cruzain, rhodesain, TbCatB and T. 
brucei by Conor Caffrey in the laboratory of Jim McKerrow at the University of 
California, San Francisco. 
 Cruzain.  Inhibitors were screened for effectiveness against the T. cruzi cathepsin 
L-like protease (cruzain) using purified recombinant protein.  Cruzain (1 nM) was 
incubated with 20-50000 nM inhibitor in 100 mM sodium acetate, 5 mM DTT buffer (pH 
5.5) for 5 min at room temperature.  An aliquot of Cbz-Phe-Arg-AMC (200 µL) was 
added to the enzyme-inhibitor reaction to give a 20 &M substrate concentration.  The 
increase in fluorescence (excitation at 355 nM and emission at 460 nM) was followed 
with an automated microtiter plate spectrofluorimeter (Molecular Devices, SpectraMAX 
Gemini).  Inhibitor stock solutions were prepared at 20 mM in DMSO, and serial 
dilutions were made in DMSO.  Controls were performed using enzyme alone and 
enzyme with DMSO.  
 Rhodesain.  Rhodesain (3 nM) was incubated with 0.5 to 10 µM inhibitor in 100 
mM sodium acetate, containing 5 mM DTT, pH 5.5 (Buffer A) for 5 min at room 
temperature. Then buffer A containing Z-Phe-Arg-AMC was added to enzyme inhibitor 
to give 20 µM substrate in 200 µL, and the increase in fluorescence (excitation at 355 nM 
and emission at 460 nM) was followed with an automated microtiter plate 
spectrofluorimeter (Molecular Devices, Flex station).  Inhibitor stock solutions were 
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prepared at 20 mM in DMSO, and serial dilutions were made in DMSO. Controls were 
performed using enzyme alone and enzyme with DMSO.  
 TbcatB.  An amount of 100 µL of TbcatB (final assay concentration, 35 nM) in 
assay buffer (0.05 M sodium acetate, pH 5.5, 4 mM DTT, 0.5 mM EDTA) was added to 
each well of a black flatbottom polystyrene 96-well plate (Corning).  An amount of 2 µL 
of inhibitor in DMSO was added, and the mixture was incubated at room temperature for 
20 min before the addition of 100 µL of Z-Phe-Arg-AMC (final assay concentration, 10 
µM) substrate in assay buffer.  Initial rates were determined by monitoring fluorescence 
((ex = 350 nm, (em = 460 nm) on an Envision plate reader (Perkin-Elmer) for 10 min. 
 Cell Proliferation Assays.  All IC50 values were determined by curve-fitting with 
GraphPad Prism software.  Culture-adapted T. brucei were grown at 37 °C in 5% CO2 in 
HMI-9 medium (HyClone) supplemented with penicillin/streptomycin (50 units/mL), 
10% heat-inactivated FBS (Omega Scientific, lot no. 3137), and 10% Serum Plus (JHR 
Biosciences) to a density of 1 ) 106 cells/mL and then diluted to 1 ) 104 cells/mL.  An 
amount of 100 µL of the diluted culture was added to each well of a white flat-bottom 
sterile 96-well plate (Greiner), and 1 µL of inhibitor in DMSO was added.  Plates were 
incubated for 48 h at 37 °C, in 5% CO2, and then equilibrated at room temperature for 1 h 
before the addition of 100 µL of Cell Titer Glo (Promega) to each well.  Plates were then 
shaken on an orbital shaker for 2 min at 500 rpm.  Luminescence was read after 8 min on 
an Envision plate reader (Perkin-Elmer).   
 General Procedure for the Synthesis of Acyl Phenylalanine Ethyl ester.  
Phenylalanine methyl ester isocyanate, which was synthesized from the hydrochloride 
salt of phenylalanine according to the procedure by Nowick et al., was dissolved in 
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CH2Cl2 and cooled down to 0 °C.  Morpholine or N-methylpiperazine was added to the 
stirred solution of phenylalanine ethyl ester isocyanate in dichloromethane.  Reaction 
mixture was stirred vigorously for 16 h at room temperature.  Solvent was removed under 
vacuum and the crude product was purified by column chromatography.  
(S)-ethyl 2-(morpholine-4-carboxamido)-3-phenylpropanoate (7, Mu-Phe-
OEt) was purified by column chromatography on silica gel using 4:1 EtOAC:Hexane as 
the eluent; white solid, yield 63%.  
1
H-NMR (CDCl3-d): 1.21-1.25 (t, 3H, CH3), 3.10 (d, 
2H, CH2Ph), 3.27-3.32 (m, 4H, morpholine), 3.62-3.65 (m, 4H, morpholine), 4.13-4.18 
(m, 2H, CH2), 4.74-4.78 (m, 1H, !-H), 4.91 (d, 1H, NH), 7.10-7.29 (m, 5H, Ph).  MS 
(ESI) m/z 307.0 [(M + 1)
+
].   
(S)-ethyl 2-(4-methylpiperazine-1-carboxamido)-3-phenylpropanoate (8, Me-
Piz-Phe-OEt) was purified by column chromatography on silica gel using 
10%MeOH/CH2Cl2 as the eluent; white solid, yield 81%.  
1
H-NMR (CDCl3-d): 1.20-1.23 
(t, 3H, CH3), 2.27-2.35 (m, 7H, piperazine and NCH3), 3.09 (d, 2H, CH2Ph), 3.29-3.38 
(m, 4H, piperazine), 4.11-4.17 (m, 2H, CH2), 4.72-4.89 (m, 1H, !-H), 4.90 (d, 1H, NH), 
7.09-7.28 (m, 5H, Ph).  MS (ESI) m/z 320.1 [(M + 1)
+
].   
Peptidyl Hydrazides.  Anhydrous hydrazine (10 equiv) was added to a stirred 
solution of a peptidyl ethyl ester (1 eq) or N-benzyloxycarbonyl leucine methyl ester 
(Cbz-Leu-OMe) in MeOH and the reaction mixture was stirred vigorously for 16 h at 
room temperature. Excess hydrazine and solvent were removed under vacuum and the 
residue was washed with ether several times to give the peptidyl hydrazide as a white 
solid. 
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Cbz-Leu-NH-NH2 (2), white solid, 64% yield.  
1
H NMR (DMSO-d6): 0.81-0.88 
(m, 6H, 2 x Leu-CH3), 1.29-1.58 (m, 3H, CH2 and CH), 3.96 (m, 1H, !-H), 4.19 (s, 2H, 
NH2), 4.47 (d, 1H, NH), 4.99 (s, 2H, CH2), 7.29-7.39 (m, 5H, Ph), 9.15 (s, 1H, NH).  MS 
(ESI) m/z 280.2 [(M + 1)
+
]. 
Mu-Phe-NH-NH2 (9), white solid, 93% yield.  
1
H-NMR (DMSO-d6): 2.78-2.91 
(m, 2H, CH2Ph), 3.12-3.25 (m, 4H, morpholine), 3.39-3.49 (m, 4H, morpholine), 4.19-
4.29 (m, 3H, !-H and NH2), 6.57 (d, 1H, NH), 7.14-7.24 (m, 5H, Ph), 9.10 (s, 1H, NH).  
MS (ESI) m/z 293.1 [(M + 1)
+
].   
Me-Piz-Phe-NH-NH2 (10), white solid, 95% yield.  
1
H-NMR (DMSO-d6): 2.11-
2.48 (m, 7H, piperazine and NCH3), 2.86-2.91 (m, 2H, CH2Ph), 3.20-3.23 (m, 4H, 
piperazine), 3.55 (s, 2H, NH2), 4.23 (m, 1H, !-H), 6.52 (d, 1H, NH), 7.15-7.34 (m, 5H, 
Ph), 10.97 (s, 1H, NH).  MS (ESI) m/z 306.1 [(M + 1)
+
].   
Peptidyl Hydrazones.  Phenylacetaldehyde or acetaldehyde (2 eq) was added to a 
stirred solution of peptidyl hydrazide (1 eq) in dry THF and the reaction mixture was 
stirred overnight at room temperature. Solvent was removed under vacuum and the crude 
product was purified by column chromatography.  
Cbz-Leu-NHN=CHCH3 (3) was purified by column chromatography on silica gel 
using 10%MeOH/CH2Cl2 as the eluent; white solid, yield 92%.  
1
H NMR (DMSO-d6): 
0.82-0.88 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.32-1.64 (m, 3H, CH2 and CH), 3.95-
3.99 (m, 1H, !-H), 4.99 (s, 2H, CH2), 7.26-7.33 (m, 6H, Ph and CH), 7.49 (d, 1H, NH), 
10.85 (s, 1H, NH).  MS (ESI) m/z 306.1 [(M + 1)
+
].   
Mu-Phe-NHN=CHCH2Ph (11) was purified by column chromatography on silica 




d6): 3.14-3.47 (m, 10H, morpholine and CH2Ph), 3.58 (d, 2H, CHCH2Ph), 4.21-4.26 (m, 
1H, !-H), 6.59 (d, 1H, NH), 7.15-7.34 (m, 10H, 2 x Ph), 7.55 (t, 1H, CH), 10.99 (s, 1H, 
NH).  MS (ESI) m/z 395.2 [(M + 1)
+
].   
Me-Piz-Phe-NHN=CHCH2Ph (12) was purified by column chromatography on 
silica gel using 15%MeOH/CH2Cl2 as the eluent; yellow solid, yield 75%.  
1
H-NMR 
(DMSO-d6): 2.18-2.30 (m, 7H, piperazine and NCH3), 3.01-3.44 (m, 6H, piperazine and 
CHCH2Ph), 3.52-3.61 (m, 2H, CH2Ph), 4.54-4.60 (m, 1H, !-H), 5.55 (d, 1H, NH), 7.11-
7.31 (m, 11H, 2 x Ph and CH), 10.51 (s, 1H, NH).  MS (ESI) m/z 408.2 [(M + 1)
+
].   
Aza-peptidyl precursor.  NaBH3CN (3 eq) was added to a solution of peptidyl 
hydrazone (1 eq) in THF.  The reaction mixture was heated to 60 °C and stirred overnight 
after the addition of HCl.  The solvent was evaporated and the residue was dissolved in 
EtOAc and washed with 10% NaHCO3, water, saturated NaCl and dried over MgSO4 and 
concentrated.  Purification on a silica gel column with the proper eluent gave the product 
with yields of 52-72%.  
Cbz-Leu-NHNHCH2CH3 (4) was purified by column chromatography on silica 
gel using 10%MeOH/CH2Cl2 as the eluent; white solid, yield 52%.  
1
H NMR (DMSO-
d6):  0.81-0.94 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.33-1.57 (m, 3H, CH2 and CH), 
2.62-2.66 (m, 2H, CH2), 3.97 (m, 1H, !-H), 4.76 (s, 1H, NH), 4.99 (s, 2H, CH2), 7.30-
7.39 (m, 6H, Ph and NH), 9.41 (s, 1H, NH).  MS (ESI) m/z 308.2 [(M + 1)
+
].   
Mu-Phe-NHNHCH2CH2Ph (13) was purified by column chromatography on silica 
gel using 10%MeOH/CH2Cl2 as the eluent; white solid, yield 68%.  
1
H-NMR (DMSO-
d6): 2.60 (t, 1H, NH), 2.81-2.88 (m, 4H, CH2CH2Ph and CH2CH2Ph), 3.15-3.23 (m, 6H, 
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morpholine and CH2Ph), 3.41-3.49 (m, 4H, morpholine), 4.23-4.28 (m, 1H, !-H), 6.61 (d, 
1H, NH), 7.13-7.29 (m, 10H, 2 x Ph), 9.43 (s, 1H, NH).  MS (ESI) m/z 397.2 [(M + 1)
+
].   
Me-Piz-Phe-NHNHCH2CH2Ph (14) was purified by column chromatography on 
silica gel using 15%MeOH/CH2Cl2 as the eluent; white solid, yield 72%.  
1
H-NMR 
(DMSO-d6): 2.25-2.31 (m, 7H, piperazine and NCH3), 2.61-2.64 (t, 2H, NHCH2CH2Ph), 
2.87-3.05 (m, 4H, CH2Ph and CH2CH2Ph), 3.27-3.32 (m, 4H, piperazine), 4.47-4.55 (m, 
1H, !-H), 5.24 (d, 1H, NH), 7.12-7.32 (m, 11H, 2 x Ph and NH), 8.19 (s, 1H, NH).  MS 
(ESI) m/z 410.3 [(M + 1)
+
].   
General Procedure for the Synthesis of Fumaric Acid Monoamides by the 
Mixed Anhydride Coupling Method.  Coupling of the amine precursors to monoethyl 
fumarate was accomplished using the mixed anhydride coupling method.  To a solution 
of the monoethyl fumarate (1 eq) in CH2Cl2 at -20 °C was added N-methylmorpholine 
(NMM, 1 eq) followed by isobutyl chloroformate (iBCF, 1 eq).  After the reaction 
mixture was allowed to stir for 30 min, the amine (1 eq) was added to the mixture.  
Hydrochloride salts of the amine were pretreated with NMM (1 eq) at -20 °C in CH2Cl2 
prior to addition.  After 30 min the reaction was continued to stir overnight at room 
temperature.  The methylene chloride was evaporated and the residue was redissolved in 
ethyl acetate and washed with 2% citric acid, saturated NaHCO3, saturated NaCl, dried 
over MgSO4, and concentrated. The product was purified by column chromatography as 
needed.   
trans-N-Methyl-N-phenylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH3)Ph) was obtained by mixed anhydride coupling of 




H-NMR (CDCl3): 1.25 (t, 3H, CH3CH2), 3.39 (s, 3H, N-CH3), 4.17 (q, 2H, 
CH3CH2), 6.93-6.97 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.10-7.14 (d, 1H, J = 15.2 Hz, 
CH=CHCON), 7.15 (t, 1H, Ph), 7.34 (t, 2H, Ph), 7.61 (d, 2H, Ph).
 
trans-N-Methyl-N-phenylcarbamoylpropenoic Acid (16b, 
HOOCCH=CHCON(CH3)Ph).  EtOOCCH=CHCON(CH3)Ph  was hydrolyzed in 
MeOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking conditions to give 
a white solid (29% yield).  
1
H-NMR (DMSO-d6): 3.14 (s, 3H, N-CH3), 6.50-6.54 (d, 1H, 
J = 15.2 Hz, CH=CHCON), 6.60-6.64 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.32 (t, 2H, 
Ph), 7.40 (d, 1H, Ph), 7.47 (d, 1H, Ph). 
trans-3-Benzylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONHCH2Ph) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and benzylamine.  Purification by column 
chromatography using 5% MeOH/CH2Cl2 gave a white powder (81% yield).  
1
H-NMR 
(DMSO-d6): 1.20-1.24 (t, 3H, CH2CH3), 4.14-4.19 (q, 2H, CH2CH3), 4.37 (d, 2H, 
NCH2Ph), 6.57-6.61 (d, 1H, CH=CHCON), 7.03-7.07 (d, 1H, CH=CHCON), 7.22-7.34 
(m, 5H, Ph), 9.04 (t, 1H, NH).
 
trans-3-Benzylcarbamoylpropenoic Acid (16c, HOOCCH=CHCONHCH2Ph).  
EtOOCCH=CHCONHCH2Ph was hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 
eq) under standard deblocking conditions to give a white solid (73% yield).  
1
H-NMR 
(DMSO-d6): 4.36 (d, 2H, NCH2Ph), 6.52-6.56 (d, 1H, CH=CHCON), 6.95-6.99 (d, 1H, 
CH=CHCON), 7.23-7.33 (m, 5H, Ph), 8.98 (t, 1H, NH).  MS (ESI) m/z 206 [(M + 1)
+
]. 
trans-3-(4-Fluorobenzylcarbamoyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CHCONH-CH2Ph-4-F) was obtained by mixed anhydride coupling of 
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equimolar amounts of monoethyl fumarate and 4-fluorobenzylamine to give a pink solid 
(66% yield).  
1
H-NMR (CDCl3):  1.32 (t, 3H, CH2CH3), 4.21 (q, 2H, CH2CH3), 4.47 (d, 
2H, N-CH2-Ph), 6.52-6.56 (d, 1H, J = 15.2 Hz, CH=CHCON), 6.94-6.98 (d, 1H, J = 15.6 
Hz, CH=CHCON), 6.99-7.04 (m, 2H, Ph), 7.20-7.27 (m, 2H, Ph). 
  trans-3-(4-Fluorobenzylcarbamoyl)propenoic Acid (16d, 
HOOCCH=CHCONH-CH2Ph-4-F).  EtOOCCH=CHCONH-CH2Ph-4-F was 
hydrolyzed in MeOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a clear, colorless syrup (45% yield).  
1
H-NMR (DMSO-d6): 4.34-4.35 
(d, 2H, N-CH2-Ph), 6.52-6.55 (d, 1H, J = 15.2 Hz, CH=CHCON), 6.93-6.94 (d, 1H, J = 
15.6 Hz, CH=CHCON), 7.14-7.16 (t, 2H, Ph), 7.27-7.31 (t, 2H, Ph), 8.99 (t, 1H, NH). 
trans-3-Phenylethylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONHCH2CH2Ph) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and phenylethylamine to give a clear colorless 
syrup (78% yield). 
 
trans-3-Phenylethylcarbamoylpropenoic Acid (16e, 
HOOCCH=CHCONHCH2CH2Ph).  EtOOCCH=CHCONHCH2CH2Ph was hydrolyzed 
in MeOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking conditions to 
give a clear, colorless syrup (81% yield).  
1
H-NMR (DMSO-d6): 3.54 (t, 2H, N-CH2-
CH2-Ph), 3.61 (t, 2H, N-CH2-CH2-Ph) 6.43-6.47 (d, 1H, J = 15.2 Hz, CH=CHCON), 
6.98-7.02 (d, 1H, J = 15.6 Hz, CH=CHCON), 7.14-7.31 (m, 5H, Ph). 
trans-3-Phenylpropylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCONHCH2CH2CH2Ph) was obtained by mixed anhydride coupling of 
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equimolar amounts of monoethyl fumarate and 3-phenyl-1-propylamine.  Purification by 
column chromatography using 1:1 EtOAc:hexane gave a white powder (80% yield).   
trans-3-Phenylpropylcarbamoylpropenoic Acid (16f, 
HOOCCH=CHCONHCH2CH2CH2Ph).  EtOOCCH=CHCONHCH2CH2CH2Ph was 
hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white powder (81% yield).  
1
H-NMR (DMSO-d6): 1.68-1.76 (m, 2H, 
NH-CH2-CH2-CH2-Ph), 2.49-2.59 (t, 2H, NH-CH2-CH2-CH2-Ph), 3.12-3.17 (q, 2H, NH-
CH2-CH2-CH2-Ph) 6.47-6.51 (d, 1H, J = 15.6 Hz, CH=CHCON), 6.90-6.94 (d, 1H, J = 
15.6 Hz, CH=CHCON), 7.15-7.28 (m, 5H, Ph), 8.51 (t, 1H, NH). 
trans-3-(1-Naphthylmethylcarbamoyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CH-CONHCH2-1-Napth) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and naphthalen-1-ylmethanamine.  
Purification by column chromatography using 2:1 Hexanes:EtOAc to give white powder 
(86% yield).  
1
H-NMR (CDCl3): 1.20 (t, 3H, CH3), 3.99 (q, 2H, CH2), 4.93 (d, 2H, CH2-
naphth), 6.84 (d, 1H, CH=CHCON), 6.90 (d. 1H, CH=CHCON), 7.38-7.44 (m, 2H, 
naphthyl), 7.47-7.54 (m, 2H, naphthyl), 7.79 (d, 1H, naphthyl), 7.84 (d, 1H, naphthyl), 
7.95 (d, 1H, naphthyl).  
trans-3-(1-Naphthylmethylcarbamoyl)propenoic Acid (16g, HOOCCH=CH-
CONHCH2-1-Napth).  EtOOCCH=CHCONHCH2-1-napth  was hydrolyzed in EtOH 
using NaOH (1 M aqueous, 1.1 eq) under standard deblocking conditions to give a white 
solid (76% yield).  
1
H-NMR (DMSO-d6): 4.82 (d, 2H, CH2-naphth), 6.56-6.60 (d, 1H, J 
= 15.6 Hz, CH=CHCON), 6.91-6.95 (d. 1H, , J = 15.6 Hz, CH=CHCON), 7.40-7.57 (m, 
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4H, naphthyl), 7.84-7.86 (m, 1H, naphthyl), 7.94 (d, 1H, naphthyl), 8.03 (d, 1H, 
naphthyl), 9.00 (t, 1H, NH).  
trans-3-(Methyl-1-naphthylmethylcarbamoyl)propenoic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH3)CH2-1-Napth) was obtained by mixed anhydride coupling 
of equimolar amounts of monoethyl fumarate and N-methyl-1-naphthylmethylamine 
hydrochloride.  Purification by column chromatography using 1:1 EtOAc:hexane gave a 
white powder (62% yield).  
1
H-NMR (CDCl3): 1.29 (t, 3H, CH3), 3.01 (s, 3H, CH3), 5.11 
(s, 2H, CH2), 6.87-6.92 (d, 1H, CH=CHCON), 7.40-7.52 (m, 5H, CH=CHCON and 
naphthyl), 7.78-7.89 (m, 3H, naphthyl). 
trans-3-(Methyl-1-naphthylmethylcarbamoyl)propenoic Acid (16h, 
HOOCCH=CHCON(CH3)CH2-1-Napth).  EtOOCCH=CHCON(CH3)CH2-1-Napth  
was hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a white solid (13% yield).  
1
H-NMR (DMSO-d6): 3.01 (s, 3H, CH3), 
5.01 (s, 2H, CH2), 6.61-6.65 (d, 1H, J = 15.2 Hz, CH=CHCON), 7.17-7.21 (d, 1H, 
CH=CHCON), 7.37-7.60 (m, 4H, naphthyl), 7.85-8.01 (m, 3H, naphthyl). 
trans-3-Dibenzylcarbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CHCON(CH2Ph)2) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and dibenzylamine to give a clear, pink syrup 
(87% yield). 
 
trans-3-Dibenzylcarbamoylpropenoic Acid (16j, 
HOOCCH=CHCON(CH2Ph)2). EtOOCCH=CHCON(CH2Ph)2 was hydrolyzed in EtOH 
using NaOH (1 M aqueous, 1.1 eq) under standard deblocking conditions to give a white 
powder (91% yield).  
1
H-NMR (DMSO-d6): 4.57 (s, 2H, NCH2Ph), 4.65 (s, 2H, 
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NCH2Ph), 6.61-6.65 (d, 1H, CH=CHCON), 7.15-7.17 (d, 1H, CH=CHCON), 7.25-7.50 
(m, 10H, 2 x Ph). 
trans-3-(2-(1H-indol-3-yl)ethyl)carbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CH-CONH(CH2)2indole) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and 2-(1H-indol-2-yl)ethylamine to give a 
brown solid (64% yield).   
trans-3-(2-(1H-indol-3-yl)ethyl)carbamoylpropenoic Acid (16i, 
HOOCCH=CH-CONH(CH2)2indole).  EtOOCCH=CH-CONH(CH2)2indole was 
hydrolyzed in EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking 
conditions to give a off-white solid (87% yield).  
1
H-NMR (DMSO-d6): 2.47 (t, 1H, CH), 
2.84-2.87 (t, 2H, CH2), 3.41-3.46 (t, 2H, CH2), 6.49-6.53 (d, 1H, CH=CHCON), 6.89-
6.93 (d, 1H, CH=CHCON), 6.96-7.06 (m, 2H, 2 x CH), 7.14 (s, 1H, CH), 7.31 (d, 1H, 
CH), 7.51 (d, 1H, CH), 8.60 (t, 1H, NH), 10.81 (s, 1H, COOH). 
trans-3-(3,3-diphenylpropyl)carbamoylpropenoic Acid Ethyl Ester 
(EtOOCCH=CH-CONH(CH2)2CH(Ph)2) was obtained by mixed anhydride coupling of 
equimolar amounts of monoethyl fumarate and 3,3-diphenylpropan-1-amine to give a 
yellow oil (74% yield). 
 
trans-3-(3,3-diphenylpropyl)carbamoylpropenoic Acid (16k, HOOCCH=CH-
CONH(CH2)2CH(Ph)2).  EtOOCCH=CH-CONH(CH2)2CH(Ph)2 was hydrolyzed in 
EtOH using NaOH (1 M aqueous, 1.1 eq) under standard deblocking conditions to give a 
white solid (83% yield).  
1
H-NMR (DMSO-d6): 2.18-2.30 (m, 2H, CH2), 3.02-3.07 (m, 
2H, CH2), 3.99 (t, 1H, CH), 6.47-6.51 (d, 1H, CH=CHCON), 6.90-6.94 (d, 1H, 
CH=CHCON), 7.12-7.30 (m, 10H, 2 x Ph), 8.53 (t, 1H, NH). 
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General Procedure for Coupling of the Mono Ethyl Ester Epoxysuccinates to 
Amines.  The method used was the mixed anhydride coupling method.  The mono ethyl 
ester epoxysuccinate (1 eq) was dissolved in CH2Cl2 and cooled to -20 °C. To the 
reaction mixture was added NMM (3 eq) and then iBCF (3 eq).  The reaction mixture 
was stirred at -20 °C for 15-20 minutes and then the amine (3 eq) was added. The 
reaction mixture was then stirred at -20 °C for one hour and then at room temperature 
overnight. The solvent was removed, and the crude product was dissolved in EtOAc.  The 
organic layer was then washed with of 2% citric acid, saturated NaHCO3 and brine.  The 
product was purified with column chromatography as needed. Hydrolysis of the ethyl 
ester with 1 M NaOH (1.5 eq) in EtOH gave the desired amides. 
(2S,3S)-Oxirane-2,3-dicarboxylic Acid Dibenzyl Amide (18m, HOOC-EP-
CON(CH2Ph)2) was obtained by mixed anhydride coupling of the mono ethyl ester 
epoxysuccinate and dibenzylamine to give a clear oil and then hydrolyzed in basic 
conditions to the corresponding acid.  
1
 H NMR (DMSO-d6): 3.51 (d, 1H, epoxy CH), 
4.03 (d, 1H, epoxy CH), 4.50 (dd, 2H, NCH2Ph), 4.70 (dd, 2H, NCH2Ph), 7.18-7.36 (m, 
10H, 2 x Ph). 
(2S,3S)-Oxirane-2,3-dicarboxylic Acid 1-Naphthylmethyl Amide (18l, 
HOOC-EP-CONH-1-CH2-Napth) was obtained by mixed anhydride coupling of the 
mono ethyl ester epoxysuccinate and 1-naphthylmethylamine to give a yellow powder 
and then hydrolyzed in basic conditions to the corresponding acid.  
1
H NMR (Acetone-
d6): 3.59 (d, 1H, epoxy CH), 3.82 (d, 1H, epoxy CH), 5.21-5.36 (m, 4H, N(1-CH2-
naphthyl)2), 7.37-7.56 (m, 8H, N(1-CH2- naphthyl)2), 7.84-7.96 (m, 5H, N(1-CH2- 
naphthyl)2), 8.15-8.18 (m, 1H, N(1-CH2- naphthyl)2).  
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General Procedure for the Synthesis of Aza-Peptide Michael Acceptors and 
Aza-Peptide Epoxides by the HOBt/EDC Coupling Method.  To a stirred solution of 
the fumaric acid or epoxide precursor (1.5 eq) in DMF at -10 °C was added HOBt (1.5 
eq), the peptidyl hydrazide precursor (1 eq) and EDC (1.5 eq) was added.  The mixture 
was allowed to react for 16 h at room temperature.  The DMF was evaporated, and the 
residue was redissolved in EtOAc.  The organic layer was washed with 2% citric acid, 
saturated NaHCO3, saturated NaCl, dried over MgSO4, and concentrated.  Column 









ethoxycarbonylpropenoyl)hydrazine (19a, Cbz-Leu-AAbu-CH=CH-COOEt).  This 
compound was obtained using the HOBt/EDC coupling method and purified by column 
chromatography using 10% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (20% yield).  
1
H-NMR (CDCl3): 0.92-1.07 (m, 9H, 2 
x Leu-CH3 and Abu-CH3), 1.26 (t, 3H, CH3), 1.56-1.73 (m, 3H, Leu-CH and CH2), 3.66 
(m, 2H, CH2), 4.15-4.25 (m, 3H, !-H and CH2), 5.12 (s, 2H, CH2), 5.31 (d, 1H, NH), 
6.78-6.82 (d, 1H, CH=CHCON), 7.20-7.24 (d, 1H, CH=CHCON), 7.33 (m, 5H, Ph), 8.86 
(s, 1H, NH).  HRMS (FAB) Calcd. for C22H32N3O6:  434.2291.  Observed m/z 434.2287.   
Anal. Calcd. for C22H31N3O6#0.15H2O: C, 60.58; H, 7.23; N, 9.63.  Found: C, 60.59; H, 









CON(CH3)CH2-1-naphthyl).  This compound was obtained using the HOBt/EDC 
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coupling method and purified by column chromatography using 5% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with EtOAc/hexane gave a white powder (41% yield).  
1
H-
NMR (DMSO-d6): 0.85-1.06 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.46-1.64 (m, 3H, 
Leu-CH and CH2), 2.97 (s, 3H, CH3), 3.27 (s, 1H, CH), 3.74 (s, 1H, CH), 4.08 (m, 1H, !-
H), 5.04-5.18 (m, 4H, 2 x CH2), 7.11-7.70 (m, 12H, Ph, naphthyl, CH=CHCON, 
CH=CHCON and NH), 7.85-8.05 (m, 3H, naphthyl), 10.76 (s, 1H, NH).  HRMS (FAB) 
Calcd. for C32H39N4O5: 559.2921.  Observed m/z 559.2896.   Anal. Calcd. for 









CON(CH3)Ph).  This compound was obtained using the HOBt/EDC coupling method 
and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (28% yield).  
1
H-NMR 
(DMSO-d6): 2.92-2.98 (m, 2H, CH2CH2Ph), 3.20-3.48 (m, 15H, morpholine, CH2CH2Ph 
and CH2Ph and CH3), 4.38 (m, 1H, !-H), 6.55-6.59 (d, 1H, CH=CHCON), 6.90 (d, 1H, 
NH), 7.04-7.46 (m, 16H, 3 x Ph and CH=CHCON), 10.75 (s, 1H, NH).  HRMS (FAB) 
Calcd. for C33H38N5O5: 584.2867.  Observed m/z 584.2868.   Anal. Calcd. for 









CONHCH2Ph).  This compound was obtained using the HOBt/EDC coupling method 
and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  




(DMSO-d6): 2.10-2.14 (m, 7H, piperazine and NCH3), 2.95 (m, 2H, CH2CH2Ph), 3.22-
3.44 (m, 8H, morpholine, CH2CH2Ph and CH2Ph), 4.34 (m, 3H, CH2Ph and !-H), 6.85-
6.89 (m, 2H, CH=CHCON and NH), 7.13-7.29 (m, 16H, 3 x Ph and CH=CHCON), 8.89 
(s, 1H, NH), 10.75 (s, 1H, NH).  HRMS (FAB) Calcd. for C33H38N5O5: 584.2880.  
Observed m/z 584.2867.   Anal. Calcd. for C33H37N5O5#0.4H2O: C, 67.08; H, 6.45; N, 









CONH(CH2)2CH(Ph)2).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (46% yield).  
1
H-NMR 
(DMSO-d6): 2.16-2.20 (m, 2H, CH2), 2.89-2.99 (m, 4H, CH2Ph and CH2), 3.23-3.32 (m, 
4H, morpholine, CH2CH2Ph and CH2Ph), 3.44 (s, 4H, morpholine), 3.95-3.99 (t, 1H, 
CH), 4.35 (m, 1H, !-H), 6.79-6.88 (m, 2H, CH=CHCON and NH), 7.05-7.26 (m, 21H, 4 
x Ph and CH=CHCON), 8.44 (s, 1H, NH), 10.75 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C41H46N5O5: 688.3493.  Observed m/z 688.3461.   Anal. Calcd. for C41H45N5O5#0.3H2O: 







Mu-Phe-AHph-EP(S,S)-CONHCH2-1-naphthyl).  This compound was obtained using 
the HOBt/EDC coupling method and purified by column chromatography using 15% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(30% yield).  
1
H-NMR (DMSO-d6): 2.94 (m, 2H, CH2CH2Ph), 3.20-3.53 (m, 12H, 
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morpholine, CH2CH2Ph and CH2Ph), 3.72 (s, 1H, epoxy-CH), 4.04 (s, 1H, epoxy-CH), 
4.31 (m, 1H, !-H), 4.72 (m, 2H, CH2), 6.93 (d, 1H, NH), 7.18-7.52 (m, 14H, 2 x Ph, 
naphthyl), 7.82-7.98 (m, 3H, naphthyl), 8.94 (s, 1H, NH), 10.78 (s, 1H, NH).  HRMS 
(FAB) Calcd. for C37H40N5O6: 650.2979.  Observed m/z 650.2993.  Anal. Calcd. for 







(22m, Mu-Phe-AHph-EP(S,S)-CON(CH2Ph)2).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 15% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(20% yield).  
1
H-NMR (DMSO-d6): 2.99 (m, 2H, CH2CH2Ph), 3.23-3.46 (m, 12H, 
morpholine, CH2CH2Ph and CH2Ph), 3.72 (s, 1H, epoxy-CH), 3.87 (s, 1H, epoxy-CH), 
4.03 (m, 1H, !-H), 4.222-4.70 (m, 4H, 2 x CH2Ph), 6.95 (d, 1H, NH), 7.18-7.36 (m, 20H, 
4 x Ph),  10.75 (s, 1H, NH).  HRMS (FAB) Calcd. for C40H44N5O6: 690.3292.  Observed 
m/z 690.3281.  Anal. Calcd. for C40H43N5O6#0.7H2O: C, 68.40; H, 6.37; N, 9.97.  Found: 









CH=CH-CON(CH3)Ph).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  





H-NMR (DMSO-d6): 2.10-2.14 (m, 7H, piperazine and NCH3), 2.96-2.98 
(m, 2H, CH2CH2Ph), 3.23-3.27 (m, 8H, piperazine, CH2CH2Ph and CH2Ph and CH3), 
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4.35 (m, 1H, !-H), 6.55-6.59 (d, 1H, CH=CHCON), 6.83 (d, 1H, NH), 7.13-7.45 (m, 
16H, 3 x Ph and CH=CHCON), 10.73 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C34H41N6O4: 597.3184.  Observed m/z 597.3184.  Anal. Calcd. for C34H40N6O4#0.65H2O: 









CONHCH2Ph).  This compound was obtained using the HOBt/EDC coupling method 
and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (11% yield).  
1
H-NMR 
(DMSO-d6): 2.10-2.14 (m, 7H, piperazine and NCH3), 2.95 (m, 2H, CH2CH2Ph), 3.24-
3.33 (m, 8H, piperazine, CH2CH2Ph and CH2Ph), 4.35 (m, 3H, CH2Ph and !-H), 6.84-
6.88 (m, 2H, CH=CHCON and NH), 7.18-7.29 (m, 16H, 3 x Ph and CH=CHCON), 8.89 
(s, 1H, NH), 10.74 (s, 1H, NH).  HRMS (FAB) Calcd. for C34H41N6O4: 597.3189.  
Observed m/z 597.3229.  Anal. Calcd. for C34H40N6O4#1.1H2O: C, 66.24; H, 6.90; N, 









CONHCH2Ph-4-F).  This compound was obtained using the HOBt/EDC coupling 
method and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (23% yield).  
1
H-NMR 
(DMSO-d6): 2.10-2.14 (m, 7H, piperazine and NCH3), 2.95 (m, 2H, CH2CH2Ph), 3.24-
3.32 (m, 8H, piperazine, CH2CH2Ph and CH2Ph), 4.33 (m, 3H, CH2Ph and !-H), 6.83-
6.87 (m, 2H, CH=CHCON and NH), 7.09-7.28 (m, 15H, 2 x Ph, Ph-F and CH=CHCON), 
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8.90 (s, 1H, NH), 10.74 (s, 1H, NH).  HRMS (FAB) Calcd. for C34H40N6O4F: 615.3095.  
Observed m/z 615.3136.  Anal. Calcd. for C34H39N6O4F#0.5H2O: C, 65.47; H, 6.46; N, 









CONH(CH2)2Ph).  This compound was obtained using the HOBt/EDC coupling method 
and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (23% yield).  
1
H-NMR 
(DMSO-d6): 2.11-2.17 (m, 7H, piperazine and NCH3), 2.70-2.74 (t, 2H, CH2CH2Ph), 
2.95 (m, 2H, CH2CH2Ph), 3.27-3.32 (m, 10H, piperazine, CH2CH2Ph, CH2Ph and 
CH2CH2Ph), 4.34 (m, 1H, !-H), 6.82 (m, 2H, CH=CHCON and NH), 7.07-7.30 (m, 16H, 
3 x Ph and CH=CHCON), 8.49 (s, 1H, NH), 10.73 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C35H43N6O4: 611.3346.  Observed m/z 611.3361.  Anal. Calcd. for C35H42N6O4#0.15H2O: 









CONH(CH2)3Ph).  This compound was obtained using the HOBt/EDC coupling method 
and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (15% yield).  
1
H-NMR 
(DMSO-d6): 1.67-1.74 (m, 2H, CH2CH2CH2), 2.10-2.15 (m, 7H, piperazine and NCH3), 
2.54-2.58 (t, 2H, CH2CH2CH2Ph), 2.96 (m, 2H, CH2CH2Ph), 3.12-3.32 (m, 10H, 
piperazine, CH2CH2Ph, CH2Ph and CH2CH2CH2Ph), 4.32 (m, 1H, !-H), 6.81-6.84 (m, 
2H, CH=CHCON and NH), 7.07-7.29 (m, 16H, 3 x Ph and CH=CHCON), 8.42 (s, 1H, 
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NH), 10.73 (s, 1H, NH).  HRMS (FAB) Calcd. for C36H45N6O4: 625.3458.  Observed m/z 
625.3463.  Anal. Calcd. for C36H44N6O4#0.8H2O: C, 67.65; H, 7.19; N, 13.15.  Found: C, 









CH=CH-CONHCH2-1-naphthyl).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography using 15% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with EtOAc/hexane gave a white powder (28% yield).  
1
H-
NMR (DMSO-d6): 2.08-2.13 (m, 7H, piperazine and NCH3), 2.97 (m, 2H, CH2CH2Ph), 
3.23-3.32 (m, 8H, piperazine, CH2CH2Ph and CH2Ph), 4.33 (m, 1H, !-H), 4.81 (d, 2H, 
CH2), 6.84-6.91 (m, 2H, CH=CHCON and NH), 7.18-7.53 (m, 15H, 2 x Ph, naphthyl and 
CH=CHCON), 7.83-8.02 (m, 3H, naphthyl), 8.93 (s, 1H, NH), 10.76 (s, 1H, NH).  
HRMS (FAB) Calcd. for C38H43N6O4: 647.3340.  Observed m/z 647.3249.  Anal. Calcd. 










CH=CH-CON(CH3)CH2-1-naphthyl).  This compound was obtained using the 
HOBt/EDC coupling method and purified by column chromatography using 15% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(12% yield).  
1
H-NMR (DMSO-d6): 2.11-2.19 (m, 7H, piperazine and NCH3), 2.96-2.99 
(m, 2H, CH2CH2Ph and CH3), 3.27-3.33 (m, 8H, piperazine, CH2CH2Ph, CH2Ph), 4.34 
(m, 1H, !-H), 5.01-5.17 (m, 2H, CH2), 6.86 (d, 1H, NH), 7.10-7.59 (m, 16H, 2 x Ph, 
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naphthyl, CH=CHCON and CH=CHCON), 7.84-8.06 (m, 3H, naphthyl), 10.74 (d, 1H, 
NH).  HRMS (FAB) Calcd. for C39H45N6O4: 661.3497.  Observed m/z 661.3486.   Anal. 
Calcd. for C39H44N6O4#0.75H2O: C, 69.47; H, 6.80; N, 12.46.  Found: C, 69.41; H, 6.77; 









CH=CH-CONH(CH2)2indole).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography using 15% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with EtOAc/hexane gave a white powder (32% yield).  
1
H-
NMR (DMSO-d6): 2.10-2.17 (m, 7H, piperazine and NCH3), 2.82-2.86 (t, 2H, CH2), 2.98 
(m, 2H, CH2CH2Ph), 3.28-3.43 (m, 10H, piperazine, CH2CH2Ph, CH2Ph and CH2), 4.35 
(m, 1H, !-H), 6.84-7.51 (m, 18H, 2 x Ph, indole, CH=CHCON, CH=CHCON and NH), 
8.54 (s, 1H, NH), 10.75-10.81 (m, 2H, 2 x NH).  HRMS (FAB) Calcd. for C37H44N7O4: 
650.3455.  Observed m/z 650.3473.   Anal. Calcd. for C37H43N7O4#0.9H2O: C, 66.73; H, 









CON(CH2Ph)2).  This compound was obtained using the HOBt/EDC coupling method 
and purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (34% yield).  
1
H-NMR 
(DMSO-d6): 2.10-2.14 (m, 7H, piperazine and NCH3), 2.97 (m, 2H, CH2CH2Ph), 3.26-
3.33 (m, 8H, piperazine, CH2CH2Ph and CH2Ph), 4.34 (m, 1H, !-H), 4.48-4.59 (m, 4H, 2 
x CH2Ph), 6.85 (d, 1H, NH), 7.14-7.37 (m, 22H, 4 x Ph, CH=CHCON and 
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CH=CHCON), 8.89 (s, 1H, NH), 10.75 (s, 1H, NH).  HRMS (FAB) Calcd. for 
C41H47N6O4: 687.3659.  Observed m/z 687.3662.  Anal. Calcd. for C41H46N6O4#0.3H2O: 









CH=CH-CONH(CH2)2CH(Ph)2).  This compound was obtained using the HOBt/EDC 
coupling method and purified by column chromatography using 15% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with EtOAc/hexane gave a white powder (19% yield).  
1
H-
NMR (DMSO-d6): 2.09-2.19 (m, 9H, piperazine, NCH3 and CH2), 2.94-2.99 (m, 4H, 
CH2CH2Ph and CH2), 3.23-3.32 (m, 8H, piperazine, CH2CH2Ph, CH2Ph and CH2), 3.95-
3.99 (t, 1H, CH), 4.32 (m, 1H, !-H), 6.79-6.83 (m, 2H, CH=CHCON and NH), 7.06-7.26 
(m, 21H, 4 x Ph and CH=CHCON), 8.43 (s, 1H, NH), 10.71 (s, 1H, NH).  HRMS (FAB) 
Calcd. for C42H49N6O4: 701.3810.  Observed m/z 701.3796.  Anal. Calcd. for 
C42H48N6O4#0.2H2O: C, 71.61; H, 6.92; N, 11.93.  Found: C, 71.51; H, 6.94; N, 11.83. 
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CHAPTER 4 
DESIGN, SYNTHESIS AND EVALUATION OF  
PEPTIDYL KETOAMIDES, AMINOKETONES AND  




Calpains are cysteine proteases that require calcium for activation.  They belong 
to Clan CA of cysteine proteases together with cruzain, rhodesain, papain and cathepsins.  
There are multiple isoforms of calpain that are both ubiquitous and tissue specific.  
Calpain I (µ-calpain) and calpain II (m-calpain) are the two major calpain isoforms that 
are widely distributed in mammalian cells.  These two isoforms are very similar but differ 
in the calcium concentration that they require to become activated.  Calpain I is activated 
by micromolar concentration of Ca
+2
 whereas calpain II is activated by millimolar 
concentration of Ca
+2
.  Calpains are involved in a variety of calcium-regulated biological 
processes, such as cell proliferation and differentiation, apoptosis, membrane fusion, 
signal transduction and platelet activation.  Enhanced calpain activity has been observed 




















 diseases and 
multiple sclerosis.
117, 118
  Involvement of calpains in a wide variety of biological 
processes and diseases makes them an important target for the development of inhibitors.  
 132 
Synthetic calpain inhibitors can be divided into two groups: peptidic inhibitors 
and non-peptidic inhibitors.  Peptidic inhibitors can further be divided into two groups: 











 and !-keto phosphorus
123, 124
 are 










examples of irreversible peptidyl inhibitors of calpain.  Reversible inhibitors of calpain 
are favored over the irreversible inhibitors for drug development since there are many 
isoforms of calpains and nonspecific inhibition of these isoforms can cause severe side 
effects. 
Synthetic calpain inhibitors have been shown to protect against neuronal loss and 





 optic nerve degeneration,
132
 spinal cord injury,
133
 Taxol-induced sensory 
neuropathy.
134
  The neuroprotective effects of calpain inhibitors have been well 
established but their use in treatment of human diseases is challenged by their inability to 
cross the blood-brain barrier.  The blood brain barrier (BBB) is a metabolic or cellular 
structure in the central nervous system (CNS) that restricts the passage of various 
chemical substances between the bloodstream and the neural tissue itself, while still 
allowing the passage of substances essential to metabolic function.   
Several attempts are reported in the literature to allow the entry of these 
compounds into central nervous system.  In most designs calpain inhibitors were 
combined structural features recognized by specific transporters in the brain.  For 
example, the calpain inhibitor leupeptin was fused with taurine to facilitate access to the 
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brain and spinal cord via the taurine transport system
135
 and a leupeptin analog was 
covalently bound to L-aminocarnitine for the penetration of the inhibitor into muscle cells 
via the carnitine transporter.  A series of ketoamide calpain inhibitors were coupled to 
various muscle cell targeting capping groups to assist the accumulation of the compounds 
in muscle cells for the treatment of Duchenne Muscular Dystrophy and an improved 
uptake into muscle cells have been observed.
136
    
  
 
Figure 4.1.  Cbz-Leu-Abu-CONH-(CH2)3-morpholinyl (AK295) 
 
AK295 is a reversible !-ketoamide calpain inhibitor and it has been shown that 
AK295 is effective in the treatment of experimental head trauma,
131
 focal brain 
ischaemia
137





  Although the therapeutic efficacy of AK295 has been well 
established, its development as a drug is hampered by its inability to cross the BBB.  We 
decided to design new analogs of AK295 that can cross the BBB.  For the design of 
AK295 analogs, we decided to incorporate structural features that could be recognized by 
several BBB transport systems.  Thus, we expected that these new calpain inhibitors 
would be more permeable to the BBB than AK295 and penetration into the brain and 
spinal cord would provide increased therapeutic efficacy through increased access of the 
calpain inhibitors to the nervous system.  
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Charged and polar compounds, many of which are essential to the brain, do not 
cross the BBB and there are multiple transport systems to facilitate the delivery of these 
compounds to the brain.  We have focused on two transport systems; choline and 
nucleoside transport systems.  Choline, a positively charged molecule, has a critical role 
in the CNS as a precursor to the neurotransmitter acetylcholine.  As a charged molecule, 
choline does not cross the BBB and its uptake into brain is dependent upon carrier-
mediated transport.  The BBB choline transporter is responsible for the transportation of 
choline across the BBB and it has been showed that this transporter can be used as a brain 
drug delivery vector for choline analogs.
139
  Nucleosides, the building blocks of RNA and 
DNA, are hydrophilic compounds and do not readily penetrate cell membranes by 
passive diffusion.  There are several nucleoside transporters for the active transport of 
these molecules.
140
  Nucleoside transporters are sensitive or specific for different 
heterocyclic bases.  It has been shown that several nucleoside reverse transcriptase 
inhibitors that are used in the treatment of HIV infection are transported into the CNS by 
these nucleoside transporters.
141
   









4.1. PEPTIDYL !-KETOAMIDES: POTENT INHIBITORS OF CALPAIN 
INHIBITOR DESIGN 
 
 Peptidyl inhibitors of calpain usually contain an electrophilic warhead that reacts 
with the active site cysteine to inhibit the enzyme.  Among the various kinds of warheads, 
we focused on the synthesis of !-ketoamides.  Peptidyl !-ketoamides inactivate the 
enzyme by forming a reversible hemithioketal adduct, and therefore minimizing possible 
side effects which could be observed with irreversible inhibitors.  Peptidyl !-ketoamides 
are also more stable both chemically and metabolically compared to other reversible 
warheads, such as peptidyl aldehydes.
10
  The major problem with !-ketoamides for their 
development as potential therapeutic targets is their inhibition of other cysteine proteases.  
Therefore, there is a need for calpain-specific inhibitors that will not affect other cysteine 
proteases.   
A wide variety of !-ketoamides have been synthesized to develop more selective 
calpain inhibitors by increasing the calpain specificity versus other cysteine proteases.  
Most of these compounds were designed to explore the interactions in the unprimed side 
of calpain to enhance selectivity.
142, 143
  From these studies, it has been found that 
phenylalanine and leucine were preferred in the P1 and P2 positions; respectively.
144
  
However, targeting the unprimed region to improve specificity is not sufficient since 
there are other cysteine proteases that also prefer these amino acids in P1 and P2 
positions.
145
  To target calpain specifically, researchers focused on extending the 
inhibitors into the primed side of calpain.
146, 147
  Peptidyl !-ketoamides previously 
synthesized in our group showed that the extension of the inhibitors into the primed 
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region increased the potency of the inhibitors, and N-monosubstituted peptidyl !-













Figure 4.1.2.  Crystal Structure of ZLAK3002 bound to Calpain I.  
 
To synthesize compounds that can cross the BBB and selectivity inhibit calpain, 
peptidyl !-ketoamides with choline-like structures in the primed side and a peptidyl !-
ketoamide with an adenine residue in the primed side were synthesized by Dr. Zhao Zhao 
Li from our lab.  Crystal structures of ZLAK3001 (Figure 4.1.1) and ZLAK3002 (Figure 
4.1.2.) bound to rat calpain I protease core (µI-II) were obtained by Campbell et al.
148
  It 
has been demonstrated that the adenine moiety of ZLAK3001 stacks against a tryptophan 
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in the catalytic site of calpain I and the amino group of adenine is forming a hydrogen 
bond to Glu300.  Neither this stacking nor hydrogen bond formation was observed 
between the piperazinyl ring of ZLAK3002 and the primed side region.  It has been 
shown that ZLAK3001 and ZLAK3002 penetrate into the brain by highly sensitive and 
specific HPLC/mass spectrometry assays.   
Design of Novel Calpain Inhibitors  
A hydrophobic pocket formed by Ala262, Ile263 and Val269 near the C2 carbon 
of adenine moiety has been observed in the crystal structure of ZLAK3001 bound to 
calpain I.  To facilitate interactions with this hydrophobic pocket, we have synthesized 
peptidyl !-ketoamides with 2-methoxyadenine moiety in the primed region.  We 
proposed that this modification will increase the potency and selectivity and generate 
compounds that have the potential to cross the BBB.  We have synthesized two peptidyl 
!-ketoamides with cytosine in the primed region since the cytosine derivative can make 
the same interactions as observed with ZLAK3001.  We have also synthesized an analog 
of ZLAK3001 where we changed the P1 residue from Abu to Phe, since Phe in P1 




Synthesis of the peptidyl !-ketoacids are shown in Figure 4.1.3.  This chemistry 
has previously been reported.
149, 150
  N-benzyloxycarbonylleucine was reacted with 
aminobutyric acid methyl ester or phenylalanine methyl ester using the HOBt and DCC 
coupling procedure.  The dipeptide methyl esters were hydrolyzed with 1 M NaOH under 
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standard deblocking conditions.  The !-ketoesters were prepared by a two step Dakin-
West reaction from the corresponding dipeptide acid.  The dipeptide acids were reacted 
with ethyl oxalyl chloride in the presence of pyridine and 4-dimethylaminopyridine 
(DMAP) to form peptidyl !-enol esters.  The peptidyl !-enol esters were then converted 
to peptidyl !-ketoesters by reacting with triethylamine.  The peptidyl !-ketoacids were 





Figure 4.1.3.  Synthesis of the Peptidyl !-Ketoacids.  
 
Amines like 9-(3-aminopropyl)adenine (Figure 4.1.4) and  9-(3-aminopropyl)-2-




  Adenine and 2-methoxyadenine
152
 were reacted with dihaloalkanes to add 
the linker by a single alkylation reaction.  The halogen on the linker was then reacted 
with sodium azide to obtain the corresponding azide derivatives.  The catalytic reduction 
of the azides in the presence of palladium activated on carbon and hydrogen gas gave the 
precursor amines. 
     
 




Reagents: (i) BrCH2CH2CH2Cl, K2CO3, DMF (ii) NaN3, DMF (iii) H2, Pd/C, MeOH 
Figure 4.1.5.  Synthesis of 9-(3-aminopropyl)-2-methoxyadenine.  
  
For the synthesis of 1-(3-aminopropyl)cytosine,
153
 N-acetylcytosine was reacted 
with 1-bromo-3-chloropropane and then with sodium azide to form 1-(3-azidopropyl)-N-
acetylcytosine.  The acetyl group was deblocked with the ammonia and then the catalytic 
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reduction of azide was completed in the presence of palladium activated on carbon and 




Figure 4.1.6.  Synthesis of 1-(3-aminopropyl)cytosine. 
 
The peptidyl !-ketoamides were obtained by using HOBt and EDC coupling of 




Figure 4.1.7. Synthesis of Peptidyl !-Ketoamides. 
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RESULTS AND DISCUSSION 
 
A series of !-ketoamides as calpain inhibitors were synthesized and tested against 
calpain I, calpain II and cathepsin B (Table 4.1.1).  The inhibition studies showed that the 
compounds with adenine and 2-methoxyadenine in the primed region were more potent 




Figure 4.1.8.  Proposed Binding Interactions of the Peptidyl !-Ketoamides with the 
Active Site of Calpain I. 
 
The interactions of the peptidyl !-ketoamides with the active site of calpain I are 
shown in Figure 4.1.8.  On the unprimed region, hydrogen bonds are formed between the 
inhibitor’s peptide backbone atoms (amide nitrogen and carbonyl oxygen of the P2 
residue and amide nitrogen of the P1 residue) and Gly208 and Gly271.  The carbonyl of 
the carboxyamide provides stabilization via two hydrogen bonds with the side chain of 
Gln109 and the amide nitrogen of Cys115.     
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The best calpain I inhibitors were Cbz-Leu-Abu-CONH-(CH2)3-2-
methoxyadenine (8) and Cbz-Leu-Phe-CONH-(CH2)3-2-methoxyadenine (9) with Ki 
values of 23 and 41 nM, respectively.  Cbz-Leu-Abu-CONH-(CH2)3-adenine 
(ZLAK3001) and Cbz-Leu-Phe-CONH-(CH2)3-adenine (7) were slightly less potent than 
the 2-methoxyadenine derivatives but still have Ki values of 55 and 57 nM, respectively.  
The increased potency of 2-methoxyadenine derivatives confirmed that these compounds 
interact with the hydrophobic pocket in the primed region discovered in the crystal 
structure.  There is a hydrogen bond between the amino group of the adenine and the side 
chain of Glu300, resulting in favorable electrostatic interaction.  The peptidyl !-
ketoamides containing adenine and 2-methoxyadenine are further stabilized by the 
aromatic stacking of the adenine ring on Trp298.  Compounds 10 and 11 with cytosine in 
the primed side (Cbz-Leu-Abu-CONH-(CH2)3-cytosine, Ki = 165 nM; Cbz-Leu-Phe-
CONH-(CH2)3-cytosine, Ki = 480 nM) were 3- to 8-fold less potent than the adenine 
derivatives.  The amino group of the cytosine can also interact with the Glu300 and the 
lower potency of these compounds can be explained by the lack of aromatic stacking 
against Trp298.  Among the compounds with nucleotide bases in the primed region, Abu 
in the P1 position is slightly favored over Phe.   
Compounds containing N-methyl piperazine (ZLAK3002, Ki = 0.64 µM and 
ZLAK3006, Ki = 1.37 µM) and choline analogs (ZLAK3005, Ki = 26.5 µM; ZLAK3003, 
Ki = 0.226 µM; and ZLAK3004, Ki = 0.711 µM) in the primed side were less potent than 
AK295 and compounds with nucleotide bases in the primed side; but are still reasonable 
inhibitors of calpain I.  The N-methyl piperazine derivatives ZLAK3002 and ZLAK3006 
were less potent than the adenine derivatives ZLAK3001 and 7, since these compounds 
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were lacking the stacking interactions with Trp298.  Decreasing the alkyl spacer by one 
methylene group in compound ZLAK3004 resulted in 3-fold decrease in potency.  
Changing the amino acid in the P1 position from an Abu to a Phe resulted in 100-fold 
increase in potency in compound ZLAK3003.         
Calpain II Inhibition.  There is no crystal structure for calpain II but the active 
site of calpain II should be similar to the active of calpain I, therefore the same 
interactions shown in Figure 4.1.8 can occur between calpain II and peptidyl !-
ketoamides.  Cbz-Leu-Abu-CONH-(CH2)3-adenine (ZLAK3001) and Cbz-Leu-Phe-
CONH-(CH2)3-adenine (7) were the most potent inhibitors of calpain II with Ki values of 
70 nM and 68 nM, respectively.  Introduction of the methoxy group to the C2 carbon of 
adenine did not change the potency much for Cbz-Leu-Abu-CONH-(CH2)3-2-
methoxyadenine (8, Ki = 77 nM) but resulted in 3-fold decrease in potency for Cbz-Leu-
Phe-CONH-(CH2)3-2-methoxyadenine (9, Ki = 209 nM).  Cytosine derivatives Cbz-Leu-
Abu-CONH-(CH2)3-cytosine (10, Ki = 1.14 µM) and Cbz-Leu-Phe-CONH-(CH2)3-
cytosine (11, Ki = 0.438 µM) were less potent than the adenine and  
2-methoxyadenine derivatives.   
 The N-methyl piperazine derivatives Cbz-Leu-Abu-CONH-(CH2)3-N-(1-
methyl)piperazine (ZLAK3002, Ki = 0.286 µM) and Cbz-Leu-Abu-CONH-(CH2)3-N-(1-
methyl)piperazine (ZLAK3006, Ki = 6.36 µM) were less potent than the adenine 
derivatives ZLAK3001 and 9.  The choline analogs ZLAK3005, ZLAK3003 and 
ZLAK3004 have Ki values of 25.9 µM, 0.844 µM and 3.52 µM; respectively.  Again, 
decreasing the alkyl spacer length by one methylene group decreased the potency 4-fold 
for Cbz-Leu-Phe-CONH-(CH2)2-N-(CH3)2.  Replacement of Abu with Phe in the P1         
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 Cbz-Leu-Abu-CONH-(CH2)3-adenine 0.053  0.070  0.80   
 Cbz-Leu-Phe-CONH-(CH2)3-adenine 0.055  0.068  1.75   
 Cbz-Leu-Abu-CONH-(CH2)3-2-methoxyadenine 0.023 0.077  0.88   
 Cbz-Leu-Phe-CONH-(CH2)3-2-methoxyadenine 0.041  0.209  2.34   
 Cbz-Leu-Abu-CONH-(CH2)3-cytosine  0.165  1.14  0.75   
 Cbz-Leu-Phe-CONH-(CH2)3-cytosine  0.48  0.438  0.44   
 Cbz-Leu-Abu-CONH-(CH2)3-N-(1-methyl)piperazine 0.640  0.286  1.42   
 Cbz-Leu-Phe-CONH-(CH2)3-N-(1-methyl)piperazine 1.37  6.36  111   
 Cbz-Leu-Abu-CONH-(CH2)3-N-(CH3)2  26.5  25.9  44.9   
 Cbz-Leu-Phe-CONH-(CH2)3-N-(CH3)2   0.226  0.844  75.5   
 Cbz-Leu-Phe-CONH-(CH2)2-N-(CH3)2  0.711  3.52  475   
 Cbz-Leu-Abu-CONH-(CH2)3-morpholine 0.150  0.041 6.9  
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position resulted in 30-fold increase in potency for compound Cbz-Leu-Phe-CONH-
(CH2)3-N-(CH3)2.  
Selectivity.  The heterocyclic peptidyl !-ketoamides displayed lower affinity 
toward cathepsin B, since they were designed to target calpains.  Calpains cleave peptide 
substrates with a bulky residue (Phe, Abu or Met) in the P1 position and Val or Leu in the 
P2 position.  Cathepsin B preferentially cleaves peptide substrates having a bulky residue 
such as Phe in the P2 position and a small hydrophobic residue in the P1 position.  
Cathepsin B was inhibited by peptidyl !-ketoamides but selectivity was obtained for 
calpain I and calpain II in various peptidyl !-ketoamides.  The hydrophobic pocket found 
near the active site of calpain I was not observed in the primed side cleft of cathepsin B 
and addition of a hydrophobic group on the adenine ring resulted in an increased 
inhibitory potency toward calpain I and a decreased inhibitory potency toward cathepsin 
B.  Cbz-Leu-Abu-CONH-(CH2)3-2-methoxyadenine with a Ki value of 23 nM is 3- and 
38-fold poorer with calpain II and cathepsin B, respectively.  Cbz-Leu-Phe-CONH-
(CH2)3-2-methoxyadenine (Ki = 41 nM) is 5- and 57-fold more potent on calpain I than 
on calpain II and cathepsin B.  Cbz-Leu-Phe-CONH-(CH2)3-cytosine was equally potent 
against calpains and cathepsin B.  Cbz-Leu-Phe-CONH-(CH2)3-N-(CH3)2 having a Ki 
value of 0.226 µM is 3-, 334-fold more potent on calpain II and cathepsin B.   
  Mechanism of Inhibition.  The mechanism of inhibition of calpain by  
!-ketoamides involves the formation of a reversible enzyme-inhibitor complex prior to 
the attack of the active site cysteine residue (Cys 115) on the keto carbonyl group of the 
!-ketoamides.  This leads to the formation of a stable but reversible tetrahedral 
hemithioketal adduct (Figure 4.1.9).  This hemithioketal adduct resembles the transition-
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state for peptide bond hydrolysis, and it is quite stable.  There is a hydrogen bond 




Figure 4.1.9.  Mechanism of Interaction of Peptidyl !-Ketoamides with the Active Site 
of Calpain I. 
 
CONCLUSIONS and SIGNIFICANCE 
 
We have shown that peptidyl !-ketoamides with the general structure of Cbz-Leu-
D,L-AA-CONH(CH2)3-R, where R is a heterocyclic base, are effective inhibitors of 
calpains.  It has been observed that Abu, which is small hydrophobic residue, is slightly 
favored over the large hydrophobic residue Phe in the P1 position.  We have obtained Ki 
values in the nanomolar range. 
We have designed novel calpain inhibitors based on the crystal structure obtained 
with ZLAK3001.  We have proposed to introduce a hydrophobic group on the adenine 
ring to to facilitate interactions with the hydrophobic pocket observed in the crystal 
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structure.  Our design strategy worked and we successfully developed new calpain 
inhibitors with increased potency.   
All these peptidyl !-ketoamides were designed based on the structure of AK295 
which has been shown to be effective in the treatment of peripheral neuropathy.  The 
problem with this compound was that it does not get to the brain.  For calpain inhibitors 
to be used in the treatment of neurodegenerative diseases, they should be able to cross the 
BBB.  Our aim was to synthesize effective calpain inhibitors that can cross the BBB.  To 
do that, we have incorporated nucleoside and choline-like groups into the structure of our 
peptidyl !-ketoamides.  There are specific transporters that can facilitate the 
transportation of nucleosides and choline to the brain.   
 
AK295 in brain           0 microgram/g tissue 
ZLAK3001 in brain  1.17 microgram/g tissue 
 ZLAK3002 in brain  1.16 microgram/g tissue 
 
It has been shown that two of our compounds ZLAK3001 (with an adenine 
residue) and ZLAK3002 (with an N-methylpiperazine residue) have therapeutically 
useful concentrations in brain after administered to mice (Christina Hampton, Dr. 
Fernandez).  We have synthesized peptidyl !-ketoamides with cytosine and 2-
methoxyadenine in the primed side since these compounds also have the potential to 
cross the BBB.  
Increased levels of calpain activity have been observed in a number of 
neurodegenerative diseases including Alzheimer’s, Huntington’s and Parkinson’s 
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diseases and multiple sclerosis.  Development of selective calpain inhibitors that can 
cross the BBB is required for the treatment of these diseases.  Here, we have shown that 
peptidyl !-ketoamides are novel calpain inhibitors that can cross or have the potential to 
cross the BBB.  Heterocyclic peptidyl !-ketoamides have good potential to be used in the 
treatment of neurodegenerative diseases. 
 






















 In an effort to find new reversible inhibitors of calpain, we have designed peptidyl 
aminoketones (Figure 4.2.1).  These inhibitors yield a new patentable class of inhibitors 
that have the potential to cross the BBB.  The design of peptidyl aminoketones were 
based on peptidyl !-ketoamides.  The only difference between peptidyl aminoketones and 
peptidyl !-ketoamides was the carbonyl of the carboxyamide.  We removed this carbonyl 
group to develop peptidyl aminoketones as a new class of inhibitors.  The Cbz group was 
used as the N-terminal blocking group.  Since the compounds possessing an Abu in the 
P1 position had a modest advantage over those with Phe for peptidyl !-ketoamides, we 
used Abu in the P1 position and Leu in the P2 position.   
 
Figure 4.2.1.  Structures of ZLAK3001 and Peptidyl Aminoketone Derivative of 
ZLAK3001, 17. 
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 Peptidyl aminoketones have the advantage of being extended in the primed region 
of the inhibitor like the peptidyl !-ketoamides.  We have incorporated nucleoside bases 
like adenine, 2-methoxyadenine and 2-chloroadenine to the primed side of the inhibitor to 
facilitate an aromatic stacking interaction between the adenine moiety and the side chain 
of Trp298.  All these compounds can interact with Glu300 by forming a hydrogen bond 
with their amino groups.  We have anticipated that 2-methoxyadenine and 2-
chloroadenine derivatives would reach into the hydrophobic pocket formed by Ala262, 
Ile263 and Val269.  We also hypothesized that the attachment of nucleoside bases to 
peptidyl aminoketones would result in new calpain inhibitor structures with improved 




The synthesis of peptidyl chloromethyl ketone was shown in Figure 4.2.2.  
Commercially available N-benzyloxycarbonyl leucine (12) was coupled to H•Abu-OCH3 
using HOBt and DCC coupling procedure to form the dipeptidyl methyl ester Cbz-Leu-
Abu-OMe (13).  The peptidyl methyl ester (13) was hydrolyzed with 1 M NaOH (1.1 eq) 
in methanol under standard deblocking conditions to obtain Cbz-Leu-Abu-OH (14).  The 
dipeptidyl acid (14) was activated at the carboxy group by the mixed anhydride coupling 
method using isobutyl chloroformate (iBCF) and N-methyl morpholine (NMM) and 
reacted with ethereal diazomethane to form the corresponding peptidyl diazomethane 
ketone Cbz-Leu-Abu-CHN2 (15).  The diazomethane solution was prepared from N-
methyl-N-nitroso-4-toluenesulfonamide according to the literature.  The generated 
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peptidyl diazomethyl ketone (15) was reacted with HCl immediately to form the 
dipeptidyl chloromethyl ketone Cbz-Leu-Abu-CH2Cl (16).   
 
Figure 4.2.2. Synthesis of Dipeptidyl Chloromethyl Ketones. 
 
The heterocyclic amine 9-(3-aminopropyl)-2-chloroadenine (Figure 4.2.3) was 
synthesized from 2-chloroadenine in three steps.
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  The heterocyclic base, 2-
chloroadenine was reacted with 1-bromo-3-chloropropane to add the linker by a single 
alkylation reaction.  The halogen on the linker was then reacted with sodium azide to 
obtain the corresponding azide derivative.  The catalytic reduction of the azide in the 
presence of palladium activated on carbon and hydrogen gas gave the 9-(3-aminopropyl)-
2-chloroadenine.     
 
Figure 4.2.3.  Synthesis of 9-(3-aminopropyl)-2-chloroadenine 
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Peptidyl chloromethyl ketone was dissolved in THF and then reacted with 
heterocyclic amines in the presence of triethylamine under refluxing conditions to form 
the peptidyl aminoketones (Figure 4.2.4). 
 
 
Figure 4.2.4. Synthesis of Peptidyl Aminoketones. 
         




Figure 4.2.5.  Proposed Binding Interactions of Peptidyl Aminoketones with the Active 
Site of Calpain I. 
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17 Cbz-Leu-Abu-CH2-NH-(CH2)3-adenine 5.59 0.785 4.57 0.82 
18 Cbz-Leu-Abu-CH2-NH-(CH2)3-2-methoxyadenine 3.50 231  7.69   2.20 
19 Cbz-Leu-Abu-CH2-NH-(CH2)3-2-chloroadenine 3.07 14.5 0.41 0.13 
 
 
Calpain I Inhibition.  Peptidyl aminoketones were less potent than peptidyl !-
ketoamides, but they were still reasonable inhibitors of calpain I.  The decreased potency 
of peptidyl aminoketones compared to peptidyl !-ketoamides can be explained by the 
disturbance of hydrogen bond network by removal of the carbonyl of the carboxyamide 
(Figure 4.2.5).  Cbz-Leu-Abu-CH2-NH-(CH2)3-adenine (17, Ki = 5.59 µM) were less 
potent than Cbz-Leu-Abu-CH2-NH-(CH2)3-2-methoxyadenine (18, Ki = 3.50 µM) and 
Cbz-Leu-Abu-CH2-NH-(CH2)3-2-chloroadenine (19, Ki = 3.07 µM).  Introduction of 
hydrophobic groups to the C2 carbon of resulted in increased potency against calpain I 
where chlorine was favored over the methoxy group.   
Calpain II Inhibition.  Cbz-Leu-Abu-CH2-NH-(CH2)3-adenine was the most 
potent inhibitor against calpain II with a Ki value of 0.785 µM.  Replacement of adenine 
with 2-methoxyadenine in compound Cbz-Leu-Abu-CH2-NH-(CH2)3-2-methoxyadenine 
(18, Ki = 231 µM) resulted in drastic decrease in potency.  Cbz-Leu-Abu-CH2-NH-
 155 
(CH2)3-2-chloroadenine with a Ki value of 14.5 µM was 20-fold less potent than Cbz-
Leu-Abu-CH2-NH-(CH2)3-adenine.   
Cathepsin B Inhibition.  Cbz-Leu-Abu-CH2-NH-(CH2)3-2-chloroadenine was 
the most potent inhibitor of cathepsin B with a Ki value of 0.41 µM.  Removal of the 
chlorine group in compound Cbz-Leu-Abu-CH2-NH-(CH2)3-adenine (17, Ki = 4.57 µM) 
resulted in 10-fold decrease in potency.  Introduction of methoxy group into the C2 
carbon of adenine resulted in 2-fold decrease in compound Cbz-Leu-Abu-CH2-NH-
(CH2)3-2-methoxyadenine (18, Ki = 7.69 µM). 
Selectivity.  Cbz-Leu-Abu-CH2-NH-(CH2)3-2-methoxyadenine with a Ki value of 
3.50 µM toward calpain I was 66- and 2-fold poorer with calpain II and cathepsin B; 
respectively.  Cbz-Leu-Abu-CH2-NH-(CH2)3-adenine had a Ki value of 0.785 µM toward 
calpain II and this compound was 7-fold poorer with calpain I and almost equally potent 
toward cathepsin B with a Ki value of 4.57 µM.  Cbz-Leu-Abu-CH2-NH-(CH2)3-2-
chloroadenine with a Ki value of 0.41 µM toward cathepsin B was 7- and 35-fold more 




 Peptidyl aminoketones were designed as a new class of inhibitors for calpain with 
the general structure of Cbz-Leu-Abu-CH2-NH-(CH2)3-R where the R group is adenine, 
2-methoxyadenine and 2-chloroadenine.  Peptidyl aminoketones were less potent than the 
peptidyl !-ketoamides.  The carbonyl group of the carboxyamide was missing from the 
peptidyl aminoketones.  The carbonyl oxygen of the carboxyamide was stabilized by two 
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hydrogen bonds from Gln109 and Cys115 in peptidyl !-ketoamides.  Probably, the 
disturbance of this hydrogen network by removing the carbonyl group to form the 
peptidyl aminoketones resulted in less potent inhibitors.   
Addition of hydrophobic groups to the adenine ring resulted in an increased 
inhibitory potency toward calpain I, where the chlorine group is favored over the 
methoxy group.  On the other hand; introduction of hydrophobic groups led to a decrease 
in inhibitory potency toward calpain II.  Peptidyl aminoketones inhibited calpains as well 
as cathepsin B effectively. 
Calpains are involved in a wide range of biological processes and elevated levels 
of calpain activity have been observed in a number of neurodegenerative diseases.  
Calpains are ideal targets for the development of inhibitors.  There are many isoforms of 
calpains and nonspecific inhibition of these isoforms can cause severe side effects.  
Therefore, reversible inhibitors of calpain are favored over the irreversible inhibitors.  We 
have extended our inhibitors to the prime side by introducing nucleoside bases.  These 
compounds have the potential to cross the BBB.  Here, we report a new class of 
reversible calpain inhibitors with the potential to cross the BBB.       








4.3. AZA-PEPTIDYL KETONES 
  
 We have synthesized seven aza-peptide ketones, which are aza-derivatives of our 




 The design of aza-peptide ketone inihibitors was based on the peptidyl !-
ketoamides synthesized by our group (Figure 4.3.1).   In aza-peptide ketones, the !- 
carbon of the P1 amino acid residue (Abu) was replaced with a nitrogen atom to form the 
aza-amino acid residue (AAbu).  This modification changes the geometry of the alpha 
position from tetrahedral to trigonal and reduces the electrophilicity of the P1 carbonyl 
group.
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  Some aza-peptides are more resistant to hydrolysis than their peptide analogs 
due to these reasons.
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  We used Leu in the P2 position and Cbz as the capping group 
same as !-ketomaides.  To keep the bases in the primed side of the aza-peptide ketone 
inhibitors at the same distance as peptidyl !-ketomides we used an alkyl spacer.  The 
carbonyl group that is attacked by the active site cysteine is in the same position as 
peptidyl !-ketomaides but the second carbonyl group and amide NH groups present in 
ketoamides were missing from the aza-peptide ketones.  Aza-peptidyl ketone derivative 
of AK295, aza-peptidyl ketones with nucletiode bases (adenine, 2-chloroadenine, 
cytosine, etc) and choline type base (N-methyl piperazine) were synthesized. 









The synthesis of aza-peptidyl ketones were described in Figure 4.3.2.  N-
benzyloxycarbonyl leucyl hydrazide (21) was synthesized from the reaction of 
commercially available N-benzyloxycarbonyl leucine methyl ester (20) with excess 
hydrazine (10 eq) in methanol.  For the introduction of the aminobutyric acid (Abu) side 
chain, the hydrazide Cbz-Leu-NH-NH2 (21) was reacted with acetaldehyde in THF to 
form the hydrazone Cbz-Leu-NH-N=CH-CH3 (22) and followed by subsequent reduction 
with NaBH3CN to form the hydrazide Cbz-Leu-NH-NH-CH2CH3 (23).  The linker, 6-
bromocaproic acid was coupled to the hydrazide (23) using HOBt and EDC coupling 
method to form Cbz-Leu-AAbu-(CH2)5-Br (24).  Cbz-Leu-AAbu-(CH2)5-Br was 
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dissolved in DMF and reacted with heterocyclic bases like, adenine, morpholine, etc. in 
the presence of K2CO3 to form the heterocyclic aza-peptidyl ketones (25-31). 
 
 
Figure 4.3.2.  Synthesis of Aza-peptide Ketones.  
 
RESULTS AND DISCUSSION 
 
 Calpain I Inhibition.  Aza-peptide ketones did not inhibit calpain I probably due 
to the conversion of ketone carbonyl to an amide carbonyl.  This modification resulted in 
a carbonyl which is much less susceptible to an attack by the active site cysteine for the 
formation of hemithioketal adduct.  Previous work with E-64c analogs and aza-
derivatives of these compounds showed that the change of the !-carbon to a nitrogen 
atom, to form the aza-residue, reduced the potency of aza-E-64c and derivatives for clan 
CA proteases (unpublished results).  Modeling studies done by Dr. Juliana Asgian  
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showed that papain would not tolerate aza-E-64c.  Another study with aza-peptide 
chloromethyl ketones discovered that changing the P1 residue from AGly to even a 
simple AAla residue resulted in complete loss of inhibitory activity against calpain.
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 No inhibition at 1.2 µM, 
b
 No inhibition at 0.5 µM, 
c
 No inhibition at 1.2 µM, 
d
 No 
inhibition at 4.7 µM, 
e
 No inhibition at 2.4 µM, 
f
 No inhibition at 2.4 µM, 
g
 No inhibition 
at 2.4 µM, 
h
 1% inhibition at 1.2 µM, 
i
 No inhibition at 2.4 µM, 
j
 6% inhibition at 2.4 µM, 
k






Aza-peptides are more rigid than their peptide analogs due to their trigonal planar 
geometry and the inability of the N2-CO bond to rotate, as opposed to the !-CH-CO bond 
which can rotate.  Clan CA proteases do not have the flexibility to accommodate the rigid 
aza-peptide compounds. The active site of papain and other clan CA proteases has a 
narrow, canyon like shape, and therefore clan CA proteases could not tolerate an aza-
residue due to the topology of their active sites.  Clan CD proteases, on the other hand, 
can tolerate aza-peptides very well since the active sites of clan CD proteases are wider 
and more solvent exposed than those of clan CA proteases.  As a result, aza-peptide 
epoxides and Michael acceptors are potent inhibitors of clan CD proteases (Chapter 2). 
 
Cathepsin B Inhibition.  Cbz-Leu-AAbu-(CH2)5-adenine (25), Cbz-Leu-AAbu-
(CH2)5-2-methoxyadenine (26) and Cbz-Leu-AAbu-(CH2)5-2-chloroadenine (27) did not 
inhibit cathepsin B.  Cbz-Leu-AAbu-(CH2)5-N4-acetylcytosine (28) was a weak inhibitor 
of cathepsin B with a Ki value of 7.83 mM.  Removal of the N-acetyl group resulted 10-
fold increase in potency for compound Cbz-Leu-AAbu-(CH2)5-cytosine (29, Ki = 0.745 
mM).  Cbz-Leu-AAbu-(CH2)5-morpholine (30), aza-peptidyl ketone derivative of 
AK295, was a poor inhibitor of cathepsin B with a Ki value of 16. 84 mM.  The aza-
peptidyl ketone derivative of ZLAK3002, Cbz-Leu-AAbu-(CH2)5-N-Me-piperazine (31) 








 We have designed aza-peptidyl ketones with the sturucture of Cbz-Leu-AAbu-
(CH2)5-R as a new class of inhibitors for calpains.  Design of these compounds was based 
on the peptidyl !-ketoamides.  The differences between the aza-peptidyl ketones and the 
peptidyl !-ketoamides were the AAbu residue and the carboxyamide moiety.  We have 
removed the carboxyamide moiety found in the peptidyl !-ketoamides and changed the 
!-carbon of Abu to nitrogen to form the aza-peptidyl ketones.  When we tested these 
compounds with calpain, they did not inhibit the enzyme.  Most of these compounds did 
not inhibit cathepsin B, either.  Only a few of them inhibited cathepsin B and they were 
only poor inhibitors of the enzyme.  The inability of these compounds to inhibit calpain 
and cathepsin B can be explained by the topologies of the active sites of these enzymes.  
Calpain and cathepsin B belong to clan CA of cysteine proteases.  Clan CA cysteine 
proteaeses have a narrow active site and the active sites of this family of enzymes are not 
flexible enough to accommodate the rigid aza-peptides.  We thought that the structural 
changes introduced by the replacement of !-carbon to nitrogen prevented the aza-peptidyl 




Material and Methods.  Materials were obtained from Acros, Bachem 
Bioscience Inc., or Sigma Aldrich and used without further purification.  The purity of 
each compound was confirmed by TLC, 
1
H NMR, MS, and elemental analysis.  
 163 
Chemical shifts are reported in ppm relative to an internal standard (trimethylsilane).  
TLC was performed on Sorbent Technologies (250 µm) silica gel plates.  The 
1
H NMR 
spectra were obtained on a Varian Mercury 400 MHz spectrometer.  Electrospray 
ionization (ESI), fast-atom-bombardment (FAB) and high-resolution mass spectrometry 
were obtained using Micromass Quattro LC and VG Analytical 70-SE instruments.  
Elemental analysis was carried out by Atlantic Microlab Inc., Norcross, GA. 
Calpain I and Calpain II Assays.  The fluorogenic substrate Suc-Leu-Tyr-AMC 
was obtained from Bachem.  Calpain I from porcine erythrocytes and calpain II from 
porcine kidney were purchased from Calbiochem.  Fluorescence was followed by Tecan 
Spectrafluor microplate reader.  AMC was used as the calibration standard and 
calibration curves were plotted with RFU versus different concentrations of AMC within 
the range of 5-0.08 µM.  Inhibitor stock solutions (50 mM to 0.01 mM) were prepared in 
DMSO and kept in the fridge prior to use.  Calpain assays were performed in 50 mM Tris 
HCl, 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% CHAPS, pH 7.5, 10 mM DTT, 5 
mM CaCl2 and three different substrate (Suc-Leu-Tyr-AMC) concentrations (0.8, 0.4, 0.2 
µM as final concentrations in the assay).  To this buffer (200 µL) was added a 10 µL 
aliquot of DMSO (control) or inhibitor solution in DMSO where the DMSO content of 
the final mixture did not exceed 5%.  The reaction was initiated by the addition of a 2 µL 
aliquot of enzyme (with a final concentration of 10 nM) to the well.  The reaction was 
monitored by the release of 7-amino-4-methylcoumarin ((ex = 360 nm, (em = 465 nm).  
Total volume in the reaction well was 212 µL and controls were run every hour.  
Velocities were determined at room temperature at five or more concentrations of 
inhibitor and at three fixed concentrations of substrate.  Plot of 1/v versus [I] gave 
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intersecting lines with a correlation coefficient of > 0.95.  Ki values were determined by 
Dixon plots.
24
   
Cathepsin B Assay.  The fluorogenic substrate Cbz-Arg-Arg-AMC was obtained 
from Bachem. Cathepsin B from human liver was purchased from Calbiochem.  
Fluorescence was followed by Tecan Spectrafluor microplate reader.  AMC was used as 
the calibration standard and calibration curve was plotted against RFU versus different 
concentrations of AMC within the range of 5-0.08 µM.  Inhibitor stock solutions (50 mM 
to 0.01 mM) were prepared in DMSO and kept in the fridge prior to use.  Cathepsin B 
assay was performed in 0.1 M NaHPO4, 1.25 mM EDTA, 0.01% Brij, pH 6.0 buffer and 
three different substrate (Cbz-Arg-Arg-AMC) concentrations (0.5, 0.2, 0.1 µM as final 
concentrations in the assay).  To this buffer (200 µL) was added a 10 µL aliquot of 
DMSO (control) or inhibitor solution in DMSO where the DMSO content of the final 
mixture did not exceed 5%.  The reaction was initiated by the addition of a 5 µL aliquot 
of activated enzyme (with a final concentration of 0.2 nM) to the well.  The enzyme was 
activated by the addition of cathepsin B kinetic buffer (267 µL) and 0.1 M DTT (3 µL) to 
the enzyme stock solution (30 µL).  The reaction was monitored by the release of 7-
amino-4-methylcoumarin ((ex = 360 nm, (em = 465 nm).  Total volume in the reaction 
well was 215 µL and controls were run every hour.  Velocities were determined at room 
temperature at five or more concentrations of inhibitor and at three fixed concentrations 
of substrate.  Plot of 1/v versus [I] gave intersecting lines with a correlation coefficient of 
> 0.95.  Ki values were determined by Dixon plots.
24




Synthetic Procedures for the Synthesis of Peptidyl !-Ketoamides 
General Procedure for the Synthesis of Dipeptidyl Methyl Ester.  To a stirred 
solution of the Cbz-Leu-OH (1 eq) in DMF at -15 °C, HOBt (1.5 eq) was added.  
Hydrochloride salt of the amino acid methyl ester was pretreated with NMM (1.5 eq) at  
-15 °C DMF prior to addition.  DCC (1.5 eq) was added to the solution and reaction 
mixture was allowed to react for 16 h at room temperature.  The DMF was evaporated, 
and the residue was redissolved in EtOAc.  The organic layer was washed with 2% citric 
acid, saturated NaHCO3, saturated NaCl, dried over MgSO4, and concentrated.  
Purification on a silica gel column with the proper eluent gave the product with yields of 
68-76%.  
Cbz-Leu-Abu-OMe (2a) was purified by column chromatography on silica gel 
using 9:1 EtOAc:hexane as the eluent; white solid, yield 68%.  
1
H NMR (CDCl3): 0.85-
0.94 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.48-1.91 (m, 5H, 2 x CH2 and CH), 3.74 (s, 
3H, OCH3), 4.23 (m, 1H, !-H), 4.53 (m, 1H, !-H), 5.10 (s, 2H, CH2), 5.26 (d, 1H, NH), 
6.55 (d, 1H, NH), 7.31-7.37 (m, 5H, Ph).  MS (ESI) m/z 365.2 [(M + 1)
+
].   
Cbz-Leu-Phe-OMe (2b) was purified by column chromatography on silica gel 
using 1:1 EtOAc:hexane as the eluent; white solid, yield 76%.  
1
H NMR (CDCl3): 0.90 
(d, 6H, 2 x Leu-CH3), 1.46 (m, 1H, CH), 1.62 (m, 2H, CH2), 3.03-3.15 (m, 2H, CH2), 
3.70 (s, 3H, OCH3), 4.19 (m, 1H, !-H), 4.84 (m, 1H, !-H), 5.05-5.12 (m, 2H, CH2), 5.20 
(d, 1H, NH), 7.08 (d, 1H, NH), 7.22-7.34 (m, 5H, Ph).  MS (ESI) m/z 427.2 [(M + 1)
+
].   
General Procedure for the Synthesis of Dipeptidyl Acids.  The dipeptidyl 
methyl esters were hydrolyzed in MeOH using 1 M aqueous NaOH (1.1 eq) under 
standard deblocking conditions.    
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Cbz-Leu-Abu-OH (3a), white solid, yield 89%.  
1
H NMR (DMSO-d6): 0.79-0.84 
(m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.41-1.73 (m, 5H, 2 x CH2 and CH), 4.07-4.10 (m, 
2H, 2 x !-H), 5.00 (s, 2H, CH2), 7.32-7.40 (m, 6H, Ph and NH), 7.98-8.07 (d, 1H, NH).  
MS (ESI) m/z 351.1 [(M + 1)
+
].   
Cbz-Leu-Phe-OH (3b), white solid, yield 85%.  
1
H NMR (DMSO-d6): 0.87 (d, 
6H, 2 x Leu-CH3), 1.45-1.61 (m, 3H, CH2 and CH), 2.96-3.20 (m, 2H, CH2), 4.26 (m, 
1H, !-H), 4.81 (m, 1H, !-H), 5.06-5.13 (m, 2H, CH2), 5.54 (d, 1H, NH), 6.88 (d, 1H, 
NH), 7.10-7.34 (m, 5H, Ph).  MS (ESI) m/z 413.1 [(M + 1)
+
].   
General Procedure for the Synthesis of Dipeptidyl !-Ketoesters.  The 
dipeptide acid (1 eq) was dissolved in dry THF and 4-dimethylaminopyridine (0.05 eq), 
pyridine (3 eq), and ethyl oxalyl chloride (2.1 eq) were added sequentially.  The resulting 
mixture was stirred at reflux temperature for 4 hours.  After removing the heat source, 1 
M HCl (50 mL) was added to the brown solution.  The mixture was extracted with ethyl 
acetate (2 x 100 mL).  The combined extract was washed with 100 mL of saturated NaCl, 
dried over MgSO4 overnight, and filtered.  Ethyl acetate was removed from the filtrate to 
give a mixture of products containing the dipeptidyl enol ester.  The mixture of products 
was dissolved in 20 mL of absolute ethanol and stirred in an ice bath.  Triethylamine (1 
eq) was added in one portion and stirring was continued for 1 hour at room temperature.  
Solvent was removed from the final mixture using a rotary evaporator.  The crude oil was 
subjected to column chromatography to give the dipeptidyl !-ketoester.     
Cbz-Leu-Abu-COOEt (5a), light yellow oil, 76% yield.  
1
H NMR (CDCl3): 0.86-
0.93 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.26-1.37 (m, 4H, CH3 and Leu-CH), 1.49-
1.98 (m, 4H, Abu-CH2, Leu-CH2 and CH3), 4.23-4.38 (m, 2H, 2 x !-H), 4.42-4.46 (m, 
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2H, CH2), 5.03-5.13 (m, 2H, Cbz), 5.67-5.73 (m, 1H, NH), 7.21-7.32 (m, 6H, Ph and 
NH).  HRMS (FAB) Calcd. for C21H31N2O6: 407.2182.  Observed m/z 407.2178. 
Cbz-Leu-Phe-COOEt (5b), light yellow oil, 68% yield.  
1
H NMR (CDCl3): 0.79-
0.90 (m, 6H, 2 x Leu-CH3), 1.22-1.61 (m, 6H, Leu-CH2, CH3 and Leu-CH), 2.93-3.07 
(m, 1H, CH), 3.19-3.28 (m, 1H, CH), 4.14-4.33 (m, 4H, CH2 and 2 x !-H), 5.08 (d, 2H, 
Cbz), 5.23-5.33 (m, 1H, NH), 6.77-6.84 (m, 1H, NH), 7.12-7.29 (m, 5H, Ph), 7.33 (s, 5H, 
Ph).  HRMS (FAB) Calcd. for C26H33N2O6: 469.2339.  Observed m/z 469.2337. 
General Procedure for the Synthesis of Dipeptidyl !-Ketoacids.  Dipeptidyl !-
ketoesters (1eq) were dissolved in ethanol and 1 M NaOH solution (1.1 eq) was added in 
portions while stirring in an ice bath.  The resulting mixture was stirred at room 
temperature for an hour and extracted with anhydrous ether (4 x 30 mL).  The aqueous 
layer was acidified to pH 4 with 2 M HCl in an ice bath and extracted with Et2O (2 x 50 
mL).  The combined ether extract was washed with saturated NaCl, dried over MgSO4 
overnight, and filtered.  Ether was removed from the filtrate by evaporation and the 
product was dried under reduced pressure.   
Cbz-Leu-Abu-COOH (6a), pale yellow hygroscopic flakes, 96% yield.  
1
H NMR 
(CDCl3): 0.91 (d, 9H, Abu-CH3 and 2 x Leu-CH3), 1.47-1.75 (m, 5H, Leu-CH2, Abu-
CH2, Leu-CH), 4.13-4.35 (m, 2H, 2 x !-H), 5.04-5.13 (m, 3H, Cbz and NH), 7.32 (s, 5H, 
Ph), 8.35-8.41 (d, 1H, NH).  HRMS (FAB) Calcd. for C19H27N2O6: 379.1869.  Observed 
m/z 379.1870. 
Cbz-Leu-Phe-COOH (6b), pale yellow hygroscopic flakes, 89% yield.  
1
H NMR 
(CDCl3): 0.77-0.86 (m, 6H, 2 x Leu-CH3), 1.09-1.56 (m, 3H, Leu-CH2 and Leu-CH), 
2.49-2.51 (m, 1H, CH), 2.75-2.91 (m, 1H, CH), 4.01-4.08 (m, 2H, 2 x !-H), 4.89-5.06 
 168 
(m, 3H, Cbz and NH), 7.18-7.40 (m, 10H, 2 x Ph), 8.49 (t, 1H, NH).  HRMS (FAB) 
Calcd. for C24H29N2O6: 441.2026.  Observed m/z 441.2025.  
General Procedure for the Synthesis of 9-(3-aminopropyl)adenine.  A mixture 
of adenine (1 eq), 1-bromo-3-chloropropane (4.3 eq), and potassium carbonate (2.35 eq) 
in DMF (200 mL) was stirred at room temperature under argon for 4 days, filtrated, and 
evaporated to dryness.  The crude product was washed with water and dried.  
Recrystallization from ethanol gave 9-(3-chloropropyl)adenine in 59% yield.  MS (ESI) 
m/z 212.0 [(M + 1)
+
].   
A mixture of 9-(3-chloropropyl)adenine (1 eq) and sodium azide (3 eq) in DMF 
was stirred at 80 °C for 24 hours, cooled to room temperature, and filtered.  The solid 
was washed with CH2Cl2.  The solvent was removed from the combined filtrates and the 
residue was taken up in water with sonication.  The aqueous layer was extracted with 
CH2Cl2 (3 x 60 mL).  After removing solvent, the crude product was recrystallized from 
ethanol to give 9-(3-azidopropyl)adenine as a white crystalline solid in 81% yield.  
1
H 
NMR (DMSO-d6): 2.04 (m, 2H, CH2), 3.36 (m, 2H, CH2), 4.19 (m, 2H, CH2), 7.22 (s, 
2H, NH2), 8.12 (s, 2H, CH of adenine).   
A mixture of 9-(3-azidopropyl)adenine and 5 % palladium on carbon in methanol 
was reacted with hydrogen gas at room temperature for 22 hours.  The catalyst was 
removed by filtration, the solvent removed to give 9-(3-aminopropyl)adenine as a white 
solid in 76% yield.  
1
H NMR (DMSO-d6): 1.80 (m, 2H, CH2), 2.45 (m, 2H, CH2), 3.35 (s, 
2H, NH2), 4.20 (m, 2H, CH2), 7.20 (s, 2H, NH2), 8.10 (s, 2H, CH).  MS (ESI) m/z 193.0 
[(M + 1)
+
].   
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General Proceure for the Synthesis of 9-(3-aminopropyl)-2-methoxyadenine.  
A mixture of 2-chloroadenine (1 eq), sodium methoxide (7.5 eq) in anhydrous methanol 
(50 mL) was sealed in pressure vessel. The reaction mixture was heated to an internal 
temperature of 100 °C and the reaction mixture was maintained at 100 °C for 24 hours 
before cooling to room temperature. Once cooled, the pressure vessel was opened and the 
suspension was diluted with water (50 mL).  The resulting solution was evaporated under 
reduced pressure to give a final volume of 70 mL; water (30 mL) was added to this 
solution to give a final volume of 100 mL.  The solution was transferred to a 3-neck flask 
equipped with a stirrer, thermometer and pH meter.  The solution was heated to 60°C 
(internal temperature) and 50% aq. HCl was added to adjust the pH to 9.5.  The resulting 
suspension was stirred at 60 °C for 1 hour and cooled slowly to room temperature and 
stirred for 16 hours.  The suspension was filtered and the filter cake was washed with 
water (10 mL) and methanol (2 x 10 mL). The solid was dried under vacuum to give 2-
methoxyadenine in 70% yield.  
1
H NMR (DMSO-d6): 3.76 (s, 3H, OCH3), 7.12 (s, 2H, 
NH2), 7.86 (s, 1H, CH). 
A mixture of 2-methoxyadenine (1 eq), 1-bromo-3-chloropropane (4.3 eq), and 
potassium carbonate (2.35) in DMF (200 mL) was stirred at room temperature under 
argon for 4 days, filtered, and evaporated to dryness.  The crude product was purified by 
column chromatography and gave 9-(3-chloropropyl)-2-methoxyadenine in 66% yield.  
MS (ESI) m/z 241.9 [(M + 1)
+
].   
A mixture of 9-(3-chloropropyl)-2-methoxyadenine (1 eq) and sodium azide (3 
eq) in DMF was stirred at 80 °C for 24 hours, cooled to room temperature, and filtered.  
The crude product was purified by column chromatography to give 9-(3-azidopropyl)-2-
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methoxyadenine as a white crystalline solid in 74% yield.  
1
H NMR (DMSO-d6): 1.99-
2.06 (m, 2H, CH2), 3.33-3.37 (m, 2H, CH2), 3.80 (s, 3H, OCH3), 4.10 (t, 2H, CH2), 7.21 
(s, 2H, NH2), 7.92 (s, 1H, CH).  MS (ESI) m/z 249.0 [(M + 1)
+
].     
A mixture of 9-(3-azidopropyl)-2-methoxyadenine and 5 % palladium on carbon 
in methanol was reacted with hydrogen gas at room temperature for 20 hours.  The 
catalyst was removed by filtration, the solvent removed to give 9-(3-aminopropyl)-2-
methoxyadenine as a white solid in 75% yield.  
1
H NMR (DMSO-d6): 1.82-1.85 (m, 2H, 
CH2), 2.46-2.49 (m, 2H, CH2), 3.03 (s, 2H, NH2), 3.79 (s, 3H, OCH3), 4.09 (t, 2H, CH2), 
7.20 (s, 2H, NH2), 7.92 (s, 1H, CH).  MS (ESI) m/z 223.2 [(M + 1)
+
].  
General Procedure for the Synthesis of 1-(3-aminopropyl)cytosine.  A mixture 
of N4-acetylcytosine (1eq), 1-bromo-3-chloropropane (1.5 eq), and potassium carbonate 
(1.5 eq) in DMF was stirred at room temperature under argon for 4 days, filtered and 
evaporated to dryness.  The crude product was purified by column chromatography and 
gave 1-(3-chloropropyl)-N4-acetylcytosine.  MS (ESI) m/z 230.0 [(M + 1)
+
].  
A mixture of 1-(3-chloropropyl)-N4-acetylcytosine and sodium azide in 
acetonitrile was refluxed for 24 hours, cooled to room temperature, and filtered.  The 
crude product was purified by silica gel column chromatography and gave 1-(3-
azidopropyl)-N4-acetylcytosine as a white solid.  
1
H NMR (DMSO-d6): 1.85-1.91 (m, 
2H, CH2), 2.06 (s, 3H, CH3), 3.35-3.39 (t, 2H, CH2), 3.81-3.84 (t, 2H, CH2), 7.12 (d, 1H, 
CH), 8.04 (s, 1H, CH), 10.79 (s, 1H, NH).  MS (ESI) m/z 237.0 [(M + 1)
+
].  
A mixture of 1-(3-azidopropyl)-N4-acetylcytosine was reacted with 7N ammonia 
solution in methanol at room temperature for 2 days to give 1-(3-azidopropyl)cytosine as 
a white solid.  
1
H NMR (DMSO-d6): 1.73-1.83 (m, 2H, CH2), 3.31-3.34 (t, 2H, CH2), 
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3.64-3.67 (t, 2H, CH2), 5.62 (d, 1H, CH), 7.01 (d, 2H, NH2), 7.53 (s, 1H, CH).  MS (ESI) 
m/z 195.0 [(M + 1)
+
].  
A mixture of 1-(3-azidopropyl)cytosine and 5% palladium on carbon in methanol 
was reacted with hydrogen gas at room temperature for 8 h.  The catalyst was removed 
by filtration, the solvent was removed to give 1-(3-aminopropyl)cytosine as a white solid.  
1
H NMR (DMSO-d6): 1.66 (m, 2H, CH2), 2.96 (t, 2H, CH2), 2.96 (s, 2H, CH2), 3.57-3.67 
(m, 4H, CH2 and NH2), 5.59 (d, 1H, CH), 6.97 (d, 2H, NH2), 7.54 (d, 1H, CH).  MS (ESI) 
m/z 169.9 [(M + 1)
+
].  
General Procedure for the Synthesis of Peptidyl !-Ketoamides by the HOBt 
and EDC Coupling Method.  To a stirred solution of the dipeptidyl !-ketoacid (1.5 eq) 
in DMF at -10 °C was added HOBt (1.5 eq), the heterocyclic amine (1 eq) and EDC (1.5 
eq) was added.  The mixture was allowed to react for 16 h at room temperature.  The 
DMF was evaporated, and the residue was redissolved in EtOAc.  The organic layer was 
washed with 2% citric acid, saturated NaHCO3, saturated NaCl, dried over MgSO4, and 
concentrated.  Column chromatography on silica gel afforded the peptidyl !-ketoamides. 
(7, Cbz-Leu-Phe-CONH-(CH2)3-adenin-9-yl).  The ketoamide product Cbz-
Leu-Phe-CONH-(CH2)3-adenin-9-yl was obtained from 9-(3-aminopropyl)adenine and 
the ketoacid Cbz-Leu-Phe-COOH using the EDC and HOBt coupling method, purified by 
column chromatography on silica gel with 85:15 CH2Cl2:MeOH as the eluent, then 
recrystallization from EtOAc/hexane to give a white solid (21% yield).  
1
H NMR 
(DMSO-d6): 0.69-0.86 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.15-1.36 (m, 5H, 2 x CH2 
and CH), 1.92-2.00 (m, 2H, CH2), 3.04-3.15 (m, 4H, 2 x CH2), 4.07-4.14 (m, 2H, CH2 
and 2 x !-H), 4.95-5.01 (m, 2H, Cbz), 5.18 (s, 1H, NH), 7.12-7.40 (m, 12H, 2 x Ph and 
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NH2), 8.08-8.14 (m, 2H, 2 x Adenine-CH), 8.33-8.39 (d, 1H, NH), 8.83-8.89 (t, 1H, NH).  
HRMS (FAB) Calcd. for C32H39N8O5: 615.3043.  Observed m/z 615.3094.   Anal. Calcd. 
for C32H38N8O5#0.75H2O: C, 61.18; H, 6.34; N, 17.84.  Found: C, 61.14; H, 6.37; N, 
17.89.       
3-(Benzyloxycarbonyl-L-leucylamino)-N-(3-(6-amino-2-methoxy-9H-purin-9-
yl)propyl)-2-oxopentanamide (8, Cbz-Leu-Abu-CONH-(CH2)3-2-methoxyadenin-9-
yl).  The ketoamide product Cbz-Leu-Abu-CONH-(CH2)3-2-methoxyadenin-9-yl was 
obtained from of 9-(3-aminopropyl)-2-methoxyadenine and the ketoacid Cbz-Leu-Abu-
COOH using the EDC and HOBt coupling method, purified by column chromatography 
on silica gel with 85:15 CH2Cl2:MeOH as the eluent, then recrystallization from 
EtOAc/hexane to give a yellowish white solid (26% yield).  
1
H NMR (DMSO-d6): 0.72-
0.93 (m, 9H, 2 x CH3 of Leu and CH3 of Abu), 1.37-1.60 (m, 4H, CH2 of Leu and CH2 of 
Abu), 1.76 (m, 1H, CH of Leu), 1.93-1.97 (m, 2H, CH2), 3.09 (m, 2H, CH2), 3.78 (s, 3H, 
OCH3), 3.98-4.14 (m, 3H, CH2 and !-H), 4.84 (m, 1H, !-H), 4.99 (s, 2H, Cbz), 7.20 (s, 
2H, NH2), 7.28-7.40 (m, 6H, Ph and NH), 7.93 (s, 1H, CH of adenine), 8.24-8.31 (m, 1H, 
NH), 8.77 (m, 1H, NH).  HRMS (FAB) Calcd. for C28H41N6O6: 583.2993.  Observed m/z 
583.2900.  Anal. Calcd. for C28H39N8O6#0.55H2O: C, 56.75; H, 6.65; N, 18.91.  Found: 
C, 56.72; H, 6.63; N, 18.97.        
(9, Cbz-Leu-Phe-CONH-(CH2)3-2-methoxyadenin-9-yl).  The ketoamide 
product Cbz-Leu-Phe-CONH-(CH2)3-2-methoxyadenin-9-yl was obtained from of 9-(3-
aminopropyl)-2-methoxyadenine and the ketoacid Cbz-Leu-Phe-COOH using the EDC 
and HOBt coupling method, purified by column chromatography on silica gel with 85:15 
CH2Cl2:MeOH as the eluent, then recrystallization from EtOAc/hexane to give a yellow 
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solid (24% yield).  
1
H NMR (DMSO-d6): 0.73-0.75 (d, 6H, 2 x CH3 of Leu), 1.11-1.35 
(m, 4H, CH2 Leu and CH2 of Phe), 1.54 (m, 1H CH of Leu), 1.95-1.98 (m, 2H, CH2), 
3.09-3.12 (m, 2H, CH2), 3.77 (s, 3H, OCH3), 4.03 (m, 3H, CH2 and !-H), 4.97 (s, 2H, 
Cbz), 5.17 (m, 1H, !-H), 7.20-7.33 (m, 12H, 2 x Ph and NH2), 7.93 (d, 1H, CH of 
adenine), 8.38 (d, 1H, NH), 8.84 (m, 1H, NH).  HRMS (FAB) Calcd. for C33H41N6O6: 
645.3149.  Observed m/z 645.3067.  Anal. Calcd. for C33H40N8O6#0.25H2O: C, 61.05; H, 
6.29; N, 17.26.  Found: C, 59.98; H, 6.22; N, 17.37.       
(10, Cbz-Leu-Abu-CONH-(CH2)3-cytosin-3-yl).  The ketoamide product Cbz-
Leu-Abu-CONH-(CH2)3-cytosin-3-yl was obtained from of 1-(3-aminopropyl)cytosine 
and the ketoacid Cbz-Leu-Abu-COOH using the EDC/HOBt coupling method, purified 
by column chromatography on silica gel with 85:15 CH2Cl2:MeOH as the eluent, then 
recrystallization from EtOAC/hexane to give a yellowish white solid (11% yield).  
1
H 
NMR (DMSO-d6): 0.72-0.95 (m, 9H, 2 x CH3 of Leu and CH3 of Abu), 1.41-1.73 (m, 
5H, CH2 of Leu, CH2 of Abu and CH of Leu), 2.13-2.19 (m, 2H, CH2), 3.07 (m, 2H, 
CH2), 3.56 (m, 1H, !-H), 3.93-4.10 (m, 3H, !-H and CH2), 4.99 (s, 2H, Cbz), 5.60 (d, 1H, 
CH of cytosine), 6.97 (d, 2H, NH2), 7.32-7.44 (m, 6H, Ph and NH), 7.68 (d, 1H, CH of 
cytosine), 8.22-8.28 (m, 1H, NH), 8.73 (m, 1H, NH).  HRMS (FAB) Calcd. for 
C26H37N6O6: 529.2775.  Observed m/z 529.2781.  Anal. Calcd. for C26H36N6O6#1EtOAc: 
C, 58.43; H, 7.19; N, 13.63.  Found: C, 58.37; H, 7.38; N, 13.62.        
(11, Cbz-Leu-Phe-CONH-(CH2)3-cytosin-3-yl).  The ketoamide product Cbz-
Leu-Phe-CONH-(CH2)3-cytosin-3-yl was obtained from of 1-(3-aminopropyl)cytosine 
and the ketoacid Cbz-Leu-Phe-COOH using the EDC and HOBt coupling method, 
purified by column chromatography on silica gel with 85:15 CH2Cl2:MeOH as the eluent, 
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then recrystallization from EtOAc/hexane to give a yellow solid (12% yield).  
1
H NMR 
(DMSO-d6): 0.74-0.76 (d, 6H, 2 x CH3 of Leu), 1.11-1.37 (m, 4H, CH2 Leu and CH2 of 
Phe), 1.59 (m, 1H CH of Leu), 2.11-2.15 (m, 2H, CH2), 3.01-3.10 (m, 2H, CH2), 3.82-
4.03 (m, 3H, !-H and CH2), 4.99 (s, 2H, Cbz), 5.18 (m, 1H, NH), 5.61 (d, 1H, CH of 
cytosine), 6.97 (d, 2H, NH2), 7.13-7.57 (m, 11H, 2 x Ph and CH of cytosine), 8.36 (d, 1H, 
NH), 8.80 (m, 1H, NH).  HRMS (FAB) Calcd. for C31H39N6O6: 591.2886.  Observed m/z 
591.2852.  Anal. Calcd. for C31H38N6O6#1EtOAc: C, 61.93; H, 6.83; N, 12.38.  Found: C, 
61.71; H, 6.82; N, 12.27.  
Synthetic Procedures for the Synthesis of Peptidyl AminoKetones 
General Procedure for the Synthesis of Dipeptidyl Methyl Ester (13, Cbz-
Leu-(L)Abu-OMe).  First, commercilally available L-(2)-aminobutyric acid is esterified 
with SOCl2 in the presence of MeOH and then coupled to Cbz-Leu-OH using HOBt/DCC 
coupling method.  To a stirred solution of the Cbz-Leu-OH (1 eq) in DMF at -15 °C, 
HOBt (1.5 eq) was added.  Hydrochloride salt of the L-Abu-OMe was pretreated with 
NMM (1.5 eq) at -15 °C DMF prior to addition.  DCC (1.5 eq) was added to the solution 
and reaction mixture was allowed to react for 16 h at room temperature.  The DMF was 
evaporated, and the residue was redissolved in EtOAc.  The organic layer was washed 
with 2% citric acid, saturated NaHCO3, saturated NaCl, dried over MgSO4, and 
concentrated.  Purification on a silica gel column with the proper eluent gave the product 
with 65% yield.  
1
H NMR (CDCl3-d): 0.82-0.87 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 
1.41-1.74 (m, 5H, 2 x CH2 and CH), 3.59 (s, 3H, OCH3), 4.06-4.18 (m, 2H, 2 x !-H), 
5.00 (s, 2H, CH2), 7.29-7.39 (m, 6H, Ph and NH), 8.19 (d, 1H, NH). 
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General Procedure for the Synthesis of Dipeptidyl Acid (14, Cbz-Leu-
(L)Abu-OH).  Cbz-Leu-(L)Abu-OH was obtained by hydrolysis of Cbz-Leu-(L)Abu-
OMe in MeOH using NaOH (1 M aqueous, 1.1 eq); white solid, yield 88%.  
1
H NMR 
(DMSO-d6): 0.79-0.84 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.41-1.73 (m, 5H, 2 x CH2 
and CH), 4.07-4.10 (m, 2H, 2 x !-H), 5.00 (s, 2H, CH2), 7.32-7.40 (m, 6H, Ph and NH), 
7.98-8.07 (d, 1H, NH). 
General Procedure for the Synthesis of Dipeptidyl Chloromethyl Ketone (16, 
Cbz-Leu-Abu-CH2Cl).  To a cooled solution of Cbz-Leu-Abu-OH (1 eq) and NMM (1 
eq) in dry THF (50 mL) was added iBCF (0.9 eq) at -10 °C with stirring.  After 15 min, 
the mixture was filtered rapidly and the filtrate was added dropwise to cold CH2N2 in 
ether with stirring.  When the addition was complete, the reaction mixture was left at 
room temperature for 1 h.  The reaction mixture was cooled down to 5 °C and 4 M HCl 
in dioxane was added dropwise until the mixture was colorless.  The solvents were 
removed under reduced pressure and the crude product was purified by column 
chromatography using 5%MeOH/CH2Cl2 as eluent to give a white solid with 50% yield.  
1
H NMR (DMSO-d6): 0.81-0.88 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.39-1.77 (m, 5H, 
2 x CH2 and CH), 4.04 (m, 1H, !-H), 4.24 (m, 1H, !-H), 4.54 (s, 2H, CH2), 5.01 (s, 2H, 




General Procedure for the Synthesis of 9-(3-aminopropyl)-2-chloroadenine.  
A mixture of 2-chloroadenine (1 eq), 1-bromo-3-chloropropane (4.3 eq), and potassium 
carbonate (2.35 eq) in DMF (200 mL) was stirred at room temperature under argon for 4 
days, filtered, and evaporated to dryness.  The crude product was purified by column 
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chromatography and gave 9-(3-chloropropyl)-2-chloroadenine in 57% yield.  
1
H NMR 
(DMSO-d6): 2.23-2.27 (m, 2H, NCH2CH2CH2Cl), 3.63 (t, 2H, NCH2CH2CH2Cl), 4.21 (t, 




A mixture of 9-(3-chloropropyl)-2-chloroadenine (1 eq) and sodium azide (3 eq) 
in DMF was stirred at 80 °C for 24 hours, cooled to room temperature, and filtered.  The 
crude product was purified by column chromatography to give 9-(3-azidopropyl)-2-
chloroadenine as a white crystalline solid in 34% yield.  
1
H NMR (DMSO-d6): 1.98-2.05 
(m, 2H, NCH2CH2CH2N3), 3.34-3.39 (m, 2H, NCH2CH2CH2N3), 4.15 (t, 2H, 




A mixture of 9-(3-azidopropyl)-2-chloroadenine and 5 % palladium on carbon in 
methanol was reacted with hydrogen gas at room temperature for 20 hours.  The catalyst 
was removed by filtration, the solvent removed to give 9-(3-aminopropyl)-2-
chloroadenine as a white solid in 87% yield.  
1
H NMR (DMSO-d6): 2.09-2.13 (m, 2H, 
CH2), 2.74 (m, 2H, CH2), 3.37 (s, 2H, NH2), 4.22-4.27 (m, 2H, CH2), 7.26 (s, 1H, CH), 
8.20 (s, 2H, NH2). 
General Procedure for the Synthesis of Peptidyl AminoKetones.  A solution of 
base (1 eq), Cbz-Leu-Abu-CH2Cl (1.1 eq) and Et3N (2 eq) in dry THF was heated at 
reflux for 24 h.  The crude product was purified by column chromatography to give the 
aminoketones. 
(17, Cbz-Leu-Abu-CH2-NH-(CH2)3-adenine).  This compound was obtained by 
the reaction of Cbz-Leu-Abu-CH2Cl and 9-(3-aminopropyl)adenine. The crude product 
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was purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (9% yield).  
1
H NMR 
(DMSO-d6): 0.54-0.59 (m, 3H, Abu-CH3), 0.79-0.88 (m, 6H, 2 x Leu-CH3), 1.31-1.75 
(m, 5H, 2 x CH2 and CH), 1.87-2.26 (m, 6H, 3 x CH2), 2.62 (t, 1H, NH), 3.97-4.15 (m, 
4H, 2 x !-H and CH2), 4.95-5.07 (m, 2H, CH2), 7.15-7.30 (m, 7H, Ph and NH2), 7.58 (d, 
1H, NH), 8.02-8.07 (m, 3H, 2 x Adenine-CH and NH).  HRMS (FAB) Calcd. for 
C27H39N8O4: 539.3094.  Observed m/z 539.3088.  Anal. Calcd. for C27H38N8O4#0.1H2O: 
C, 60.00; H, 7.12; N, 20.73.  Found: C, 60.32; H, 7.16; N, 19.92.   
(18, Cbz-Leu-Abu-CH2-NH-(CH2)3-2-methoxyadenine).  This compound was 
obtained by the reaction of Cbz-Leu-Abu-CH2Cl and 9-(3-aminopropyl)-2-
methoxyadenine. The crude product was purified by column chromatography using 15% 
MeOH/CH2Cl2 as the eluent.  Recrystallization with EtOAc/hexane gave a white powder 
(8% yield).  
1
H NMR (DMSO-d6): 0.53-0.59 (m, 3H, Abu-CH3), 0.79-0.85 (m, 6H, 2 x 
Leu-CH3), 1.31-1.76 (m, 5H, 2 x CH2 and CH), 1.83-2.26 (m, 6H, 3 x CH2), 2.62 (t, 1H, 
NH), 3.78 (s, 3H, OCH3), 3.95-4.06 (m, 4H, 2 x !-H and CH2), 4.94-5.07 (m, 2H, CH2), 
7.15 (s, 2H, NH2), 7.24-7.33 (m, 5H, Ph), 7.57 (d, 1H, NH), 7.87 (s, 1H, CH), 8.03 (d, 
1H, NH).  HRMS (FAB) Calcd. for C28H41N8O5: 569.3200.  Observed m/z 569.3211.   
Anal. Calcd. for C28H40N8O5#0.2H2O: C, 58.77; H, 7.12; N, 19.58.  Found: C, 58.83; H, 
7.09; N, 18.75.       
(19, Cbz-Leu-Abu-CH2-NH-(CH2)3-2-chloroadenine).  This compound was 
obtained by the reaction of Cbz-Leu-Abu-CH2Cl and 9-(3-aminopropyl)-2-chloroadenine. 
The crude product was purified by column chromatography using 15% MeOH/CH2Cl2 as 




NMR (DMSO-d6): 0.54-0.59 (m, 3H, Abu-CH3), 0.79-0.86 (m, 6H, 2 x Leu-CH3), 1.33-
1.75 (m, 5H, 2 x CH2 and CH), 1.83-2.25 (m, 6H, 3 x CH2), 2.60 (t, 1H, NH), 3.97-4.09 
(m, 4H, 2 x !-H and CH2), 4.95-5.07 (m, 2H, CH2), 7.27-7.33 (m, 5H, Ph), 7.57 (d, 1H, 
NH), 7.70 (s, 2H, NH2), 8.03 (s, 1H, CH), 8.10 (d, 1H, NH).  HRMS (FAB) Calcd. for 
C27H37N8O4Cl: 573.2699.  Observed m/z 573.2658.  Anal. Calcd. for 
C28H40N8O5#0.15H2O: C, 56.32; H, 6.53; N, 19.46.  Found: C, 56.33; H, 6.53; N, 18.93. 
Synthetic Procedures for the Synthesis of Aza-peptidyl Ketones 
N-Benzyloxycarbonylleucine hydrazide (21, Cbz-Leu-NH-NH2).  Anhydrous 
hydrazine (10 equiv) was added to a stirred solution of Cbz-Leu-OMe (1 eq) in MeOH 
and the reaction mixture was stirred vigorously for 16 h at room temperature. Excess 
hydrazine and solvent were removed under vacuum and the residue was washed with 
ether several times to give the peptidyl hydrazide as a white solid.  
1
H NMR (DMSO-d6): 
0.81-0.88 (m, 6H, 2 x Leu-CH3), 1.29-1.58 (m, 3H, CH2 and CH), 3.96 (m, 1H, !-H), 
4.19 (s, 2H, NH2), 4.47 (d, 1H, NH), 4.99 (s, 2H, CH2), 7.29-7.39 (m, 5H, Ph), 9.15 (s, 
1H, NH).  MS (ESI) m/z 280.2 [(M + 1)
+
].     
(22, Cbz-Leu-hydrazoneAbu).  Cbz-Leu-NH-NH2 (1 eq) was dissolved in dry 
THF and cooled down to 4 °C. Acetaldehyde (2 eq) was added to the cooled solution and 
the reaction mixture was continued to be stirred at 4 °C for 16 h.  Solvent was removed 
under vacuum and the product was purified by column chromatography on silica gel 
using 10%MeOH/CH2Cl2 as the eluent; white solid, yield 92%.  
1
H NMR (DMSO-d6): 
0.82-0.88 (m, 9H, 2 x Leu-CH3 and Abu-CH3), 1.32-1.64 (m, 3H, CH2 and CH), 3.95-
3.99 (m, 1H, !-H), 4.99 (s, 2H, CH2), 7.26-7.33 (m, 6H, Ph and CH), 7.49 (d, 1H, NH), 
10.85 (s, 1H, NH).  MS (ESI) m/z 306.1 [(M + 1)
+
].     
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(23, Cbz-Leu-AAbu).  NaBH3CN (3 eq) was added to a solution of peptidyl 
hydrazone (1 eq) in dry THF.  The reaction mixture was heated to 60 °C and stirred 
overnight after the addition of HCl.  The solvent was evaporated and the residue was 
dissolved in EtOAc and washed with 10% NaHCO3, water, saturated NaCl and dried over 
MgSO4 and concentrated.  Purification on a silica gel column with the proper eluent gave 
the product with 52% yield.  
1
H NMR (DMSO-d6):  0.81-0.94 (m, 9H, 2 x Leu-CH3 and 
Abu-CH3), 1.33-1.57 (m, 3H, CH2 and CH), 2.62-2.66 (m, 2H, CH2), 3.97 (m, 1H, !-H), 
4.76 (s, 1H, NH), 4.99 (s, 2H, CH2), 7.30-7.39 (m, 6H, Ph and NH), 9.41 (s, 1H, NH).  
MS (ESI) m/z 308.2 [(M + 1)
+
].     
(24, Cbz-Leu-AAbu-(CH2)5Br).  To a stirred solution of the 6-bromocaproic acid 
(1.5 eq) in DMF at -10 °C was added HOBt (1.5 eq), the peptidyl hydrazide precursor (1 
eq) and EDC (1.5 eq) was added.  The mixture was allowed to react for 16 h at room 
temperature.  The DMF was evaporated, and the residue was redissolved in EtOAc.  The 
organic layer was washed with 2% citric acid, saturated NaHCO3, saturated NaCl, dried 
over MgSO4, and concentrated.  Purification on a silica gel column with the proper eluent 
gave the product with 41% yield.  
1
H NMR (DMSO-d6):  0.92-1.03 (m, 9H, 2 x Leu-CH3 
and Abu-CH3), 1.36-1.79 (m, 7H, 3 x CH2 and CH), 2.18-2.12 (m, 2H, CH2), 3.32-3.53 
(m, 6H, 3 x CH2), 4.24 (m, 1H, !-H), 5.07 (s, 2H, CH2), 5.62 (d, 1H, NH), 7.26-7.31 (m, 
5H, Ph), 8.94 (s, 1H, NH).  MS (ESI) m/z 485.2 [(M + 1)
+
].     
General Procedure for the synthesis of Aza-peptidyl Ketones.  Cbz-Leu-
AAbu-(CH2)5Br (1 eq) was dissolved in DMF, anhydrous K2CO3 (1.5 eq)and the base 
(1.5 eq) were added to the solution and the reaction mixture was stirred overnight at room 
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temperature.  The DMF was evaporated and the crude product was subjected to column 
chromatography to obtain the product.        
(25, Cbz-Leu-AAbu-(CH2)5-adenine).  This compound was obtained by reacting 
Cbz-Leu-AAbu-(CH2)5Br and adenine.  The crude product was purified by column 
chromatography using 15% MeOH/CH2Cl2 as the eluent.  Recrystallization with 
EtOAc/hexane gave a white powder (25% yield).  
1
H NMR (DMSO-d6): 0.82-0.96 (m, 
9H, 2 x Ile-CH3 and Abu-CH3), 1.16 (t, 2H, CH2), 1.37-1.75 (m, 7H, 3 x CH2 and CH), 
2.09 (m, 2H, CH2), 3.12 (s, 1H, CH), 3.62 (s, 1H, CH), 3.99-4.07 (m, 3H, !-H and CH2), 
4.99 (s, 2H, Cbz), 7.15-7.30 (m, 7H, Ph and NH2), 7.63 (d, 1H, NH), 8.09 (d, 2H, 2 x 
Adenine-CH), 10.45 (s, 1H, NH).  HRMS (FAB) Calcd. for C27H39N8O4: 539.3094.  
Observed m/z 539.3118.  Anal. Calcd. for C27H38N8O4#0.125EtOAc#0.3H2O: C, 59.51; H, 
7.19; N, 20.19.  Found: C, 59.46; H, 7.26; N, 20.19.       
(26, Cbz-Leu-AAbu-(CH2)5-2-methoxyadenine).  This compound was obtained 
by reacting Cbz-Leu-AAbu-(CH2)5Br and 2-methoxyadenine.  The crude product was 
purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (23% yield).  
1
H NMR 
(DMSO-d6): 0.83-0.97 (m, 9H, 2 x Ile-CH3 and Abu-CH3), 1.13-1.16 (t, 2H, CH2), 1.34-
1.74 (m, 7H, 3 x CH2 and CH), 2.10 (m, 2H, CH2), 3.11 (s, 1H, CH), 3.61 (s, 1H, CH), 
3.77 (s, 3H, OCH3), 3.98-4.03 (m, 3H, !-H and CH2), 4.99 (s, 2H, Cbz), 7.16-7.30 (m, 
7H, Ph and NH2), 7.63 (d, 1H, NH), 7.89 (s, 1H, CH), 10.46 (s, 1H, NH).  HRMS (FAB) 
Calcd. for C28H41N8O5: 569.3200.  Observed m/z 569.3195.  Anal. Calcd. for 
C28H40N8O5#0.4H2O: C, 58.40; H, 7.14; N, 19.46.  Found: C, 58.45; H, 7.16; N, 19.33.         
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(27, Cbz-Leu-AAbu-(CH2)5-2-chloroadenine).  This compound was obtained by 
reacting Cbz-Leu-AAbu-(CH2)5Br and 2-chloroadenine.  The crude product was purified 
by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  Recrystallization 
with EtOAc/hexane gave a white powder (18% yield).  
1
H NMR (DMSO-d6) 0.83-0.97 
(m, 9H, 2 x Ile-CH3 and Abu-CH3), 1.14-1.17 (t, 2H, CH2), 1.37-1.73 (m, 7H, 3 x CH2 
and Leu-CH), 2.10 (m, 2H, CH2), 3.21 (s, 1H, CH), 3.62 (s, 1H, CH), 3.97-4.02 (m, 3H, 
!-H and CH2), 4.95-5.03 (m, 2H, Cbz), 7.30 (m, 5H, Ph), 7.63 (d, 1H, NH), 7.71 (s, 2H, 
NH2), 8.11 (s, 1H, CH), 10.46 (s, 1H, NH).  HRMS (FAB) Calcd. for C27H38N8O4Cl: 
573.2705.  Observed m/z 573.2710.  Anal. Calcd. for C27H37N8O4Cl#0.2H2O: C, 56.23; H, 
6.54; N, 19.43.  Found: C, 56.38; H, 6.64; N, 19.27.         
(28, Cbz-Leu-AAbu-(CH2)5-N4-acetylcytosine).  This compound was obtained 
by reacting Cbz-Leu-AAbu-(CH2)5Br and N-acetylcytosine.  The crude product was 
purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (18% yield).  
1
H NMR 
(DMSO-d6) 0.83-0.97 (m, 9H, 2 x Ile-CH3 and Abu-CH3), 1.14-1.18 (t, 2H, CH2), 1.38-
1.60 (m, 7H, 3 x CH2 and Leu-CH), 2.05-2.16 (m, 5H, CH2 and CH3), 3.12 (s, 1H, CH), 
3.62-3.73 (m, 3H, CH2 and CH), 4.00-4.03 (m, 1H, !-H), 5.00 (s, 2H, Cbz), 7.09 (d, 1H, 
NH), 7.30-7.33 (m, 5H, Ph), 7.62-7.64 (d, 1H, CH), 8.01-8.03 (d, 1H, CH), 10.46 (s, 1H, 
NH), 10.76 (s, 1H, NH).  HRMS (FAB) Calcd. for C28H41N6O6: 557.3088.  Observed m/z 
557.3065.   Anal. Calcd. for C28H40N6O6#0.1EtOAc#0.5H2O: C, 59.38; H, 7.33; N, 14.63.  
Found: C, 59.53; H, 7.38; N, 14.53.        
(29, Cbz-Leu-AAbu-(CH2)5-cytosine).  This compound was obtained by reacting 
Cbz-Leu-AAbu-(CH2)5-N-acetylcytosine with 7N NH3 in methanol.  The crude product 
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was purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (82% yield).  
1
H NMR 
(DMSO-d6): 0.84-0.97 (m, 9H, 2 x Ile-CH3 and Abu-CH3), 1.14 (t, 2H, CH2), 1.39-1.62 
(m, 7H, 3 x CH2 and Leu-CH), 2.09 (m, 2H, CH2), 3.12 (s, 1H, CH), 3.53-3.61 (m, 3H, 
CH2 and CH), 3.98-4.04 (m, 1H, !-H), 4.97-5.04 (m, 2H, Cbz), 5.57 (d, 1H, NH), 6.87-
6.96 (s, 2H, NH2), 7.32 (m, 5H, Ph), 7.49 (d, 1H, CH), 7.64 (d, 1H, CH), 10.47 (s, 1H, 
NH).  HRMS (FAB) Calcd. for C26H39N6O5: 515.2982.  Observed m/z 515.3004.   Anal. 
Calcd. for C26H38N6O5#0.1EtOAc#1.5H2O: C, 57.61; H, 7.65; N, 15.27.  Found: C, 57.65; 








yl)hexanoyl)hydrazine (30, Cbz-Leu-AAbu-(CH2)5-morpholine).  This compound was 
obtained by reacting Cbz-Leu-AAbu-(CH2)5Br and morpholine.  The crude product was 
purified by column chromatography using 15% MeOH/CH2Cl2 as the eluent.  
Recrystallization with EtOAc/hexane gave a white powder (13% yield).  
1
H NMR 
(CDCl3): 0.94-1.09 (m, 9H, 2 x Ile-CH3 and Abu-CH3), 1.45-1.80 (m, 7H, 3 x CH2 and 
CH), 2.20 (m, 2H, CH2), 2.31 (m, 4H, morpholine), 2.55-2.75 (m, 4H, 2 x CH2), 3.52 (m, 
4H, morpholine), 3.81 (s, 2H, CH2), 4.29 (m, 1H, !-H), 5.04-5.14 (m, 2H, Cbz), 5.98 (s, 
1H, NH), 7.33 (s, 5H, Ph), 9.28 (s, 1H, NH).  HRMS (FAB) Calcd. for C26H43N4O5: 
491.3234.  Observed m/z 491.3239.   Anal. Calcd. for C26H42N4O5#0.6CH2Cl2#1H2O: C, 








yl)hexanoyl)hydrazine (31, Cbz-Leu-AAbu-(CH2)5-N-Me-piperazine).  This 
compound was obtained by reacting Cbz-Leu-AAbu-(CH2)5Br and N-methyl piperazine.  
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The crude product was purified by column chromatography using 15% MeOH/CH2Cl2 as 
the eluent.  Recrystallization with EtOAc/hexane gave a white powder (15% yield).  
1
H 
NMR (CDCl3): 0.87-1.08 (m, 9H, 2 x Ile-CH3 and Abu-CH3), 1.24-1.81 (m, 10H, 3 x 
CH2, Leu-CH and CH3), 2.23-2.47 (m, 6H, 3 x CH2), 2.88 (s, 4H, piperazine), 3.53 (m, 
4H, piperazine), 4.04 (t, 2H, CH2), 4.30 (m, 1H, !-H), 5.10 (s, 2H, Cbz), 5.92 (s, 1H, 
NH), 7.33 (s, 5H, Ph).  HRMS (FAB) Calcd. for C27H46N5O4: 503.3472.  Observed m/z 
503.3464.  Anal. Calcd. for C27H45N5O4#2CH2Cl2#0.5H2O: C, 51.03; H, 7.38; N, 10.26.  
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